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Abstract
Genome-Wide Association Studies have found genetic variation from
across the genome to be associated with various diseases and other traits.
In many cases, the exact mechanism by which a genetic variant increases
or decreases the risk of a particular condition is poorly understood. Many
efforts are now underway to combine data on disease-associated genetic
variation with other genome-wide data to understand the way in which
genetic variation can alter genomic regulation and affect disease risk.
In this project we examine whether disease-associated genetic variation, in
the form of single nucleotide polymorphisms, can be found in binding sites
for the transcription factors T-bet in Th1 cells and GATA3 in Th1 or Th2
cells. We hypothesise that, in some cases, variation within binding sites for
these transcription factors could alter transcription factor binding affinity
and subsequent gene regulation. As ’master regulators’ of T helper cell lin-
eage commitment, T-bet and GATA3 play a central role in the fate of a naïve
T helper cell and the development of an immune response. We find several
single nucleotide polymorphisms in our transcription factor binding sites,
some of which are near other genomic features such as potential enhancer
elements. Furthermore, we find an enrichment of immune related SNPs in
T-bet and GATA3 binding sites compared to the total catalogue of Genome-
Wide Association Study hits. We then develop a medium throughput as-
say which combines oligonucleotide pulldown and flow cytometry to test
whether such SNPs alter transcription factor binding in vitro.
We find three SNPs, rs1465321, rs11135484 and rs1006353 which alter bind-
ing of T-bet in vitro. Of these, rs1465321 is associated with Crohn’s disease,
coeliac disease and ulcerative colitis and is in an intron for IL18R1. There-
fore, we examine the role of T-bet in IL18R1 expression, IL-18 signalling
and two mouse models of disease.
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In February 2001 the first drafts of the human genome were published in two
separate papers by two separate groups. The International Human Genome
Project, comprising researchers from 20 institutions from across six countries
officially published their first draft in the journal Nature1 although a working
draft of their work had been released through the UCSC genome server the pre-
vious year amid much public attention. At the same time Celera Genomics, a
private company, published their first draft in the journal Science.2 The publicly
funded paper estimated only 1.5% of the human genome was protein coding.
This figure was subject to caveats but current estimates are similar3 and the
overriding message has not changed in the intervening years. A high percent-
age of the human genome does not code directly for protein. However, since
the publication of the human genome, functional or potentially functional ele-
ments have been found in over 80% of the total genome. Researchers have dis-
covered new types of non coding RNA and new elements of gene regulation,
culminating most recently in the publications of the Encyclopaedia of DNA El-
ements (ENCODE) project.3 The functional diversity of much of the genome
highlights the need to understand its regulation at multiple levels. Acquiring
the necessary data to fully understand genomic regulation will be a research
intensive task. Although helped by the recent development of standardised
methods for data generation, sharing and analysis current research also needs
a way of prioritising the workload ahead. Which aspects of genomic regula-
tion, in which cellular and physiological contexts, should be studied such that
the broad scale work of ENCODE can be applied to understanding, and pos-
sibly manipulating, specific mechanisms involved in health and disease? We
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can partly prioritise research based on observing and understanding patterns
in the genomic data itself. However, we can also prioritise such work based on
specific questions arising from other research areas such as immunology where
a finely balanced system of T helper cell action and interaction is underpinned
by genomic regulation. In this project, we combine functional genomic analy-
sis with an understanding of T helper cell lineage commitment. We do this to
examine how genetic variation can usefully be annotated and tested for a po-
tential role in the immune system response and disease mechanism of multiple
diseases and other traits.
1.1 Annotating the Genome
1.1.1 Annotating the Genome at the Molecular Level
1.1.1.1 Epigenetics
The exact definition of an epigenetic modification varies. In general an epige-
netic modification is a chromatin modification that can be inherited by a daugh-
ter cell but does not alter the DNA sequence. However, there is evidence that
not all the modifications classed as epigenetic are inherited and even those that
can be inherited are reversible.4 By altering chromatin conformation, epige-
netic changes can regulate transcription. The two major types of epigenetic
modification are DNA methylation and histone modification. DNA methyla-
tion is the addition of a methyl group to a cytosine residue which acts to re-
press transcription. DNA methylation can prevent the binding of certain tran-
scription factors and also can recruit various repressive complexes. In humans,
DNA methylation occurs predominantly at the cytosine residues of CpG din-
ucleotides. Methylation has been observed at non CpG dinucleotides, particu-
larly at CpA in pluripotent cells, but at far lower levels.5 Although DNAmethy-
lation does not directly alter the DNA sequence, spontaneous deamination of
methylated cytosine produces a thiamine molecule which is then passed on as
TpG to daughter generations. As a consequence, the occurrence of CpG in most
regions of the genome is far lower than would be expected if DNA sequence
was random. Regions with higher levels of CpG tend to result from selective
pressure against prolonged methylation. Empirically, these CpG islands are
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found near genes. High levels of CpG can be associated with both transcription
factor binding, which often activates gene expression, and nucleosome occu-
pancy which represses it. The antagonism between these two mechanisms of
regulation allows cell specific modulation of transcription.6 DNA methylation
is catalysed predominantly byDnmt1. Dnmt1 recognises hemimethylatedDNA
produced during DNA replication and uses this as a template to methylate the
newly synthesised strand thus ensuring inheritance of the epigenetic mark. In
addition, de novomethylation can be catalysed by Dnmt3a and Dnmt3b. Methyl
marks can be lost either by active demethylation or through replication in cir-
cumstances of reduced Dnmt1 which prevents reproduction of the mark.
The core histone octamer comprises two of each of four different subunits, H2A,
H2B, H3 and H4. Each of the four subunits can be covalently modified in var-
ious ways including methylation, acetylation, phosphorylation, SUMOylation
and ubiquitination. Methylation and acetylation of the H3 subunit are two of
the best studied modifications. Of these two modifications, methylation is con-
sidered a slower more stable process, marking regions that are either generally
open to transcription or generally repressed in the particular lineage of cell un-
der investigation. By contrast, acetylation is a faster process marking regions
of active transcription at the time of cell fixation.7 While different methylation
marks can be associated with active or repressed regions, acetylation marks
tend only to be associated with active regions. Histone marks have been pro-
filed in a variety of cells, including T helper (CD4+) cells in mouse8 and hu-
man.9,10 Histone methylation is the addition of one, two or three methyl groups
to one of various lysine positions on a histone subunit. Such modifications are
denoted by the letter ’K’ for lysine followed by the position of the modified ly-
sine residue in the amino acid chain and then me1, me2 or me3 for mono- di-
or tri-methylation respectively. The position of modification and the number
or methyl units added determines the effect of the modification. For exam-
ple H3K4me3 is an activating mark whereas H3K27me3 is repressive. Histone
methylation marks are added by methyltransferases which contain the catalytic
SET domain and their removal is catalysed by the JmjC domain of demethy-
lases. Neither set of proteins is specific for a particular DNA sequence but they
are often found in multi-protein complexes and can be guided to specific areas
by other transcription factors.11 A general summary of the best characterised
marks and their role is given in table 1.1. It is becoming increasingly appar-
ent that the level of transcription results from an integration of multiple some-
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times opposing histone marks. A well known example is the superposition of
H3K4me3 and H3K27me3 which poises a gene for transcription.12 Therefore,
the need to integrate multiple datasets is apparent and efforts to do this are
ongoing.13 Acetylation also occurs at lysine residues and the same residues de-
tailed in table 1.1 have the potential to be acetylated to give H3K4ac, H3K9ac
and H3K36ac. Only one acetyl group is ever added and the modification is as-
sociated with active transcription regardless of which residue is modified.
Modification Genomic Location Repressive or
Activating
H3K4me1 Enhancers and approximately
1000 base pairs (bp) either side
of TSS
Activating
H3K4me2 Promoter regions Activating
H3K4me3 Promoter regions and Transcrip-
tional Start Site (TSS)
Activating
H3K9me2 10kbp around TSS Repressive
H3K9me3 10kbp around TSS Repressive
H3K27me3 Promoters Repressive
H3K36me3 Downstream of TSS Activating
Table 1.1: Summary of major histone methylation states.
The remaining histonemodifications, phosphorylation, SUMOylation and ubiq-
uitination are also all thought to have a role in transcriptional regulation of
gene expression.14 Phosphorylation is a spatially small modification but has
been shown necessary for specific recruitment of other proteins to the chro-
matin.15 By contrast, ubiquitin and SUMO are large modifications and may act
to help disrupt chromatin in elongation16 or antagonise other modifications and
repress transcription.17 However, less is known about these modifications and
work is still ongoing to understand the mechanisms by which these modifica-
tions exert a functional effect.
Nucleosome positioning is also often considered an epigenetic mark. While
wound round the histone octamer, DNA is inaccessible and cannot be tran-
scribed. Transcriptional activation, therefore, requires loosening of the DNA.
Traditionally, this has beenmeasured by hypersensitivity to DNase treatment as
the opened DNA is now accessible to the DNase enzyme. More recently, other
techniques have been used to determine DNA loosening such as Formalde-
hyde Assisted Isolation of Regulatory Elements (FAIRE) in which DNA is cross-
linked to nucleosomes and then subjected to sonication. DNA which is not
wound round and cannot be cross-linked to a nucleosome is enriched in the
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aqueous fraction of a subsequent phenol-chloroform extraction giving results
similar to those of DNase hypersensitivity assays.18
1.1.1.2 Transcription Factor Binding
A brief search for the term ’regulation of gene transcription, DNA dependant’
(GO0006355) in the Gene Ontology yields a list of 4377 gene products. (GO
ontology accessed 18th Sept 2012.) Understanding specific examples of and
key concepts behind genomic regulation by transcription factors was acceler-
ated by the introduction of Chromatin Immunoprecipitation (ChIP) followed by
hybridisation to microarray (ChIP-Chip).19 ChIP-Chip allowed the analysis of
transcription factor binding at promoter sites, and other sites thought important
enough to include on a microarray, across the genome. The later introduction
of Chromatin Immunoprecipitation followed by high-throughput sequencing
(ChIP-Seq) allowed identification of transcription factor binding across the en-
tire genome in a way that was independent of microarray probe choice and thus
location relative to coding DNA.20 It should be noted that there are potential is-
sues with the results obtained from from both ChIP-Chip and ChIP-Seq. Firstly,
the results will only be as good as the antibody used in the immunoprecipi-
tation step. The binding affinity and specificity of antibodies for the different
transcription factors varies. Because a monoclonal antibody only recognises
one epitope it will, in general, yield fewer peaks. A polyclonal antibody, by
contrast, will bind multiple epitopes on the transcription factor under investi-
gation and so produce more peaks. Without verifying all peaks using an im-
munoprecipitation independent method, or by comparing different antibodies
for the same transcription factor, it is difficult to say how many of the extra
peaks are real and how many are false positives. ChIP-Seq experiments pro-
duce a mixture of DNA fragments enriched for those bound to the transcription
factor under investigation which must be sequenced and then aligned back to
a reference genome. Downstream analysis is complicated by the need to de-
termine the level of sequence enrichment required to call a transcription factor
binding peak over background genomic DNA in the sample. Various commer-
cial and non commercial peak calling algorithms have been designed21 with
different strengths and weaknesses22 and methods for analysing data without
calling peaks have also been developed.3 Further interpretation, downstream
of peak calling, is complicated by the complex interplay between transcription
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factors and other genomic elements in the regulation of gene expression. In-
terpretation is also complicated because transient expression of a transcription
factor can leave lasting effects through epigenetic modification.23 Because tran-
scription factors recognise and bind to DNA, binding peaks are often examined
for a consensus sequence or Position Weight Motif (PWM). Motifs should be
treated with some care as many transcription factors have more than one mo-
tif.24 Furthermore, transcription is regulated by multiple factors binding to the
same locus. Therefore, the binding sites of any particular transcription factor
may contain sequences recognised by a partner rather than the transcription
factor itself. In some cases, a transcription factor may be present at a locus but
not bound to the DNA at all and thus not acting through recognition of DNA
sequence.6 For example TCF712 can be tethered to the genome by GATA3.25
Transcription factors can be relatively promiscuous in the sequences that they
will bind. In addition, many more instances of a given motif will occur in the
genome than will be bound by the transcription factor. These issues compli-
cate the interpretation of any given DNA sequence with respect to a motif. In
vivo, transcription factor binding and functional effect will depend heavily on
DNA sequence as captured by a PWM but also on binding of other transcrip-
tion factors and on epigenetic changes and chromatin structure. Nevertheless,
sequence alone can predict transcription factor binding and can even do so in a
tissue specific way,26 especially at regions closer to the transcriptional start site
(TSS) of a gene.27. Presumably, regions close to the TSS rely less on the long
range interactions employed by enhancers and other more distal elements. To
be maximally predictive, a match to a PWM must be interpreted in the context
of other genomic features and transcription factor co-binding. The availability
of large databases of PWMs such as JASPAR and TRANSFAC allow the ex-
amination of DNA regions for potential transcription factor binding sites. For
examining transcription factor co-binding these databases are a useful starting
point. The context dependent nature of tissue specific transcription factor bind-
ing demonstrates the importance of obtaining genomic information in the ap-
propriate cell type and cell context for the question under investigation. The re-
cent efforts of the ENCODE project have yielded vast quantities of high quality
data from which many general genomic lessons can be learnt. An appropriate
next step is to apply those lessons to the capture of genomic data in the ap-
propriate kinetic and cellular context to answer specific mechanistic questions
about disease basis.
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There are many published cases of specific genetic variation altering transcrip-
tion factor binding at promoter regions. Hummelshoj et al demonstrate that a
Single Nucleotide Polymorphism (SNP) in the promoter of SPP1 (also known
as ETA1 or Osteopontin) alters binding of the SP1 transcription factor and this
alters transcriptional activity as examined by luciferase assay.28 SP1 binding at
the IL10 promoter is also altered by a SNP.29 Less is known about the func-
tional consequences of altered transcription factor binding at the genome-wide
level. Interpreting data at this level is complicated by the non-linear relation-
ship between transcription factor binding and gene expression in many cases.30
However, by profiling binding of the general transcription factor Pol II and the
specific transcription factor NF-kB, Kasowski et alwere able to show substantial
differences in transcription factor binding strength between ten different lym-
phoblastoid cell lines. Some of these differences correlated with both the pres-
ence of a SNP and altered mRNA expression.31 More recently, the ENCODE
project has found that the combination of chromatin state and transcription fac-
tor binding at promoters can be quantitatively correlatedwith RNA production.
The ENCODE project also found that disease associated SNPs are enriched in
non-coding functional elements including transcription factor binding sites.3
Furthermore, a recent Genome-Wide Association Study (GWAS) found a SNP
associated with bipolar disorder within a binding site for the Oestrogen recep-
tor ER-a32 but they did not directly show altered binding.
So far, much of the work to examine whether a SNP alters transcription factor
binding and quantity of transcript produced has been based on correlations be-
tween ChIP-Seq or ChIP-Chip data, SNP data and variation in mRNA levels
with genotype. However, there are more direct ways of testing for the func-
tional effects of some SNPs. In the case where the SNPs in question are exonic,
then allele specific expression can be assayed in heterozygotes for that SNP. In
this case, the SNP appears in the mRNA transcript and so the relative levels
of mRNA transcribed from each allele of the SNP can be compared. Levels of
mRNA are normalised to the signal for genomic DNA to control for potential
differences in probe used, as the alleles will be in a 1:1 ratio in genomic DNA.
To apply a similar approach to the whole genome, cDNA can be hybridised
to a SNP array and relative abundance of the mRNA of two different alleles
can be examined at any region where the donor is heterozygous.33 SNP arrays
can also be used to assay the relative abundance of two alleles in samples that
have undergone ChIP.34 However, although these techniques are potentially
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very powerful, they are somewhat limited by the fact that SNP arrays do not
contain every single SNP. Furthermore, allele specific techniques require a large
amount of material from any one donor. As such, these techniques tend to use
either cell lines or immortalised cells, which raises some issues about the appli-
cability of the results to primary cells. These issues are discussed later.
1.1.1.3 Chromatin Interactions
Evidence for chromosomal looping between enhancer and promoter regions
was first published in 1989.35 As techniques for unbiased genome-wide analysis
of three dimensional chromosomal conformation have developed, the impor-
tance of regulation at this level has received increasing attention. Techniques
for mapping the three dimensional conformation of chromatin have evolved
from the Chromosome Conformation Capture (3C) technique.36 This technique
involves cross-linking proximal DNA regions, cutting the DNA by restriction
enzyme, ligating together the ends of the cross-linked products, reversing the
cross-links and then determining the sequence of the ligated products by Poly-
merase Chain Reaction (PCR).37 The cross-link step does not discriminate be-
tween DNA sections that are functionally interacting and those that happen to
be in close proximity at the time of fixation. Therefore, truly interacting DNA
sections must be registered as an enrichment against a background of randomly
ligated products. The 3C technique examines interactions between specific loci
but variations on the 3C technique, including 4C and 5C, have been developed.
While 3C examines the interactions between specific loci, 4C examines all pos-
sible interactions between a specific locus and the rest of the genome. In this
case, ligated products are circularised once the cross-links have been reversed.
Primers are designed against two sections of the locus of interest allowing any
interacting sections of the genome to be amplified by inverse PCR. These am-
plified sections can then be analysed by large scale sequencing or microarray.38
In 5C, a library of ligated fragments is generated in the same way as for the 3C
technique. However, primers are then designed to multiple different loci of in-
terest. Tags of extra sequence are added to each primer. These tags allow further
amplification of the product of any primer pair by universal primers. A further
round of amplification is then used to prepare a library suitable for large scale
sequencing or microarray analysis.39
It is also possible to incorporate ChIP into the 3C type methodologies to ex-
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amine the role of a transcription factor in the DNA interactions under investi-
gation. By combining high throughput sequencing, these methodologies have
also been adapted for unbiased analysis of chromatin interactions across the
whole genome with the advent of Hi-C40 and Chromatin Interaction Analysis
followed by Paired End Tag Sequencing (ChIA-Pet).41
Data on three dimensional chromatin structure have been conceptually useful
in understanding the annotation of the genome. For example, epigenetic marks
may imply a region of DNA is an enhancer element but without three dimen-
sional information we cannot be sure which genes it is an enhancer for. Typi-
cally, it is assumed that enhancers act on their nearest gene and this is often the
case but not always. For example, the regulatory elements of the alpha-globin
locus act on the gene NME4 which is 300 kilobase pairs (kbp) away, without
affecting genes between the two regions. This regulation is through physical
interaction between enhancer regions at the alpha-globin site and the promoter
ofNME4.42 Because theNME4 promoter and the promoter regions of the alpha-
globulin genes (of which there are two copies in a healthy individual) compete,
the authors found that deletion of one or both of the alpha globin genes in-
creased expression of NME4. This finding highlights the complex role that ge-
netic variation can have on gene expression. Recent results from the ENCODE
project suggest the promoter regions of the majority of genes are involved in
tissue specific ’multi-gene’ interactions.3 Chromosomal looping occurs both at
the IFNG locus and the locus containing the genes for IL-5, RAD50, IL-13 and
IL-4 (hereafter referred to as the Th2 cytokine locus). Furthermore, interactions
between the IFNG locus and the Th2 cytokine locus, which are on different chro-
mosomes, have also been reported in naïve CD4+ cells.43
1.1.1.4 Conservation Across Species
One major way of annotating the genome has been to find Conserved Noncod-
ing Sequences (CNS) which are sequences that are conserved between species.
This is based on the theory that elements that are functionally useful are un-
der negative selection and so are more likely to be retained through evolution.
Comparisons between the mouse and human genome for example have been
used in annotating multiple loci across the genome including the IFNG and Th2
cytokine loci. Although this relatively simple technique has been very useful,
we must be somewhat cautious. Comparison is often made, for example, be-
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tween mouse and human. Wide scale analyses of these genomes suggest that
the sequence and usage of some elements, such as promoters, are highly con-
served between these species. However, the sequence or the way in which other
elements are used, such as enhancers and binding sites for the transcriptional
repressor CCCTC-binding factor are more variable between species.44 In addi-
tion, regulatory function can be conserved across species without necessarily
conserving sequence.45 Furthermore, in the case of the immune system, contin-
ual changes driven by host-pathogen interaction may render this system less
likely to be conserved compared to other systems.
1.1.2 Annotating the Genome at the Functional Level
1.1.2.1 Transcription Level
To add another level of annotation to the genome, we can assess the impact of
genetic variation at a region on a downstream product. Much work has now
been done to correlate genetic variation with levels of transcription through
analyses of expression Quantitative Trait Loci (eQTL.) Although computation-
ally intensive and subject to issues around multiple testing, genome-wide com-
parisons between SNPs and gene expression can yield many useful insights.
However, as with genomic analyses, accurate transcriptomic analysis requires
the appropriate tissue or cell type.46,47
It is also important to realise that although RNA levels result from the inte-
gration of multiple genomic signals, they themselves will be moderated before
translation. Such modification may include the action of other RNAs and post-
transcriptional processing. We cannot assume that mRNA levels will always
correlate with downstream protein levels and other outputs. A recent study
suggested that approximately 40% of variation in protein levels was explained
by variation in mRNA levels, with much of the remaining variation explained
by the rate of translation.48,49 In terms of eQTL analysis, variation has been
found that affects the 5’ Untranslated Region (UTR) of a transcript and thus
affects protein expression at the translational level.50 There are practical trade-
offs to be made in transcriptomic analysis. We can analyse the transcriptome in
a very specific cell type that we think may be affected by a DNA variant, such
as effector T cells, to try and obtain a high signal to noise ratio in that particular
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cell type. However, this approach might leave us with low cell numbers. Al-
ternatively, we can use a broader category of cell type such as whole blood or
Peripheral BloodMononuclear Cells (PBMC). However, transcriptional changes
in one small subpopulation of amore heterogeneous population of cells may get
lost in the noise of our data. In the first case, cell numbers are often increased by
immortalisation of primary cells to form a cell line. Many transcriptomic anal-
yses have been performed on the Epstein-Barr immortalised cells produced by
the HapMap and 1000 Genome Project. The immortalisation process can itself
affect genome methylation and gene expression.51. Systematic studies suggest
transformation affects over half the genes in the genome but that the effects are
relatively small in magnitude.52 Information on transcriptional variation rele-
vant to primary cells can be obtained from such lines53 even though experi-
mental artefacts may produce false positives. However, it is still important to
be aware of the limitations of such cell lines. For the analysis of heterogeneous
populations of cells, work is ongoing to deconvolute signals from microarrays
bioinformatically.54
1.1.2.2 Transcription Product
Non coding functional classes of RNA, such as rRNA and tRNA, have long
been known. However, RNA molecules are involved in a wider range of pro-
cesses and other classes such as microRNAs (miRNAs), long noncoding RNAs
(lncRNAs), piwi-interacting RNAs and enhancer RNAs have been described.
The functions and mechanisms of many of these types of RNA are still being
elucidated. One of the better defined classes are miRNAs. Mature miRNAs are
RNA molecules of approximately 21 nucleotides that act to reduce expression
of their targets by targeting mRNA for degradation or translational inhibition.
Some miRNAs are known to have an important role in gene regulation. In a
non-immune context, the first discovered miRNA family member let-7 is con-
served across multiple species including mouse and human and is important
in development.55 In an immune context miR-146a targets STAT1. Loss of this
miRNA results in loss of immune tolerance and early death in amousemodel as
a consequence of impaired Treg function.56 Dysregulation of miRNA function
has been implicated in disease. Loss of function mutations in the miR-96 locus
causes nonsyndromic autosomal dominant progressive hearing loss.57 Some
cases of Feingold syndrome are caused by heterozygous deletion of the miR-
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17-92 cluster.58 Feingold syndrome is an autosomal dominant condition which
results in an unusually small head, abnormalities of the fingers and toes, learn-
ing disabilities and often heart or kidney defects. MicroRNA dysregulation is
also implicated in cancer and various cardiac conditions.59,60 Genetic variation
can impact on miRNA action by altering the expression level or sequence of the
miRNA itself, by altering the seed sequence of an mRNA target or by creating a
seed sequence in a novel target. Although no mendelian conditions have been
found to result from alteration of a target mRNA sequence, complex diseases
have been associated with both types of variation.60–62
Long noncoding RNAs are typically defined as non coding RNAmolecules that
are over 200bp long. Genome-wide transcript analyses have identified thou-
sands of lncRNAs which are now catalogued online.63 The importance of this
functional class in the regulation of immune genes was highlighted recently.
Tmevpg1, a lncRNA that is approximately 170kbp upstream of the IFNG locus
has been reported to have a role in Th1 cells.64
1.1.3 Annotating the Genome at the Clinical Level
1.1.3.1 The Genome-Wide Association Study
By understanding and annotating the genome at the molecular and functional
level, we can begin to understand how genomic variation can impact on host
phenotype. However, the analysis can work both ways: by studying host phe-
notype, we can understand more about the genome at the molecular level. Such
studies often involve analysis of genetic variation associated with specific phe-
notypes such as a particular disease. To date, one of the most widely studied
types of genetic variation between individuals is the Single Nucleotide Poly-
morphism (SNP). There is a vast literature documenting the role of various
SNPs in health and disease mainly resulting from two types of investigative
approach candidate and genome-wide.65 In candidate-based approaches, re-
searchers pick a small number of SNPs for study, based on prior biological
knowledge, andwork from these to find diseasemechanisms. More recently de-
veloped genome-wide approaches, such as Genome-Wide Association Studies
(GWAS), analyse thousands of SNPs across the entire genome in a non-directed
fashion. Such genome-wide techniques do not require prior hypotheses or par-
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ticular biological knowledge and so they can highlight previously unconsidered
biological pathways in a hypothesis-generating manner.
The most common form of GWAS is the case-control GWAS, in which the al-
lelic frequencies of SNPs from a population with a particular illness or other
trait are compared to SNPs from a control population. Although this method
can be applied to any trait and GWAS have been performed for non disease
traits such as mathematical ability,66 most GWAS analyse a diseased versus
a healthy population. Defining the relevant populations can be problematic
in practice. As GWAS itself has highlighted, diseases can be heterogeneous
at the molecular level, with multiple pathologies resulting in the same clin-
ical outcome.67 Understanding disease at this molecular level is one way in
which many researchers hope to start a move towards personalised medicine.68
GWAS results can also be skewed by variability in non-disease related traits
such as ethnicity and gender.65,69 However, GWAS have now been conducted
on a wide range of diseases yielding huge amounts of data and some important
insights. The first GWAS, conducted in 2005, highlighted the role of comple-
ment in age-related macular degeneration.70 Other successes include the role of
the autophagy pathway in Crohn’s disease.71
In many cases of Mendelian conditions, linking genetic variation back to
molecular mechanism at the genome level is relatively straight forward. For
Mendelian conditions, the disease will be caused by the presence of a highly
penetrant SNP or other genetic variant which can be linked to the disease by
analysing inheritance of the trait within families. Segregation analysis can be
used to narrow down candidates for the causal genetic variant of the disease to
the causal variant itself and any variants genetically linked or fixed to it. Such
candidates can then be tested for functional effect. Functionally, the genetic
variation underlying Mendelian conditions alters transcriptional product. Of-
ten, this is because the variation is in a protein coding sequence and results in
dysfunctional protein, although Mendelian conditions can occur as a result of
mutations in other contexts. Mutations at splice sites will also alter the protein
product of a gene and, as already discussed, mutations in other transcriptional
products such as miRNAs can also cause Mendelian conditions.
For complex diseases linking genetic variation, molecular mechanism and dis-
ease state is more challenging. The concept of causality in complex disease is
more complicated than in cases of Mendelian conditions. Complex diseases do
31
1.1 Annotating the Genome
not have one cause; rather they result from an interplay between multiple ge-
netic and environmental factors. In the case of complex disease, a causal SNP
will not independently cause the disease but exert a far more subtle effect. For
example a SNP may increase or decrease risk of disease or moderate disease re-
sponse to a particular set of environmental parameters. Because of this incom-
plete penetrance we cannot readily find genetic variants linked to a complex
disease in the same way as for a Mendelian condition. GWAS for complex con-
ditions have yielded a wealth of data on associations between different SNPs
and diseases. However, there are relatively few cases in which any particular
moderation of disease risk or course has been linked to just a few testable SNPs,
or where one causal SNP has been identified. More commonly, a GWAS will
highlight a region of highly co-inherited SNPs that are more common in a dis-
eased population than a healthy control population and are therefore described
as associated with the disease. SNPs can be co-inherited and the r2 value gives
a measure of how much the frequency at which two SNPs are co-inherited de-
viates from the frequency of co-inheritance we would expect if those SNPs were
inherited independently of each other.72 This is a measure of their linkage dis-
equilibrium (LD). A high r2 value shows that the SNPs deviate strongly from
a pattern of independent co-inheritance: they are in strong LD and likely to
be co-inherited. Practically, this is useful as we can infer information about
some SNPs from others and do not need to analyse every SNP in a genome to
find associations. Such work has been further aided by the efforts to categorise
LD patterns across the genome in multiple individuals from multiple ethnici-
ties in the HapMap project.73,74 However, it also means that a SNP associated
with a particular condition is not necessarily causal at the molecular level: it
may simply be in high LD with a causal SNP. There are also issues with relying
on data from HapMap to give every SNP in a population. The third iteration
of HapMap, HapMap 3, genotyped SNPs in 1184 individuals across 11 popu-
lations.74 In the example of the CEU population, which are individuals with
Northern and Western European ancestry living in Utah, genotyping was per-
formed on 55 trios to make a total of 165 samples. If we assume that the 110
parents have completely different genomes then the project is trying to capture
the variation in the population across 220 samples for each autosomal chromo-
some. Thus, any SNP at a minor allele frequency of 5% in the population (the
cut-off at which a SNP is considered a common SNP) has an approximately
0.0013% chance of being absent from the samples. This would suggest approxi-
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mately 20 of the 1.6 million SNPs tested might have been missed if all the SNPs
were on the threshold of being common variants. However, a greater propor-
tion of rare variants, with a minor allele frequency of less than 5% would have
been missed. Furthermore, the HapMap data relies on genotyping of specific
SNPs rather than using full sequence data. Although the number of SNPs geno-
typed is extensive, there is still potential for SNPs to be missed without direct
sequencing of the genome.
Finding the causal SNPs, linked to complex disease, may be possible genet-
ically through the use of fine mapping and sequencing over large cohorts of
patients and controls. Such fine mapping studies, such as those using the Im-
munoChip, have found that some genomic regions probably contain more than
one causal variant for certain diseases. For example, analysis of coeliac dis-
ease, using the ImmunoChip, found multiple independent signals in the loci
surrounding, among others, IRF4, STAT4, RGS1 and TAGAP.75 Such a fine level
of detail would have been missed in early GWAS where, for reasons of cost,
studies genotyped fewer SNPs per sample. However, mechanistically the dis-
covery of multiple independent signals in some loci is perhaps not surprising
given the extensive interactions between cis and trans factors in regulating gene
expression.
Finding the functional consequences of disease-associated SNPs can be chal-
lenging. Many disease-associated SNPs have been found to reside in so called
’gene deserts’, regions devoid of any coding sequence. Given our current un-
derstanding of genome regulation, as discussed above, it is likely that most of
these ’deserts’ do have function. Understanding that function in the appropri-
ate cell type, at the appropriate time and in the appropriate context is a huge
task but progress is being made. For example, a gene desert on chromosome
nine was recently found to contain multiple enhancer regions. SNPs associated
with coronary artery disease in one of these enhancer regions were shown to
alter STAT1 binding and subsequent expression of CDKN2A and CDKN2B fol-
lowing stimulation by IFN-g.76 Disease-associated SNPs are also found at the
5’ and 3’ ends of genes, in introns and at splice sites. Both synonymous and
nonsynonymous coding region SNPs are also found. Although the presence of
a nonsynonymous SNP immediately suggests a causal mechanism, not all re-
sult in dysfunctional protein.77 An immediate focus on nonsynonymous SNPs
to the neglect of other SNPs can miss SNPs with important regulatory effects.78
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Efforts to predict nonsynonymous SNPs that negatively affect protein function
are ongoing.79,80 Interestingly, nonsynonymous SNPs seem to have a similar
size of effect, in terms of disease association, to synonymous SNPs.81
Genome-wide analysis of disease-associated SNPs in functional elements has
been explored recently by the ENCODE project. This research found an enrich-
ment of SNPs from the National Human Genome Research Institute (NHGRI)
GWAS catalogue in transcription factor binding sites versus all SNPs from the
1000 Genome Project (12% NHGRI versus 6% 1000 genome).3 Most of the EN-
CODE work was performed on cells lines and to better understand any poten-
tial biological mechanism underlying this enrichment, it is important to study
individual cases in the appropriate cell types to the phenotype in question.
It is important to note that GWAS have only explained a small proportion of
the heritability of the traits that have been studied. There is lively debate as
to the source of this ’missing heritability’ centring around three possibilities.
There may be small contributions from many common SNPs that each have
effect sizes below the limit of detection by GWAS. Alternatively, larger contri-
butions from moderately penetrant SNPs, in which each SNP is too rare in the
population to be found by a large scale screen across the population, may have
a role. Finally, the missing heritability may result from an under-appreciation
of the effect of gene-environment interactions. There are many arguments for
and against these ideas82 and it is likely that different diseases will have dif-
ferent contributions from each of these effects. Arguments for the idea of rare
variants include work from large scale sequencing such as the 1000 Genome
Project that suggest any given genome will contain a high number of rare or
private variants. Current estimates are that any genome will differ from the
reference genome at approximately 10,000 nonsynonymous SNPs and a further
10,000 synonymous SNPs.83 Under the rare variant model, we would expect
some GWAS hits to tag, not one causal SNP, but several different rare variants
in different people. However these synthetic associations do not explain all
the success that GWAS have had. As some researchers have pointed out, the
quest to find missing heritability results, in part, from confusing heritability
with genetic contribution.84 Heritability is often measured from family stud-
ies. For example one measure, the relative risk between siblings, measures
the likelihood that an individual will develop a particular disease, given that
their sibling is affected, compared to the average risk of any member of the
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population developing that disease.85 This provides an estimate of heritability
but to take it as a measure of genetic contribution would be to ignore simi-
larities in environment between the two siblings.86 Indeed, it is worth noting
that, since the development of GWAS, other ’Wide Association Studies’ have
been performed such as the ’Environmental-Wide Association Study’87 and ’the
Epigenome-wide Association Study’.88 These studies highlight the need to gen-
erate and integrate data across multiple features. The epistatic effects which re-
sult from gene-environment interactions and also from gene-gene interactions
complicate the analysis of complex conditions. At the genetic level, functional
interaction between two SNPs has been observed in psoriasis.89 At the gene-
environment level, functional interaction between genetic disposition and an
obesogenic environment has been implicated in the rise of obesity and type II di-
abetes (TIID).90,91. As a more specific example, SNPs have been found that that
associate with increased incidence of oesophageal squamous cell carcinoma, but
only in alcohol drinkers.92. Thus, a genetic variation may ’cause’ a condition
but only under certain environmental conditions. The difficulties with measur-
ing and quantifying environmental factors and calculating gene-environment
interaction may explain some of the ’missing heritability’ problem.
1.1.4 Public Data and Open Access
The story of the human genome sequencing effort is often pitched as a race
between two groups, The International Human Genome Project consortium, a
publicly funded group and the private company Celera Genomics. Concerns
that private success and the patents that would follow would limit access to
and use of data on the genome, coupled with rapid improvements in sequenc-
ing techniques, pushed the public consortia to publish earlier than originally
planned.93 As a result, the two groups published their data together in 2001.1 2
By this point, the public consortium had already made a working draft of the
genome publicly available. A section of the Nature paper published by the
consortium outlines its commitment to collaboration and timely unrestricted
access to data. This has set the tone for much of the genomic research that has
followed. However, the sheer volume of data now available presents its own
challenges in terms of data storage, data analysis and data visualisation.
Many of the commonly used databases and tools for genomics are held and
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maintained either by the American National Centre for Biotechnology Infor-
mation (NCBI) (http://www.ncbi.nlm.nih.gov/) or by the European Bioinfor-
matics Institute and UK’s Sanger Centre under the Ensembl project (http://w-
ww.ensembl.org/index.html). There are discrepancies between the data held
by the two groups, for example, the list of Ensembl genes differs slightly from
the list of RefSeq (NCBI) genes.94 However, there is also huge overlap in the
data provided by each database and better characterised genes will have both
an Ensembl identification starting ENSG (ENST for the gene transcript) and a
RefSeq annotation starting NG (NM for the transcript). A Consensus Coding
Sequence identification is assigned when there is general consensus across the
major groups that a DNA sequence is a protein coding gene. There are numer-
ous other sources of genomic information but most will not be discussed here.
Of importance to the questions addressed in this project dbSNP, another NCBI
database, provides information on SNPs including published clinical relevance.
Because repositories such as dbSNP obtain their information from data submit-
ted by researchers, in the spirit of open access, the quality of work performed
to find and analyse any particular SNP varies. As such, dbSNP also provides
information on the source of information for each SNP and on the confidence in
the accuracy of the annotation provided. Another major source of information
on other genomic features is the recently released ENCODE data.3
Both Ensembl and NCBI provide tools for analysing genomic data. In addition,
the UCSC genome browser was introduced in the International Genome Project
consortium publication1 and remains an important tool in visually aligning
multiple datasets.95 Tools for more advanced analysis, many of which can be
readily used by researchers unfamiliar with bioinformatic tools, have been de-
veloped more recently. While the many modules of the Bioconductor toolkit96
require some basic knowledge of the R programming environment,97 other tools
such as Galaxy98–100 work through a user-friendly web based interface. A re-
view of some of the available tools has been performed by Nielson et al.101
1.1.5 Systematic Functional Annotation - The ENCODEProject
The ENCODE project aimed to identify all functional elements of the human
genome.102 It started with a pilot phase in September 2003 which analysed 44
discrete regions from across the genome. These regions were chosen to repre-
36
1.1 Annotating the Genome
sent a range of functional characteristics. In total, the 44 regions covered ap-
proximately 1% of the human genome. To assay such elements in a systematic
way, that could be shared and reproduced across laboratories, the ENCODE
consortium used existing standards and, where appropriate, developed new
standards for data acquisition, analysis and sharing. In some cases, the con-
sortium also used multiple experimental protocols for obtaining data on the
same biological function. For example, transcript analysis was performed by
hybridisation of RNA to tiling arrays, sequencing of 5’ ends of transcripts and
analysis of Expressed Sequence Tags. By the time of its publication in 2007,103
the pilot phase data had already been released, primarily through the UCSC
genome browser. Among its many findings, the pilot phase concluded that
much more of the genome is transcribed than is protein-coding. The pilot phase
also showed that, in contrast to what was previously thought, there are many
examples of non-coding functional genomic elements that are not constrained
across mammalian evolution.
The full ENCODE project, which investigated the full genome, was published
in September 2012 as 30 papers across the journals Nature, Genome Research,
Genome Biology and BMC Genetics. As previously mentioned, ENCODE was
able to assign functionality to just over 80% of the human genome.3 This in-
cluded elements such as protein coding genes, promoters and enhancers but
also regions bound by transcription factors and sites of DNase hypersensitiv-
ity. ENCODE studied such features across different cell lines and primary cells.
For the purposes of the ENCODE project, cells were grouped into three tiers.
Tier one, which consisted of three cell lines, was the most extensively studied.
The three cell lines for this tier were K562, a cell line of erythroleukemia lin-
eage, GM12878, a B lymphoblastoid cell line and the H1 hESC stem cell line.
These cells were subject to the full range of ENCODE techniques. We must
be slightly cautious in the data generated from these cell lines. K562 is a cell
line isolated from Chronic Lymphocytic Leukaemia and has an abnormal kary-
otype.104 GM12878 has been immortalised with Epstein-Barr virus which may
have affected some aspects of its genomic function as previously discussed. Fur-
thermore, these cell lines do not encompass all cell types or tissues. A wider
range of cells is found in tier three, including T cells of different CD4+ subsets,
but these have not been examined by every ENCODE technique. Some func-
tional elements specific to these cells alone, or to those cells not covered at all
by ENCODE, may still be discovered. Thus the 80% figure given by ENCODE
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may be subject to alteration in the future.
However, ENCODE has provided a wealth of useful data. In particular, much
work has been undertaken to find general signatures for different genomic re-
gions in terms of histone binding, DNase hypersensitivity and transcription fac-
tor binding. Such general signatures can then be applied to those cells and tis-
sues for which we have limited data, allowing us to infer function from the data
that we do have. For example, Th1 and Th2 cells were studied by ENCODE as
a tier three cell line and, therefore, only subjected to DNase hypersensitivity
assays. However, Arvey et al105 develop a framework for predicting cell-type
specific transcription factor binding based on DNase hypersensitivity and DNA
sequence. This framework could be applied to the DNase hypersensitivity data
in Th1 and Th2 cells. Natarajan et al106 perform similar work to predict gene ex-
pression from DNase hypersensitivity data, combined with transcription factor
binding motifs.
Of particular interest to the work in this project, Schaub et al107 use the ge-
nomic information found by ENCODE and other sources to functionally an-
notate SNPs from the NHGRI GWAS catalogue. They also determine which
SNP from all the SNPs in high LD with a disease-associated SNP is most likely
functionally relevant. Through this method, Schaub et al find potential func-
tional effects for up to 80% of reported associations. However, they do not try
to confirm the effect of these functional SNPs in vitro or in vivo. Furthermore,
given its reliance on ENCODE data, their work does not necessary use cells
and tissues specific to disease. Some of the work by Schaub et al is based on
a database, RegulomeDB which was produced by another ENCODE team.108
RegulomeDB can be used to find the functional relevance of any SNP across all
the data in the database, which includes all the ENCODE data and data from
other sources. The likelihood that any queried SNP has functional relevance
is ranked based on whether it forms part of an eQTL, whether it is in a tran-
scription factor binding site or peak of DNase hypersensitivity and whether it
alters a know transcription factor binding motif. Although the data included
in the database is extensive (962 datasets over more than 100 tissues and cell
lines), it is not exhaustive. If data for the binding of a particular transcription
factor or the DNase hypersensitivity of a particular cell type does not exist then
it will not be in the database and will not be included when ranking queried
SNPs. Use of the database carries this limitation, although the authors express
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the expectation that the database will grow with time as further whole genome
analyses are conducted and added to the database.
1.2 Overview of T Helper Cell Immunology
1.2.1 Activation of the Immune Response
To infect the body, a pathogen must first cross one or more of various barriers
such as the skin or mucosal lining of the airways or gut. Once past these initial
defences, the pathogen will encounter elements of the innate immune system.
Early immune activation is triggered, in large part, by molecules that are gen-
erally expressed across a range of pathogens but are either not expressed by
cells of the host or are spatially separated from components of the innate im-
mune system. This includes components of the bacterial cell membrane such as
Lipopolysaccharide (LPS)109 and nucleic acid structures used by some viruses
such as double stranded RNA.110 These Pathogen Associated Molecular Pat-
terns (PAMPs) are recognised by pattern recognition receptors on host cells
such as the Toll Like Receptors (TLRs)111 and by components of the comple-
ment system.112 TLRs are located on both the cell surface and in endosomes
and lysosomes. They are mainly found on cells of the innate immune system
but can also be found on cells of the adaptive immune system and on cells
of non-haematopoietic lineage.113 Signalling downstream of TLR engagement
uses the same pathways as the IL-1R family114 and includes molecules such as
MyD88 and members of the IRAK family. Engagement of TLRs in conjunction
with antigen triggers the maturation of dendritic cells (DC) which then migrate
to the secondary lymphoid tissues. Dendritic cells are the only type of Anti-
gen Presenting Cell (APC) able to present peptide to naïve T cells.115 Although
produced in the thymus, naïve T cells also migrate to the secondary lymphoid
tissue where they will, during an immune response, encounter activated DCs.
The way in which the adaptive immune response is activated will broadly re-
sult from an integration of three signals, antigen recognition, costimulation and
local cytokine environment.
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1.2.2 The T Helper Cell Lineages
1.2.2.1 Overview
Most mature T cells express the a and b subunits of the T Cell Receptor (TCR)
and can be divided into one of two types, cytotoxic T cells which express the
surface molecule CD8 (CD8+ cells) and helper T cells which express the surface
molecule CD4 (CD4+ cells). Other subsets such as gd T cells exist but will not be
detailed here. Naïve CD4+ cells are activated through TCR and costimulation.
Following rapid proliferation, they produce cytokines to direct the immune re-
sponse, activate and promote isotype switching in B cells116–118 and activate
macrophages.119 CD4+ cells are generally categorised into one of several sub-
sets according to their cytokine expression pattern and transcription factor ex-
pression profile. These subsets are Th1, Th2, Th17, regulatory T cells (Treg) and
follicular helper T cells (Tfh). In general terms, a viral infection will initiate a
Th1 response and Th1 cells will then produce, among others, the cytokine IFN-
g.120 There is some debate as to the primary role of the Th2 response but it is
thought to be protective against helminths121 and other extracellular pathogens
and it results in IgE production. Various studies have demonstrated that admin-
istration of IgE based antibodies could be an effective treatment against solid
tumours122–124 and inverse correlations between certain allergies and certain
forms of cancer have been published.125,126 This suggests that a strong Th2 re-
sponse may be protective against some cancers. However, a general role for the
Th2 response in cancer surveillance and protection remains ill-defined and con-
troversial. Th2 cells produce IL-4, IL-5 and IL-13. Feedback mechanisms have
been shown to skew an immune response to either Th1 or Th2, enhancing one
response while simultaneously repressing the other. Th17 cells have been char-
acterised more recently and are generally thought to be a response to extracel-
lular bacteria and fungi: they produce, among others, the cytokine IL-17.127,128
Tregs produce IL-10 and are generally considered anti-inflammatory cells which
dampen the immune response elicited by other T helper cell subsets.129 Tfh cells
help B cells: they are needed for the formation and maintenance of germinal
centres.130 Although Tfh cells are often considered a separate subset, the devel-
opment of Tfh cells intersects with that of the Th1 lineage.131,132 Autoimmune
and inflammatory diseases often arise from an overactive or improperly trig-
gered Th1 or Th17 response. It should be noted that the CD4+ cell subset model
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is somewhat simplistic. Other subsets such as Th9 and Th22 cells133 have been
described and there is growing evidence that the cell subsets are not as fixed or
clearly defined in vivo as they are after long term cell culture. These issues are
discussed in more detail later.
Each subset can be defined by a ’master regulator’, a transcription factor which
directs the expression programme for the subset and can inhibit other subsets.
The expression of each master regulator is not necessarily confined to its own
subset. Furthermore, a master regulator is traditionally defined as the transcrip-
tion factor required for the generation of a particular subset but questions have
arisen over how we define the subsets in light of recent data. Nevertheless,
the notion of a master regulator is conceptually useful. The master regulators
for Th1, Th2, Th17, Treg and Tfh are T-bet, GATA3, RORgT, FoxP3 and Bcl-6
respectively.134
1.2.2.2 Activation and Skewing of the Adaptive Immune System
To become active, a naïve CD4+ cell must receive two main signals which are
provided in the secondary lymphoid tissue by a matured DC. The TCR of the
CD4+ cell must bind its cognate antigenic peptide presented by the class II Ma-
jor Histocompatibility Complex (MHC) on the DC. In addition, costimulation
must be provided, usually by interaction between CD28 on the surface of the
CD4+ cell and CD80 or CD86 (also known as B7-1 and B7-2) on the surface of
the DC. The requirement for costimulation helps ensure that T cell responses are
only triggered in an inflammatory setting and not in response to self peptide.
Negative selection in the thymus results in autoreactive T cells being deleted or
undergoing a process of receptor editing such that they are no longer autoreac-
tive. However, some autoreactive T cells do reach maturity and further mecha-
nisms in the periphery must exist to prevent them causing autoimmune condi-
tions. T cells which engage TCR in the periphery without costimulation become
anergic. Although CD28-/- mice can still produce some T cell responses, they
are markedly diminished.135 As a further checkpoint on activation, various in-
hibitory molecules exist such as CTLA-4. CTLA-4 also binds CD80 and CD86
but with higher affinity than CD28, particularly in the case of CD80.136 The
mechanism bywhich CTLA-4 inhibits T cell activation is still widely debated.137
Possible mechanisms include downregulation of CD80 and CD86 on APCs by
CTLA-4 expressing Treg cells or reduction of costimulation due to competition
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between CD28 and CTLA-4 for the same ligands. Either way, this added check-
point helps prevent T cell activation by self- peptide. Knockout of CTLA-4 in
mice results in fatality within 3-4 weeks.138 CD80 and CD86 can modulate IL-4
and IFN-g production.139
Antigen signal strength can also affect the type of response: it is proposed that
low and high strength signals promote a Th2 type response andmiddle strength
signals promote a Th1 type response.140 Analyses of antigen signal strength and
costimulation suggest that the interplay between the two can influence commit-
ment to the Th1 or Th2 lineage as varying signal strength is measured against a
backdrop of thresholds set by costimulation.
A greater factor in CD4+ lineage commitment is the local cytokine environment
during activation. Commitment to the Th1 lineage is generally initiated by IFN-
g concurrent with TCR signalling. Although DCs can produce IFN-g, they are
not the major producers of this cytokine. TCR signalling can result in very low
levels of IFN-g secretion from the naïve CD4+ cell itself but extra IFN-g is pro-
vided by Natural Killer (NK) cells, which can also be recruited to the lymph
node under conditions of inflammation and infection141. In one model of Th1
lineage commitment, a preliminary burst of IFN-g allows an initial small upreg-
ulation of the Th1 master regulator T-bet. T-bet then upregulates the inducible
unit of the IL-12 receptor142 following extinction of the initial TCR signal.143
Under resting conditions, DCs do not produce IL-12 but they will do so when
activated through their TLRs. In fact, TLR engagement tends to produce mature
DCs that promote a Th1 rather than a Th2 response114,115 and thus the most ap-
propriate response to the invading pathogen is initiated. IL-12 activates the
transcription factor STAT4144 and this stabilises T-bet expression and reinforces
the Th1 response by further upregulating T-bet, IFN-g and various other Th1
related genes such as Runx3 and Hlx. Of note, this model implies two distinct
waves of T-bet expression modulated by different pathways.143 However, such
linearity has been questioned by recent data suggesting a high level of redun-
dancy between IL-12 and IFN-g in promoting the expression of T-bet.145 IFN-g
(in addition to TLR stimulation) can induce IL-12 production frommacrophages
which is an important feedback mechanism to continue the Th1 response after
the activated T cell has left the lymph node and migrated to the site of inflam-
mation.146
The Notch pathway is also important in Th1 versus Th2 lineage commit-
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ment.147,148 RBPJk (also known as CSL) binds constitutively at the promoter
of TBX21, the gene for T-bet, and can recruit transcriptional repressors to this
region. However, such repressors can be displaced by the intracellular domain
of Notch1 which then recruits transcriptional activators. Cells deficient in in-
tracellular Notch1 either due to knockdown by antisense construct or treatment
with gamma secretase inhibitor (GSI) are less able to produce IFN-g. Gamma
secretase is required to cleave total Notch1 and release the intracellular domain.
Cells treated with GSI have reduced expression of T-bet. However, expression
of T-bet and of IFN-g is restored through expression of a constitutive intracel-
lular domain of Notch1.149
Th2 lineage commitment is initiated by IL-4, although the initial source and
mechanism is still not fully defined. The lymph node contains very little if any
IL-4 but TCR signalling on its own can upregulate IL-4 transcription in an ac-
tivating CD4+ cell. This small amount of IL-4 can then act in an autocrine and
paracrine manner, signalling through STAT6, to upregulate GATA3 expression
and reinforce a Th2 programme.150 Furthermore, signalling through Lck, a Src
family kinase which is a key effector in TCR signalling, acts to inhibit Th1 type
responses. Kemp et al151 showed that naïve CD4+ cells from a mouse model in
which Lck is deleted in CD4+ cells in the periphery were less able to produce
IL-4 when cultured in Th2 polarising conditions. This was accompanied by in-
creases in Runx3, IFN-g and T-bet production. Epigenetically, Th2 cells from
these mice were normal at the Th2 cytokine locus but had permissive acetyla-
tion marks at the IFN-g locus which are usually only present in Th1 cells. This
suggests that defects in this aspect of TCR signalling result in decreased initial
commitment to the Th2 lineage not due to a failure to actively promote the Th2
lineage but due to a failure to actively repress Th1 commitment. This idea is
further enforced by the finding that Lck loss did not effect Th1, Th17 or Treg
lineage commitment in conditions designed to skew to those responses. Fur-
thermore, naïve cells have been shown to default to Th2 when activated under
neutral conditions.152 This suggests a situation in vivo in which Th2might be the
default immune response as has already been proposed.153 Microbial or fungal
antigens which need to be counteracted with a Th1 or Th17 type response in-
duce IL-12 or IL-23 production from DCs leading to a dominant Th1 or Th17
type response. By contrast, an absence of this stimulation, in cases where such
responses are not required, will allow a default to Th2.
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The Notch pathway has also been shown to have a role in Th2 lineage commit-
ment. In addition to activating T-bet, the intracellular domain of Notch1 can
also upregulate GATA3 and this increase in expression is independent of IL-4
and STAT6.148
On leaving the lymphoid tissue, the activated T cells migrates to the site of infec-
tion through various chemokine receptors. Th1 cells express CXCR3 and CCR5,
both of which are T-bet targets. Th1 cells promote B cell antibody switching to
IgG2a and activation of macrophages via the ’classical’ pathway. Th2 cells ex-
press CCR3, CCR4 and CCR8, and promote B cell antibody switching to IgE and
IgG4 in human or IgG1 in mouse. They can also promote eosinophil activation
and activation of macrophages via the ’alternative’ pathway.
1.2.2.3 A Note on the ’Textbook’ Lineage Definitions
The classification of cells into distinct subsets began with the observation by
Mosmann et al120 that T cell clones could be placed into one of two groups
based on their cytokine profile. The Th1 and Th2 subsets were shown to re-
spond to different types of pathogen and modulate the immune response in
different ways, as discussed above. Both subsets have their own ’master reg-
ulator’ transcription factor and once established in the body each subset uses
various mechanisms to repress the other lineage. Other types of CD4+ cell
which express different cytokine profiles, have since been discovered, requir-
ing the addition of new subsets to the model such as Th17 and Treg. However,
questions have been raised as to whether the classification of distinct subsets
really reflects the true nature of the CD4+ cells in an immune response in vivo
and whether the responses are as fixed as first thought. Repeated stimulation
and long term culture yields the distinct subsets seen by Mosmann et al and
different autoimmune conditions can be attributed to the overactivity of one
particular subset. Nevertheless, IFN-g production has been observed from cells
skewed to Th2 in vitro and in vivo.154,155 Furthermore, although IFN-g acts to re-
press early Th17 lineage commitment,156 it can later be produced by Th17 cells
themselves. As described by Lee et al, such cells may then lose production of
IL-17 in some conditions157 and these observations raise important questions
about lineage definitions. Th2 cells cannot, by definition, produce IFN-g if we
define Th2 on the basis of IL-4 production in the absence of IFN-g production;
cells which are not producing IL-17 are not, by definition Th17 cells if we define
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Th17 on the basis of IL-17 production. These issues highlight problems with
the subset model. At the level of transcription factors, GATA3 may be the mas-
ter regulator of the Th2 lineage but it is expressed in Th1 cells.158 Furthermore,
the master regulator of the Th1 lineage, T-bet, can be found in Treg cells.159 As
previously discussed master regulators remain poised for transcription even in
opposing lineages suggesting potential for reexpression. Furthermore, Th1 and
Tfh cells may share a common developmental stage131 and conditions of low
IL-2 can increase Bcl-6 expression in Th1 cells and promote expression of some
Tfh genes.132
1.2.3 Key Cytokines in the Classical Th1, Th2 Cell Model
1.2.3.1 IL-12
Sources of IL-12 include DCs, monocytes and macrophages.160 These cells must
be stimulated to produce IL-12 through a mixture of TLR ligation,114,115 CD40-
CD40L interaction with already activated T cells,161 and exposure to cytokines
such as IFN-g.162 The main targets of IL-12 are NK and T cells but IL-12 has
also been shown to have effects on macrophages162 and DCs themselves.163 IL-
12 consists of two chains p40 and p35. Of these, it is the availability of p35 that
limits the availability of functional IL-12. Upon stimulation p40 is more highly
expressed than p35. Spare p40 can bind another subunit, p19, to form IL-23 a
cytokine important in Th17 lineage commitment.164 In symmetry to IL-12, the
formation of IL-23 is restricted by the availability of the p19 subunit. The IL-12
receptor consists of two chains: IL12Rb1 is constitutively expressed on naïve T
cells, whereas IL12Rb2 must be activated by T-bet165 before a cell can respond
to IL-12. Interestingly, the constitutive IL12Rb1 can also bind to IL23R to form
a functional receptor for IL-23 in the same way that the IL-12 subunit p40 can
bind to a different subunit p19 to form the IL-23 protein.166 This highlights the
molecular interplay between the Th1 and Th17 lineages in early T cell lineage
commitment. IL-12 primarily activates the STAT4 pathway and, through this,
upregulates and helps to stabilise IFN-g production in a Th1 type response. (See
IFN-g section for further details.) IL-12 also works synergistically with IL-18 to
produce IFN-g independently of TCR engagement in pre-activated T cells and
in NK cells. IL-12 also activates Lck and the p38 pathway.167
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1.2.3.2 IFN-g
A fully functional IFN-g protein is a homodimer of two IFN-g peptide chains168
and is the only known member of the type II interferon family. Main sources
of IFN-g are Th1 cells, cytotoxic CD8+ T cells and NK cells, although B cells,
Natural Killer T (NKT) cells and APCs can also secrete this cytokine.146 As sug-
gested by its original name, Macrophage Activating Factor, IFN-g can act on
and is important in the maturation of macrophages but it is also very important
for the Th1 pathway. Naïve T cells require TCR stimulation for initial activation
but antigen experienced T cells can produce IFN-g in both a TCR dependant
and TCR independent manner.169 TCR independent IFN-g production results
from stimulation by IL-12 and IL-18, with the combination of these cytokines
working synergistically for maximal IFN-g expression.170 IL-12 and IL-18, also
induce IFN-g from non-T cells such as NK cells. IFN-g production is downreg-
ulated by IL-4 and TGF-b.171 The IFN-g receptor consists of two IFN-gR1 units
and two IFN-gR2 units. Signal transduction is usually limited by availability
of the IFN-gR2 unit. However, although low levels of IFN-gR2 are required for
signal transduction and proliferation in response to IFN-g, high levels of IFN-
gR2 and the consequentially high levels of signalling are antiproliferative and
promote apoptosis.172 The role of relative signal strength in determining out-
come is an important theme in immunology which can allow small variations
in signal to exert broad effects.
IFN-g activates STAT1. STAT1-/- mice are developmentally normal but cells
from these mice cannot respond to IFN-g and the mice show a similarly im-
paired response to the microbial pathogen Listeria monocytogenes as IFN-gR1-/-
mice.173 However, while STAT1 is important in IFN-g signalling, not all IFN-
g responsive genes are direct STAT1 targets. For example, IL1R1 is a STAT1
target which can be downregulated in macrophages by IFN-g. This leaves
macrophages unable to upregulate other non-STAT1 targets in response to IL-
1 such as various matrix metaloproteinases.174 In order to activate transcrip-
tion, the STAT proteins must oligomerise to form dimers or trimers. Although
IFN-g usually exerts its effects through STAT1 homodimers, it can also signal
through the STAT1:STAT2:IRF-9 trimer which is more typically associated with
type I interferon signalling. IFN-g signalling results in various phosphoryla-
tion events throughout the standard JAK-STAT signalling cascade.175 However,
to be fully effective, the STAT1 homodimer must also be phosphorylated at a
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serine residue by a separate signal which can originate from various sources
including IL-2, IL-12 or TNF-a.176
In terms of broader effects, IFN-g promotes immune responses by upregulat-
ing surface expression of MHC Class I and by promoting changes to the pro-
teasome that increase the diversity and the quantity of peptides presented to
CD8+ cells.146 IFN-g can also upregulate class II MHC.177 As previously men-
tioned, IFN-g can induce IL-12 production frommacrophages. It can also prime
macrophages by increasing expression of TLRs and inhibiting negative feed-
back loops that would otherwise dampen macrophage response to PAMPs.
For example, the IL-10 pathway is activated during TLR signalling and acts
to dampen the response to TLR signalling. However, IFN-g can act to antago-
nise IL-10 signalling in this setting.178 IFN-g drives the Th1 response, which
is generally considered pro-inflammatory. However, in doing so, it antago-
nises other T helper cell responses such as the Th17 response. It is notable
that IFN-g-/- mice develop worse responses in some models of autoimmunity
which were originally thought to be Th1 driven but are now believed to be
predominantly Th17 driven. These models include Experimental Autoimmune
Encephalomyelitis (EAE). The interplay between IFN-g and T-bet is also impor-
tant in immune modulation as T-bet represses the Th17 programme179 and is
expressed in some Treg cells to allow homing to sites of inflammation159.
Given its importance in immunology, the IFN-g locus has been well studied.
The complexity in its regulation provides an example of how multiple path-
ways and mechanisms can be integrated to fine-tune an output such as gene
expression. As shown by Soutto et al, a small region around the IFNG tran-
scriptional start site (TSS) (-565bp to +64bp) can promote IFN-g production in a
lineage specific way in CD4+ cells but not in CD8+ cells.180 The proximal IFNG
promoter region contains multiple monomeric Brachyury sites that are T-bet
responsive and show cooperation between sites.181 A full Brachyury site con-
tains the palindromic sequence CACxxxxGTG and is named after the Brachyury
protein, the founder member of the T-box family to which T-bet belongs. A
monomeric or half Brachyury site consists of CAC of GTG only. In CD4+ cells,
T-bet is the primary driver of IFN-g production. However, T-bet is partly func-
tionally redundant with another transcription factor Eomesodermin (Eomes)
in CD8+ cells which may explain the promoter region discrepancies between
CD4+ and CD8+ cells.182 Enhancer regions are found in introns one and three of
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the IFNG locus but these are not able to confer lineage specificity. Indeed amuch
larger region around the IFNG locus, stretching approximately 90kbp either side
of the protein coding region, is required for robust IFN-g expression that is also
lineage specific in both CD4+ and CD8+ cells.183 Regulatory elements in this
region have been found through comparing conservation of sequence between
species. Critical enhancers at CNS regions 22kbp (CNS-22) and 34kbp (CNS-
34) bind T-bet184 and CNS-34 is involved in DNA looping at the locus. Such
looping also involves other elements within the IFNG locus as well as an ele-
ment in an intron of IL16, the nearest gene to IFNG in humans but a gene that
is not conserved in mice.185 The looping also requires the CCCTC-binding fac-
tor and cohesin.186 Use of these elements is dynamic, changing throughout the
course of T helper cell lineage commitment. DNase profiling shows a changing
chromatin structure as a naïve CD4+ cell develops towards either the Th1 lin-
eage, where chromatin must be accessible and IFN-g must be highly expressed
or the Th2 lineage, where chromatin must be tight and IFN-g must be highly
repressed. Furthermore, the range of regulatory mechanisms employed allows
the expression of IFN-g to reflect the integration of TCR dependant and inde-
pendent pathways.170 In addition to interactions between regulatory elements
around the IFNG locus, interactions are also seen across chromosomes between
the IL4 and IFNG loci.43 Further details on the epigenetic control of the locus,
such as the other cis elements involved, have been reviewed by Balasubramani
et al.165
Important transcription factors that can bind at the IFNG locus include STAT4,
T-bet and NF-kB. The NF-kB family member RelA is activated downstream of
IL-18. RelA co-binds at the IFNG locus with STAT4 in TCR independent IFN-
g induction integrating the signals of IL-12 and IL-18. RelA is also important
in TCR dependant IFN-g production.170 STAT4-/- mice can produce IFN-g but
IFN-g production by STAT4-/- cells skewed to Th1 conditions in vitro is severely
impaired.187 IFN-g production is also severely impaired in CD4+ from T-bet-/-
mice, although IFN-g production by CD8+ is less impaired188 most likely due
to the redundancy between T-bet and Eomes in these cells.182
1.2.3.3 IL-18
IL-18 was originally identified as Interferon Gamma Inducing Factor.189 It func-
tions synergistically with IL-12 to induce TCR independent IFN-g production
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in Th1 cells.170,190 IL-18 is a more potent inducer of IFN-g than IL-12 but, un-
like IL-12, IL-18 cannot, on its own, induce a Th1 type response from a naïve
cell on primary stimulation. Once a naïve cell has been stimulated through
the TCR and becomes an effector memory Th1 cell then IL-18 and IL-12 can
promote IFN-g production independently of further TCR engagement on this
cell.190 IL-18 is produced as an inactive precursor, pro-IL-18, by a wide range
of cells including macrophages, B cells, T cells, DCs, keratinocytes and intesti-
nal epithelial cells. Pro-IL-18 is then usually cleaved to form mature IL-18 by
caspase-1 before being secreted from the cell.191 However, uncleaved pro-IL-18
can be found in human blood and is secreted by human PBMCs.192 It is then
possibly cleaved extracellularly by chymase. The chymase enzyme has been
shown to cleave IL-18 although at a different site to produce a mature IL-18
fragment with less activity than IL-18 that has been cleaved by caspase-1.193 The
IL-18 receptor can be expressed on a wide variety of cells including Th1 cells,
NK cells, macrophages, B cells, neutrophils and some endothelial and epithelial
cells.194 The IL-12 and IL-18 signalling pathways crossregulate: IL-18 signalling
upregulates the IL12Rb2 subunit but downregulates the IL-18 receptor itself
whereas IL-12 signalling upregulates the IL-18 receptor.195 The receptor com-
prises IL18R1 also called IL18Ra and IL18RAP (Receptor Accessory Protein)
also called IL18Rb. The IL18R1 subunit can weakly bind IL-18 and has limited
if any signalling capacity. The necessity for a further subunit, originally called
AcPL but later renamed to IL18RAP, was first demonstrated in 1998 by Born et
al.196 This finding was confirmed by mouse knockout model in 2005 by Cheung
et al.197 IL18RAP cannot bind IL-18 at all but, when bound to IL18R1 the re-
sulting complex can both bind to and allow signalling through IL-18. IL-18 sig-
nalling activates the MyD88/IRAK/TRAF6 pathway which ultimately results
in NF-kB activation and translocation.190,198 IL-18 can also activate the MAPK
cascade in mature T cells.199 IL-18 signalling can be inhibited by a decoy pro-
tein, IL-18 binding protein, that binds IL-18 and prevents it from binding to the
IL-18 receptor. Signalling through IL-18 is therefore, very similar to signalling
through IL-1b and IL-33. A summary of some of the IL-18, IFN-g and IL-12
signalling pathways discussed can be seen in figure 1.1.
In addition to IFN-g induction from Th1 cells, IL-18 is also needed for optimal
IFN-g induction from NK cells. As with Th1 cells, IL-18 can synergise with IL-
12 to optimally induce IFN-g from these cells. Furthermore, a role for IL-18 in
priming NK cells such that they can upregulate IFN-g in response to IL-12 has
49

















Figure 1.1: Main components in IL-12, IL-18 and IFN-g signalling pathways. -
Schematic of some of the signalling interactions between IL-12, IL-18 and IFN-g in
Th1 and other cell types. Many components omitted for clarity.
been described.200 Natural killer cells from IL-18 deficient mice are impaired
in IFN-g production compared to wild-type cells when stimulated with IL-12
in vitro. This defect is not seen when IL-18 signalling is blocked at the time
as IL-12 administration to wild-type cells suggesting a role for IL-18 signalling
upstream of IL-12 in this setting, a reversal of the kinetics seen in Th1 cells.
IL-18 signalling also enhances NK cell cytotoxicity.201 Both IL18R1-/- 202 and
IL18RAP -/- 197 mice fail to increase cell killing in response to IL-18 compared
to wild-type controls. These separate studies demonstrate that both IL18R1 and
IL18RAP are required to mediate this effect.
Initial studies of the IL-18 receptor demonstrated its expression on and impor-
tance for Th1 cells and its absence on Th2 cells.195 However, the role of IL-18
signalling in other settings involving CD4+ cells has been published. It has
been suggested that low levels of IL18R1 expression on naïve cells can allow
general inflammatory signalling that, in the absence of IL-12, can skew a cell to-
wards the Th2 type lineage. Yoshimoto et al203 demonstrated that activation of
CD4+ cells in the presence of IL-18 and IL-2 resulted in a higher percentage of
IL-4 producing cells and a lower percentage of IFN-g producing cells than cells
incubated with IL-2 alone. However, this result most likely reflects the plasticity
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of naïve cells during activation and the ease with which they can be artificially
encouraged to produce an array of different cytokines at this stage. IL-18 does
not have a specific role in IL-4 production. Epigenetically, the IL18R1 locus fol-
lows a similar trend to the IFNG locus. The chromatin at the IL18R1 locus is ac-
cessible in naïve CD4+ cells as shown by hypersensitivity to DNase treatment.
The locus is then activated in Th1 cells as seen by the addition of H3K4me2,
H3K4me3 and acetylation histone marks whereas the chromatin is tightened to
become actively repressed in the Th2 state.204 The poised state of the locus in
naïve cells could allow some IL18R1 expression. IL18R1 expression has been
demonstrated on unstimulated cells and it has been suggested that such ex-
pression is seen prior to cell activation but is then downregulated as a result
of CD3 ligation.190,204–206 In the presence of IL-12, IL18R1 is then upregulated
to be expressed at high levels, while it is further downregulated by IL-4.204,206
Such results must be interpreted with some caution as most experiments have
been performed on cultures enriched for all CD4+ cells including naïve, effector
and memory cells. Few experiments have been performed on the pure popula-
tions of naïve cells that can be obtained by sorting or using an antigen specific
system such as the D011.10 or OT-II systems on a background where all other
T cells have been deleted through deletion of one of the Recombination Activa-
tion Genes (RAG). However, the studies raise some interesting questions. Are
IL18R1 and IL18RAP definitely expressed on a pure population of naïve cells
and at what levels compared to Th1 and Th2? If they are expressed, are they
expressed at high enough levels to allow signalling? Furthermore, if IL-18 sig-
nalling can promote other lineages in the very early stages of CD4+ cell lineage
commitment then what subset of conditions, in terms of relative timings and
strengths of IL-12 and IL-18 signals, allow for non-Th1 pathways to be pursued
and how relevant is this to disease?
Fully polarised Th1 cells do not produce IL-4 in response to IL-18. However,
there are some studies to suggest that fully polarised Th1 cells can be induced
to produce the typically Th2 associated cytokine IL-13, by the presence of IL-18
in the absence of IL-12, on secondary stimulation in humans207 and mice.208
The levels of IL-13 produced are lower and later than in typical Th2 cells but
are nonetheless clearly present and are thought to have a role in asthma. It is
also thought that IL-18 can induce IL-17 production under certain conditions.
Studies by Lalor et al209 show that CD4+ mouse cells that are stimulated with
aCD3, aCD28 and IL-18 produce some IL-17. IL-17 production is synergisti-
51
1.2 Overview of T Helper Cell Immunology
cally increased by the addition of IL-23. Furthermore, the combination of IL-18
and IL-23 can induce IL-17 production on unstimulated cells whereas this can
not be achieved by either cytokine alone. These results add weight to the ar-
gument that IL-18 acts as a general inflammatory signal that can be directed in
its outcome by other cytokines. However, these experiments were performed
on a bulk CD4+ population. Therefore, we cannot determine the necessary or-
der of IL-18 and IL-23 presence and TCR engagement. We cannot distinguish
IL-17 production from naïve cells undergoing primary stimulation and effec-
tor cells undergoing a further round of stimulation. Furthermore, although the
authors use a model of EAE and show increased IL18R1 in diseased mice, they
do not directly correlate IL18R1 expression with IL-17 production in CD4+ cells.
Therefore, the role of IL18R1 expression on CD4+ cells in Th17 cell development
and maintenance remains to be fully defined. However, it has been shown that
IL18R1 expression on APCs is needed for the generation of Th17 in a mouse
model of EAE.210 This same study also suggests a role for IL18R1 that is inde-
pendent of IL-18 as discussed below.
In the general model, IL18R1 and IL18RAP bind to form a complex through
which IL-18 signals. However, there are some reports showing that the IL-18
receptor has functions which are independent of IL-18. For example, IL18R1-/-
mice are resistant to EAE inductionwhereas IL-18-/- mice are susceptible. How-
ever this is not thought to result from deficiency of IL18R1 on the CD4+ cells but
on APCs. In the model, IL18R1 deficient APCs were less able to secret the p40
subunit of IL-23.210 This does suggest that another ligand, possibly of the IL-
1 superfamily, can signal through IL18R1. Interestingly, in humans IL-37, also
named IL-1H or IL-1F7, has been shown to bind to IL18R1.211 However, the
EAE studies were performed in mice and this protein has not been identified
in mice. Furthermore, IL-37 is generally seen as an anti-inflammatory molecule
which antagonises IL-18 signalling.
It is unclear as to whether IL18R1 and IL18RAP are co-regulated in terms of
their expression. The two loci neighbour each other on chromosome two in hu-
mans and chromosome one in mice which suggests potential for co-regulation
and evidence for this has been found by some studies.204 However, in mice,
some reports suggest that while low levels of IL18R1 are expressed on naïve T
cells, IL18RAP is completely absent until IL-12 stimulation.212 This raises issues
about the capacity of IL-18 to induce non Th1 associated function, such as the
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production of IL-4, from naïve CD4+ cells in the absence of IL-12. Furthermore,
the two genes seem to vary in their relative requirement for various transcrip-
tion factors and chromatin modifications for expression.23,213 As with much of
the work in the field, most of the controversies are most likely due to differ-
ences in species, strain, timepoint of assay and definition of naïve cell used.
Greater clarity over the kinetics of IL-18 signalling with respect to these param-
eters would be useful for future research. Of note, in one of the coeliac GWAS,
Hunt et al found expression of IL18RAP but not IL18R1 in whole blood corre-
lated with genotype at one of their significantly associated SNPs, rs917997.214
In this case, the risk allele correlated with lower expression of IL18RAP. At a
genetic level, this strongly implicates IL18RAP and IL-18 signalling in coeliac
disease. At a mechanistic level it, again, raises questions around the extent to
which IL18R1 and IL18RAP are co-regulated and whether co-regulation varies
across different cell subsets. For example, we might ask whether expression of
IL18R1 would vary with genotype if we specifically studied a Th1 population
rather than whole blood.
Optimal expression of the IL-18 receptor requires STAT4 and T-bet.213 STAT4
binds the proximal promoter of the IL18R1 locus.23 T-bet binds the proximal
promoter of IL18RAP but not IL18R1.158 Interestingly, however, Thieu et al found
reduced but detectable expression of IL18RAP in cells from T-bet deficient mice
whereas they found no detectable IL18R1 in the same cells. This argues for a
central role of T-bet in IL18R1 expression and, by extension, demonstrates the
importance of transcription factor binding at locations other than the proximal
promoter. It also suggests that IL18R1 and IL18RAP are, at best, only partially
co-regulated. By contrast, Balasubramani et al found that IL18R1 expression
was impaired but not abrogated in T-bet deficient mice.170 Therefore, the role
of T-bet at this locus merits further investigation. Interestingly, the nearest up-
stream gene to IL18R1 is IL1RL1 which encodes the protein T1/ST2/IL-33R.
IL-33 is thought, in many ways to be the Th2 equivalent of IL-18.194
1.2.3.4 IL-4, IL-5 and IL-13
Unlike the IL-12 receptor, a functional IL-4 receptor is expressed on naïve CD4+
cells.150 On T cells, IL-4 receptor is a heterodimer of IL4Ra and the common
gamma chain, so called because it is a subunit not just of the IL-4 receptor but
also of the receptors for IL-2, IL-7, IL-9, IL-15 and IL-21. Small amounts of
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multiple cytokines including IL-4 but also IFN-g can be produced by cells on
activation through the TCR. However, a move from low level promiscuous cy-
tokine production to the sustained IL-4 production of a differentiated Th2 cell
requires the Th2 master regulator GATA3.215 GATA3 does not bind at the IL4
promoter and once a cell is fully committed to the Th2 lineage, IL-4 can be ex-
pressedwithout GATA3, although GATA3 is still required for maximal IL-4 pro-
duction.216 GATA3 does bind to a distal enhancer element of the IL4 locus along
with NFAT,217 a transcription factor that is expressed in both Th1 and Th2 cells
but with different targets in the two lineages. It is possible that IL-4 produc-
tion requires GATA3 dependant chromatin remodelling and subsequent NFAT
binding rather than GATA3 binding itself which would explain the variation in
GATA3 requirement with time. NFAT also binds the IL4 promoter as does the
Th2 lineage restricted transcription factor c-Maf.
GATA3 is required to maintain expression of both IL-13 and IL-5 in committed
Th2 cells.216 The genes for IL-4, IL-5 and IL-13 are all found close together in
the Th2 cytokine locus on chromosome five in humans and chromosome 11 in
mice. The genes for IL-4 and IL-13 neighbour each other and are separated
from the gene for IL-5 by the gene for Rad50. Rad50 is not a Th2 associated
protein but is ubiquitously expressed and involved in DNA repair. Although
GATA3 does not bind the promoter of IL4, it does bind throughout the region
including at the IL5218 and IL13219 promoters and the first intron of the IL4
gene.220 In naïve cells, the IL4 locus is transcriptionally poised with permissive
and repressive histone marks and heavy DNAmethylation. The locus becomes
less methylated as cells move towards Th2 lineage commitment and another
early role of GATA3 may be to antagonise DNA binding protein MBD2. MBD2
binds methylated DNA but such binding is prevented by GATA3.221
Various other epigenetic changes are seen as cells progress from naïve to Th2
and these have been reviewed by Ansel et al.150 Of note, many of the cis reg-
ulatory elements which control expression of IL-4 and IL-13 stretch across two
distinct regions, one containing the IL4 and IL13 genes themselves and a Lo-
cus Control Region (LCR). An LCR is a region which co-ordinately enhances
expression of more than one gene in a tissue specific fashion. In this case, the
LCR is a 25kbp region in the 3’ end of the RAD50 gene222 (fig. 1.2). Assays us-
ing the 3C technique have shown looping at the locus which brings IL-4, IL-13
and IL-5 together. This looping is seen even in non lymphocyte cells such as
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fibroblasts but in naïve T cells the LCR is also in the loop poising the locus for
transcription. In Th2 cells the interactions become stronger. Both GATA3 and




Figure 1.2: Relative arrangement of genes and LCR at Th2 cytokine locus. -
Schematic of chromosomal region containing genes for IL-4, IL-5, IL-13 and RAD50
showing relative location of LCR.
In addition to its role in Th2 cells, IL-4 is produced by mast cells, basophils,
eosinophils andNKT cells. IL-4 also promotes antibody switching, increases the
expression of class II MHC in B cells and modifies the expression of adhesion
molecules on endothelial surfaces.224
IL-13 signals through a dimer of IL13Ra1 and IL4Ra which is expressed on a
number of cells including epithelial cells, macrophages and eosinophils but not
T cells.225 IL-4 can also signal through this receptor and, for this reason, the
receptor complex is often called the type II IL-4 receptor (the type I receptor is
the heterodimer of IL-4Ra and the gamma common chain described above). IL-
13 shares many functions with IL-4 which, given the common receptor, is not
surprising. However, distinct functions of IL-13 have been characterised. IL-
4-/- mice can expel the gastrointestinal parasiteNippostrongylus brasiliensiswith
similar efficiency to wild-type mice but IL-13-/- mice have impaired goblet cell
function and take far longer to expel these parasites.226 Furthermore, IL-13 is
a more potent inducer of fibrosis than IL-4. This is seen in chronic infection
with Schistosoma mansoni which promotes a continual Th2 response. Although
the Th2 response is mounted to fight the infection, constant exposure to Th2
cytokines leads to liver scaring. Fibrosis is reduced in IL-4 deficient mice com-
pared to wild-type controls but is reduced substantially further in wild-type
mice treated with an IL-13 inhibitor.227
IL-5 signals through the IL-5 receptor, a dimer of IL5a and IL5b. While IL5a is
only used for IL-5 signalling, IL5b is shared with receptors for IL-3 and GM-
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CSF. IL5Ra is expressed by and is important for certain subset of B cells such as
murine B1 cells. The IL-5 receptor is also expressed on eosinophils and IL-5 is
required for parasite induced eosinophilia. However, IL-5-/- mice have base-
line numbers of eosinophils that are comparable to wild-type controls.228
1.2.4 Master Regulators
1.2.4.1 T-bet
Named for its original discovery as a T-Box motif protein Expressed in T
cells, T-bet was first discovered in 2000 as a protein that bound the IL2 pro-
moter and was expressed in Th1 but not Th2 cells.229 A full crystal structure
of T-bet has not yet been published but the DNA binding sections of human
TBX1,230 TBX3231 and TBX5232 and of the T-box family founder member Xeno-
pus Brachyury233 have all be crystallised. These structures suggest that T-box
proteins bind to DNA as dimers across a region of approximately 25bp, with
contacts made in both the major and minor grooves. The relative importance,
in maintaining a DNA binding dimer, of the protein-protein contacts at the
interface of each monomer versus the protein-DNA contacts that hold each
monomer onto the DNA seems to vary between the factors.231 The binding
of the T-box family members as dimers in addition to various in vitro analy-
sis would suggest a preference for palindromic consensus motifs based around
CACxxxxGTG for DNA binding. This motif is often referred to as the Brachyury
consensus motif. However, half sites (Brachyury half-sites) are common in T-
box regulated promoters in vivo implying that a half site is sufficient. The crys-
tallisation of the TBX5 T-box on a natural half-site promoter suggests that T-box
proteins still bind as dimers at half-sites and that the dimerisation is not an arte-
fact of crystallisation on a synthetic palindromic sequence. However, the T-box
proteins do not dimerise in free form- they are monomers when in solution.232
A consensus motif for T-bet has only just been published234 and work is till
ongoing to determine the specifics of T-bet binding to DNA.
T-bet is encoded by the gene TBX21. As a family, the T-box proteins tend to be
involved in development andmutations in several of the T-box family members
are strongly associated with disease. Mutations in TBX1 are associated with
DiGeorge syndrome, mutations in TBX3 cause Ulna-mammary syndrome and
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mutations in TBX5 cause Holt-Oram syndrome. There are no knownmendelian
conditions resulting from mutations in the TBX21 gene itself. Associations be-
tween SNPs in TBX21 and asthma235 and diabetes236 in Japanese patients have
been reported but not replicated. To date, disease-associated polymorphisms in
TBX21 have not been found from any large scale GWAS that meets the criteria
for inclusion in the NHGRI GWAS catalogue, although disease-associated poly-
morphisms have been found in TBX2, TBX3, TBX4, TBX5, TBX15 and TBX20
(http://www.genome.gov/gwastudies/index.cfm).
T-bet is best known as a transactivator of the IFNG locus. However, as its ti-
tle as ’master regulator’ suggests, it has far wider functions including IFN-g
independent suppression of the Th2 lineage.229 T-bet also binds to and influ-
ences expression of a number of other genes involved in Th1 function including
CXCR3237 and IL18RAP.158 T-bet is thought to bind at many genes but only in-
fluence expression at a subset of its targets.238 This was originally shown by
Beima et al, who also demonstrated that T-bet targets were similar across B, T
and NK cells. However, this study used cell lines rather than primary cells for
the initial ChIP experiments so such data should be interpreted with some cau-
tion. More recently Kanhere et al have shown that T-bet binds some genes both
proximally and distally and that the expression of these genes is more likely to
be regulated than those genes bound only proximally by T-bet.234
T-bet knockout mice are viable and mostly normal, with normal T and B cell
development although they have fewer peripheral NK and NKT cells and im-
paired NK and NKT cell development.239 Such mice are more susceptible to in-
fection withMycobacterium tuberculosis than wild-type mice240 and cannot clear
infection by Leishmania major188 among others, as expected, given the role of a
Th1 type response in fighting such conditions. They are also more affected by
Th17 type conditions as seen in various models of arthritis. This is presumably
because T-bet acts to negatively regulate the IL17 locus through sequestration of
the IL-17 activator Runx1.179 By contrast, they are resistant to those inflamma-
tory and auto-immune type conditions known to have a substantial Th1 type
component such as type I diabetes (TID).241 Expression of T-bet seems mostly
limited to the immune system.229 In addition to Th1 cells, T-bet expression can
also be seen in B cells, NK cells, DCs, CD8+ cells and Innate Lymphoid Cells
(ILCs). T-bet is involved in promoting antibody class switching and loss of T-
bet in B cells reduces class switching to IgG2a and prevents the B cell mediated
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pathologies of a mouse model of lupus.242 T-bet expressing DCs promote the
development of inflammation in a mouse model of rheumatoid arthritis which
is likely, in part, due to T-bet’s positive regulation of IL-1a and MIP-1a in these
cells.243 By contrast, T-bet negatively regulates TNFa production in DCs. Mice
lacking an adaptive immune system through deletion of Rag2 and also lacking
T-bet can develop spontaneous colitis. Colonic DCs in these TRUC (for T-bet
and Rag deficient Ulcerative Colitis) mice hyperproduce TNFa which is nec-
essary for development of the disease.244 Development of colitis in the TRUC
model also requires colonic ILCs. Wild-type ILCs can express T-bet which re-
presses expression of IL7RA and IL-17A. The higher production of these two
proteins contributes to the development of colitis in the TRUC model.245
As previously mentioned, loss of T-bet in NK cells affects their development
and it also reduces their ability to produce IFN-g and to lyse target cells. The
loss of T-bet in CD8+ cells affects their cytolytic ability and IFN-g production
downstream of specific antigen stimulation.246 However, the loss of T-bet is less
profound in CD8+ cells than in CD4+ cells due to redundancy between T-bet
and Eomes.188 182
T-bet interacts with a variety of different proteins in order to perform different
functions. It can recruit histonemodifiers such as JMJD3, a H3K27me3 and -me2
demethylase and SET7/9, a H3K4me2methytransferase.247 248 SinceH3K27me3
is a repressive mark whereas H3K4me2 is an activating mark, this allows T-
bet to both remove repressive marks and add activating marks at key genes.
Furthermore, because methylation marks are fairly stable and inheritable, some
of the effects of T-bet remain at the locus even if T-bet itself disengages.
In naïve CD4+ cells, the TBX21 locus is in a bivalent state and shows permis-
sive H3K4me3 and repressive H3K27me3 methylation. H3K27me3 is lost on
progression to Th1 commitment with accompanying increases in H3K4me3. In
the Th2 lineage, repressive H3K27me3 is increased but H3K4me3 is not com-
pletely lost. In Th17 and Treg cells the locus resembles the naïve state of com-
bined H3K4me3 and H3K27me3, suggesting that T-bet is poised and can be
reexpressed in these lineages.8 Indeed, T-bet expression is seen in a subset of
Treg cells that have been primed by IFN-g to suppress Th1 like inflammation.
The expression of T-bet in these cells allows homing of the Tregs to sites of Th1
type inflammation through the expression of T-bet target CXCR3.159 Coexpres-
sion of master regulators is not restricted to Treg cells. In addition to T-bet, Th1
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cells also express GATA3 which binds to many of its target genes, including IL4
and STAT6 in the Th1 lineage.158 Since IL-4 is not expressed in the Th1 lineage,
this further highlights the way in which gene expression results from integra-
tion of multiple genomic events and not, for example, just the binding of one
transcription factor. T-bet interacts physically with GATA3249 and co-binding
of T-bet and GATA3 in Th1 cells suggests that one role of T-bet in Th1 lineage
commitment is the redistribution of the GATA3 protein.234
T-bet physically interacts with many different proteins. An interaction with
the NF-kB subunit RelA allows T-bet to progressively inhibit IL-2 production
in CD4+ cells as they become Th1.250 T-bet can also physically interact with
Runx3 which is needed for optimal IFN-g production in Th1 cells251 and Runx1
to prevent activation of the Th17 master regulator RORgT179. At a functional
level, cooperation between T-bet and other transcription factors is even broader.
Of particular note to this project is the cooperation between T-bet and STAT4.
Unlike the master regulators, the STAT proteins have a very broad range of
targets and functions. However, in the context of the immune system, STAT1
and STAT4 are considered to cooperate in the Th1 lineage commitment while
STAT6 is involved in Th2 lineage commitment. STAT4 is required for proper
IFNG chromatin remodelling and IFN-g expression downstream of IL-18 sig-
nalling170 and for IL18R1 expression.213
1.2.4.2 GATA3
In contrast to T-bet, GATA3 has a key role in embryonic development and full
knockout of GATA3 in mice is embryonic lethal.252 In the mature organism,
GATA3 is needed for T cell development253 in addition to Th2 lineage commit-
ment and maintenance. In humans, there are six members of the GATA family
named for their recognition of the GATA motif, (A/T)GATA(A/G). In verte-
brates, the GATA family contains two highly conserved zinc fingers called the
C-finger and N-finger after the terminus to which they are closest.254 It is the
C finger that recognises the GATA motif, although the N finger can also bind
to DNA independently of the C finger, with preference for GATC rather than
GATA.255 Although the N finger generally binds less strongly than the C fin-
ger, it can bind sufficiently to activate gene expression. However, binding is
strengthened and stabilised when both fingers bind. Recent profiling of GATA3
binding has shown that the half sites to which these two fingers bind can either
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be three or four bp apart,6 highlighting the complexity of analysing transcrip-
tion factor binding from DNA sequence. Both fingers have also been shown to
be involved in protein-protein interactions which are thought vital not just for
GATA function but for GATA targeting to appropriate sites amongst a high fre-
quency of motif occurrences across the genome. X-ray crystal structures of the
C finger of mouse GATA3 have been published which suggest that the mode
of GATA3 binding depends on the DNA sequence and relative concentration of
GATA3.256 While single GATA motifs will bind a single C finger, double GATA
motifs may bind either both the C and N fingers of one GATA3 molecule or the
C terminal fingers of two GATA3 molecules depending on relative spacing of
the motifs and availability of a second GATA3 protein to bind.
In humans, the GATA family can be divided into two subfamilies. GATA1,
GATA2 and GATA3 are expressed and important in the haematopoietic sys-
tem while GATA4, GATA5 and GATA6 are mainly expressed in the heart, liver
and small muscle cells. However, there are exceptions to these generalisations.
GATA3, for example is also expressed in skin, prostrate and kidney. Consistent
with their key roles on development, mutations in five of the six GATA proteins
either cause or are associated with disease. The one exception is GATA5. Hap-
loinsufficiency in GATA3 causes Hypoparathyroidism, sensorineural Deafness,
and Renal disease (HDR), also known as Barakat syndrome.257 The NHGRI
GWAS catalogue reports a SNP in theGATA3 locus as associatedwithHodgkin’s
lymphoma and also reports disease associations for SNPs atGATA2,GATA4 and
GATA6.
GATA3 was originally described in chickens as NF-E1c.258 Of note, its expres-
sion was seen in cells of lymphoid lineage in contrast to GATA1 (then called
NF-E1) and GATA2 (then called NF-E1b). This lead a later study, examining the
role of the human and mouse homologue of this gene, to find abundant expres-
sion of GATA3 in human T cells and a role for GATA3 in activating transcription
of the human T Cell Receptor delta gene259. The role of GATA3 as the master
regulator of the Th2 lineage, needed for expression of the Th2 cytokines, was
later demonstrated by Zheng et al in 1997.215
The role of GATA3 in the immune system has been investigated using condi-
tional knockouts and complementation systems. Such studies have shown that
GATA3 is required for T cell development, in addition to its later role in Th2
lineage commitment.253 In terms of its role in Th2 lineage commitment, GATA3
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binds to the Th2 cytokine locus as discussed above. GATA3 can also autoac-
tivate its own locus independently of STAT6 and IL-4.260 Like T-bet, GATA3
interacts both physically and functionally with a number of different proteins.
For example, GATA3 physically interacts with Runx3 and this prevents GATA3
from binding to and activating its transcriptional targets.261 GATA3 can also
bind to the promoter of the Treg master regulator FOXP3 and inhibits the ex-
pression of this factor and commitment to the Treg lineage.262
Given its role in Th2 lineage commitment, it is unsurprising that GATA3 has
been implicated in pathologies associated with a Th2 type response. Higher
levels of GATA3 are seen in the airways of asthmatic patients263 and in nasal
biopsies from patients with allergic rhinitis.264 However high levels of GATA3
are also associated with breast cancer survival265,266 consistent with a role of
Th2 cells in cancer immunosurveillance.
1.2.5 Pathological Consequences of Immune System Dysregu-
lation
As discussed above, the immune system is finely balanced and the direction
of an immune response results from integration of many signals and events.
Mechanisms exist to keep the immune system balanced. However, the vari-
ous feedback mechanisms that allow strong, robust and recallable responses
to pathogens can also, if wrongly triggered, allow such responses to host tis-
sue or non pathogenic foreign substances such as drugs or food. This results
in autoimmune or inflammatory conditions. The most common conditions are
complex in nature, resulting from a range of genetic and environmental factors
and the interplay between the two. The relative contribution of genes and en-
vironment varies across the spectrum of common complex diseases and across
the people that suffer from them. To highlight some of these points, some of
the genetic and environmental factors and the role of the immune system in the
complex conditions of Type I Diabetes (T1D), coeliac disease, obesity and the in-
flammatory bowel diseases ulcerative colitis and Crohn’s are discussed briefly
below.
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1.2.5.1 Type I Diabetes
Diabetes usually results from an impaired ability to produce insulin in the body
(type I) or to respond to the insulin that is produced (type II). In both cases,
the body is unable to upregulate glucose metabolism and physical symptoms
include high levels of thirst and tiredness. As its alternative name, juvenile dia-
betes, suggests T1D commonly occurs in younger people. Until the medical use
of insulin began in 1922, T1D was a fatal condition. Although no fully effective
treatment exists, TID can now be controlled by regular injections of insulin com-
bined with healthy diet and other behaviours. More permanent treatments for
T1D including islet transplantation have been developed.267 However, techni-
cal issues remain and such treatments are not currently in widespread use.
The presence of autoantibodies and autoreactive T cells make T1D an exemplar
of autoimmunity. Genetically, the largest risk factor is the haplotype at the Hu-
man Leukocyte Antigen (HLA) Class II locus. At least 90% of patients have class
II HLA genes of type either DRB1*04-DQB1*0302 or DRB1*03.268 These presum-
ably allow good presentation of autoantigenic peptides such as peptides from
preproinsulin and glutamic acid decarboxylase to CD4+ cells. These CD4+ then
provide help to CD8+ cells in destroying the pancreatic tissue fromwhich those
peptides emanate. However, this is clearly not the only risk factor. Although
90% of patients have the risk alleles, only 5% of people with the risk alleles go on
to develop T1D.67 The haplotype at the HLA class I locus, which allows peptide
presentation directly to CD8+ T cells, is also a risk factor.269 Other risk alleles
are found at the insulin gene itself and various other immune-gene loci such as
CD25 (IL2Ra)270 and IL10.271 Rare protective variants have been found at the
IFIH1 locus highlighting the importance of rare variant hunting in addition to
GWAS.272 Some SNPs that predict increased risk in T1D predict decreased risk
in other conditions. For example, SNPs in the IL18RAP and TAGAP loci are as-
sociated with decreased risk of TID but increased risk of coeliac disease.273 In
general, there is much overlap between disease associated loci for the different
autoimmune and inflammatory conditions. For T1D, many of these overlap-
ping loci have been annotated on T1Dbase (http://www.t1dbase.org/page/-
Welcome/display). Overlapping loci include RGS1, which is associated with
T1D and also coeliac disease and multiple sclerosis. SNPs in IL10 are associ-
ated with ulcerative colitis and coeliac disease in addition to T1D and SNPs in
STAT4 are associated with T1D and also rheumatoid arthritis, systemic lupus
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erythematosus and, again, coeliac disease.
In terms of understanding the underlying immunology, GWAS have helped by
confirming the importance of the MHC region in disease susceptibility and sug-
gesting other avenues of investigation in understanding the disease. Such av-
enues have been reviewed recently268 and include a potential role for B cells, as
highlighted by the discovery of associated SNPs near BACH2, a gene involved
in B cell gene regulation.
The incidence of T1D has been steadily rising over the past few decades point-
ing to a role for environmental factors in disease mechanism. Type 1 dia-
betes was initially thought to be triggered by infection on a genetically sus-
ceptible background. However, more recent work has shown that, while some
pathogens can trigger the immune response, the relative lack of immune chal-
lenge in the modern world can also increase the risk of T1D. Evidence for other
environmental risk factors has also been found including early introduction to
solid food, childhood obesity and birth by caesarean section.274 Althoughmuch
work remains to be done to confirm and evaluate the roles of such factors, these
results highlight the complex interplay between different aspects of the immune
system and different environmental factors.
1.2.5.2 Ulcerative Colitis and Crohn’s Disease
Both ulcerative colitis and Crohn’s disease have an aberrant immune and in-
flammatory component and are thought to result from an immune reaction
to microbial products in the gut.67 Traditionally, these diseases have been de-
scribed as having distinct but overlapping pathologies. Macroscopically, ulcer-
ative colitis is characterised by ulcers in the colon and it has been categorised
as a Th2 type condition. Published genetic susceptibility loci include genes im-
portant for epithelial barrier function such as HNF4A.275 By contrast, Crohn’s
disease is characterised by lesions throughout the small and large bowel and
has generally been considered to be Th1 driven. GWAS susceptibility loci in-
clude NOD2 (also know as CARD15)276,277 and ATG1671 which has implicated
the innate immune system and autophagy in disease mechanism. However,
both diseases share multiple susceptibility genes, notably including some in-
volved in the Th17 lineage.278 Furthermore, a recent large meta-anlysis of the
two diseases has shown that, at the genetic level, the diseases are very similar.
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Most susceptibility loci are, in fact, shared between the two diseases. It is now
thought that the same biological pathways are involved, to a greater or lesser
extent in both conditions.279
The role of the immune system in both diseases has not only been highlighted
by genetic associations with immune related genes but also by various mouse
models. Transfer of naïve CD4+ cells into an immunodeficient host allows rapid
proliferation of the transferred cells and the mice lose weight and develop in-
flammation in the gut,280 although not if the transferred cells are deficient in T-
bet.281 Mice lacking an adaptive immune system through deletion of the RAG2
gene but also lacking the T-bet transcription factor can develop bowel diseases
resembling ulcerative colitis. Disease from these TRUC (T-bet-/- ⇥ Rag2-/-)
mice is transmissible to immunocompetent hosts and onset can be prevented by
antibiotic treatment which implicates bacteria in the disease initiation.244 One
bacterial species that can trigger colitis under these genetic conditions has now
been identified as Helicobacter typhlonius. Although there may be others, this
species was absent in a rederived T-bet-/-, Rag2-/- double knockout colony in
which the mice did not develop spontaneous colitis.245 Furthermore, adminis-
tration of H. typhlonius to members of the rederived colony induced colitis. By
contrast, administration ofH. typhlonius to Rag2-/- and T-bet sufficient mice did
not induce the same levels of colitis. This shows the importance of the interplay
between gut microbiota composition and a genetically susceptible background
for disease development.
Another example of this was described by Cadwell et al282 who showed that
administration of a persistent strain of murine norovirus can induce paneth cell
abnormalities in mice with mutant ATG16L1. These abnormalities are not seen
in wild-type mice infected with the same strain of norovirus or in ATG16L1mu-
tant mice without infection. Mutant mice carrying the infection displayed vil-
lus blunting on administration of low doses of dextran sodium sulphate which
was not seen in infected wild-type or non-infected mutant mice. Thus, a ge-
netic factor had allowed an invading pathogen to promote phenotypic abnor-
malities in the gut which then worsened outcome to a further environmental
challenge. Further examples of this interplay have been reviewed by Virgin
and Todd.67
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1.2.5.3 Coeliac Disease
In coeliac disease, an immune reaction is mounted to a foreign peptide but
one that is non pathogenic and present in food, specifically gluten. Although
it is therefore not strictly autoimmune, coeliac disease does share similarities
with T1D. Antibodies are found in the blood against the offending peptides
and to transglutaminase the enzyme that modifies them.283 Furthermore, the
HLA class II region has been found to be the strongest genetic susceptibility lo-
cus confirming the importance of the immune system in the disease284. Other
immune related susceptibility loci shared between Coeliac disease and T1D in-
clude CTLA4, TAGAP and IL18RAP although SNPs in IL18RAP and TAGAP
were shown to have opposite effects in susceptibility to or protection from T1D
and coeliac disease.273 The overlap in regions found by GWAS between coeliac
disease and T1D is not surprising as the two diseases have a tendency to co-
occur.285 Other disease susceptibility loci shared between coeliac disease and
other conditions include PTPN2 (shared with Crohn’s disease and T1D), ETS1
(sharedwith systemic lupus erythematosus) and LPP (sharedwith vitiligo).286
Studies of coeliac disease in monozygotic twins show a concordance of approx-
imately 75%,287 suggesting the disease is highly heritable with a strong genetic
component. However, symptoms are also entirely dependent on environment,
specifically the presence or absence of gluten in the diet, highlighting the im-
portance of the gene-environment interaction in disease progression.
Typical symptoms of coeliac disease include diarrhoea, bloating and abdominal
pain. In the UK, a diagnosis of coeliac disease follows a blood test for the appro-
priate antibodies and then a confirmatory biopsy of the small intestine. Because
of the highly heritable nature of coeliac disease, such testing is performed on
close family members of anyone who becomes diagnosed with coeliac disease
in addition to people with the typical symptoms. Testing is also performed on
type 1 diabetics. Coeliac disease is recorded to affect approximately 1% of the
population. However, there is some thought that this could be an underestimate
due to underreporting of milder cases.
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1.2.5.4 Obesity
Obesity is usually measured on the basis of a individual’s Body Mass Index,
with Body Mass Index of between 25 and 30 defined as overweight and of over
30 defined as obese. Obesity is associated with increased risk of type 2 diabetes,
cardiovascular disease and some types of cancer.288
Obesity rates started noticeably rising in high income countries in the 1970s. As
such, the rise has occurred over too brief a timescale to be fully attributed to ge-
netic changes. The increase has coincided with more food availability and less
requirement for physical activity (the so-called obesogenic environment). In-
terventions which tackle this environment, including low fat diet programmes
and reductions in advertising of unhealthy food to children have moderate to
strong evidence of effectiveness.289 Clearly then, the environment plays a huge
role in obesity. However, obesity is a heterogeneous condition and not all in-
dividuals in the obesogenic environment are obese suggesting other factors are
important. At the extreme end, rare cases of obesity have a very strong genetic
component. Leptin regulates the feeding response and disruption of the LEP
gene (also known as Ob) results in overeating and increase in body weight as
described in mice lacking the leptin gene (Ob/Ob mice).290,291 In humans, indi-
viduals that are homozygous for mutations in the LEP gene also develop severe
obesity associated with increased demand for feeding as a result of loss of leptin
secretion and function.292 Another condition, Prader-Wili syndrome, occurs be-
cause a section of the paternally derived chromosome 15 is not expressed, often
due to a 4Mbp deletion in the region293. Prader-Wili syndrome is characterised
by multiple behavioural and developmental issues but also food hoarding and
obesity.
More commonly, GWAS have found multiple regions associated with obesity.
The first GWAS hits, in the FTO gene, associated with an increased body mass
of 3kg in the homozygous risk allele group294 but other SNPs have been found
near genes such as MCAR4 and NPC1.295 Some risk loci have been found to
overlap between studies of extreme obesity and studies of overall Body Mass
Index suggesting that studying the genetics of extreme obesity can yield im-
portant insight into less extreme and more common forms of the condition.296
These loci include both FTO and MCAR4 as well as TMEM18, NRXN3, BDNF
and FAIM2. In addition to its association with Body Mass Index, FTO is also
associated with waist circumference and fat mass.
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The immune system has also been implicated in obesity, as has a role for the gut
microbiota. Weight loss is associated with changing microbiota composition
and germ free mice gavaged with microbiota from mice fed on a high fat ’West-
ern’ diet gain more weight than germ free mice gavaged with microbiota from
lean controls.297 Mice deficient for the innate immune molecule TLR5 have in-
sulin resistance, increased adiposity and a different microbiota from wild-type
controls. Microbiota from these mice can confer obesity and insulin resistance
when transferred to wild-type germ free mice.298 Furthermore, recent publica-
tions have shown the importance of adipose infiltration by immune cells such
as T cells and macrophages.299
1.3 Hypothesis
In this project, we hypothesise that some binding sites for the transcription fac-
tors T-bet and GATA3 will contain genetic variation in the form of SNPs, which
will alter the binding of the transcription factor to the DNA at that site and con-
sequentially alter the regulation of gene expression. Because T-bet and GATA3
have a central role in the development of an immune response we hypothesise
that such variation and its downstream effect on genomic regulation will alter
disease risk. As such, we hypothesise that this variation will be found amongst
the significantly disease-associated SNPs found in GWAS. Examining GWAS
SNPs with respect to genomic features such as the presence of a transcription
factor binding site will provide a way to causally link genetic variation and dis-
ease mechanism.
1.4 Aims
Specific aims of this project are:
1. To examine whether disease-associated genetic variation in the form of SNPs
found from GWAS can be analysed and annotated with respect to alterations
in transcription factor binding on a broad scale across multiple diseases and
traits.
2. To apply the ideas from large scale projects such as ENCODE to cells and
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transcription factors that are functionally relevant to disease mechanisms.
3. To establish and evaluate components of an in vitro pipeline for moving from
statistical association from wide-scale genomic data to an in vitro mechanism
and in vivo pathological consequences thus evaluating best way to move from
in silico analysis to disease effects.




2.1 In Silico Analysis
2.1.1 Determination and Annotation of SNPs in Binding Sites
for T-bet and GATA3
Data on binding sites for the transcription factors T-bet and GATA3 had previ-
ously been obtained by ChIP-Seq.234 The authors had performed the ChIP-Seq
for T-bet with a polyclonal antibody; ChIP-Seq for Gata3 had been with a mon-
oclonal antibody (D-16, Santa Cruz). Peak summits had been called from tag
coordinate bed files using MACS (Model-based Analysis of ChIP-Seq), normal-
ising to whole cell extract from Th1 or Th2 cells as appropriate, with a p-value
cut-off of 1 ⇥ 10 6. Binding sites were then defined as 100bp either side of
each summit. The GWAS catalogue was downloaded from the National Hu-
man Genome Research Institute (http://www.genome.gov/gwastudies/inde-
x.cfm) on November 4th 2011. Some entries did not contain information on the
chromosome on which the SNP was found and this was added in using db-
SNP (www.ncbi.nlm.nih.gov/projects/SNP/). In this process, two SNPs were
deleted as they were called suspect or unverified by dbSNP. SNPs on the X
and Y chromosomes were also deleted for the systematic analysis. Data was
analysed using the bioconductor snpMatrix package (now updated to snpStats)
within an in-house R based script (see appendix).96,97,300 Chromosomal loca-
tions of SNPs and identification of SNPs in high LD (r2> 0.8 with a SNP from
the GWAS catalogue) were obtained from HapMap3.74
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Tag coordinate bed files for H3K4me1, H3K4me3 andH3K27me3 ChIP-Seqwere
obtained from previously published data.10 Peaks were called using the MACS
algorithm on the Galaxy/Cistrome platform (http://cistrome.org/ap/root).301
We used a p-value cut-off of 1⇥ 10 6. Wewere unable to normalise the data to a
control dataset as there was none available. Therefore, normalisation was to lo-
cal genomic background within the sample (using lambda = TRUE as a setting
for MACS.) The MACS algorithm has been shown to function with reasonable
reliability under these conditions.302 We set the algorithm to deal with dupli-
cate tags by modelling the genome on ’Auto by Binomial’ and the data was
produced and analysed on the Hg18/b36 annotation of the human genome. All
other settings were kept as default. Peaks were taken as called and overlapped
with binding sites for T-bet or GATA3 using the main Galaxy platform (http://-
galaxyproject.org/).98–100 Overlap was performed by selecting the ’Operate on
Genomic Intervals’ and then the ’Intersect’ options within Galaxy. Intersection
returned full length of any transcription factor binding site that overlapped a
site of histone modification by at least 1bp. Data on DNase hypersensitivity was
obtained from ENCODE.303,304 (GEO Accession GSM736592 (for Th1 cells) and
GSM736502 (for Th2 cells)). The authors had isolated Th1 and Th2 cells from pe-
ripheral blood using bead based CD4+ T cell selection followed by Fluorescence
Activated Cell Sorting (FACS) based on expression of surface markers. Surface
markers for Th1 had been CD45RO+, CCR6-, CCR4-, CXCR3+. Surface mark-
ers for Th2 had been CD45RO+, CCR6-, CCR4+, CXCR3-). Cells had then been
subjected to DNase-Seq. Detailed protocols for data generation can be found on
the ENCODE website. Narrowpeak files on genome build Hg18/b36 were up-
loaded onto Galaxy. DNase hypersensitive peaks on autosomal chromosomes
in Th1 cells were intersected with binding sites for T-bet and for GATA3 in Th1
cells. DNase hypersensitive sites on autosomal chromosomes in Th2 cells were
intersected with binding sites for GATA3 in Th2 cells. Intersections were per-
formed as for histonemodifications. Transcription factor binding site peaks that
intersected a DNase hypersensitive site were analysed for the presence of SNPs
as above.
Locations of all hit SNPs were downloaded from dbSNP using dbSNP Batch
query (http://www.ncbi.nlm.nih.gov/SNP/batchquery.html). Results were re-
turned as a chromosome report which gave locations of all SNPs mapped to
genome build Hg19/ 37. We used Galaxy to obtain 100bp of sequence either
side of each SNP in FASTA format. These were submitted to MEME (Multiple
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Em for Motif Elicitation) through the web interface to search for other tran-
scription factor binding motifs. We also looked for published motifs for T-bet
and GATA3 using the dreg tool from European Molecular Biology Open Soft-
ware Suite (EMBOSS) and using the FIMO (Find Individual Motif Occurrences)
tool through the web interface.305,306 In each case the FASTA sequences were
submitted as obtained and also with each SNP manually altered to the opposite
allele using dbSNP for reference. For the dreg tool, we searched 20bp either
side of the SNP for the following regular expressions:
For T-bet: (tt[atcg][atcg]cac)|(cacac)|(gtgtg)|(gtg[atcg][atcg]aa)
For GATA3: (gata)|(tatc)
For the FIMO tool, we used the motifs generated for T-bet and GATA3 as gener-
ated by Kanhere et al234 and ran these against the entire 200bp FASTA sequence
as obtained from Galaxy.
2.1.2 Testing for Transcription Factor Co-binding
Potential binding of other transcription factors in the regions around hit-SNPs
was examined using MEME306 and TRAP (Transcription Factor Affinity Predic-
tion).307 For MEME analysis, sequences were uploaded onto web interface and
settings used for analysis were as follows:
Distribution of occurrences of a singlemotif across sequences =Any number
Minimum motif width = 3
Maximum motif width = 50
Maximum number of motifs to find = 10
All optional settings were left blank.
Results included many motifs that were not well conserved across multiple in-
put sequences. Manual examination revealed onemotif that waswell conserved
across multiple sequences and this was found to match the Runx motif by man-
ual comparison to the JASPAR database.
For TRAP analysis, sequences were uploaded onto the web interface and anal-
ysed for potential transcription factor binding events against the JASPAR ver-
tebrates database with background model of human promoters. TRAP ranks
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transcription factor binding based on biophysical measurements of affinity be-
tween DNA and transcription factor rather than using a PWM. The programme
returns a p-value reflecting the affinity measurement and a corrected p-value
which accounts for multiple testing over many sequences. Control sequences,
of the same length as the hit-SNP sequences, but that were chosen as random se-
quences from the human genome, were also analysed. The highest corrected p-
value reached for the control sequences was taken as the cut-off for background
noise in the hit-SNP analysis and only transcription factors scoring more highly
than this value are listed in the results.
2.1.3 Testing for Enrichment of Inflammatory Conditions
A list of all unique traits in the GWAS catalogue was compiled and each trait
was scored independently as definitely immunemediated (Y), possibly immune
mediated (?) or definitely non immune mediated (N) by three clinicians. Scores
were then aggregated. Final scores were assigned to traits using the system
shown in table 2.1 to give a list of conditions on which there was consensus of
definite immune involvement (Y) and a list of conditions in which there was
fair support for the idea of some immune involvement (?). These lists can be
found in the appendix. Of note, we were stricter with our definition of an im-
mune mediated trait than of a non immune mediated trait. This was because it
was the lists of immune mediated traits that we intended to use in our subse-
quent analysis. Hence, traits were only called strictly immune mediated if they
were scored as strictly immune mediated by all three clinicians. By contrast,
traits were classified as non immune mediated if they were were scored as non
immune mediated by all three clinicians or if they were scored as non immune
mediated by two clinicians and possibly immune mediated by a third.
Once each trait had been classified, SNPs were classified as strictly immune
mediated if they had only been found in GWAS for traits classified as Y, non-
immune mediated if they had only been found in GWAS for traits classified as
N and loosely immune mediated otherwise.
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Classification 1 Classification 2 Classification 3 Overall
Classification
Y Y Y Y
? Y Y ?
? ? Y ?
N N N N
? N N N
? ? N ?
Y N N ?
Y ? N ?
Table 2.1: Classifying traits. Traits in the NHGRI GWAS catalogue were classified
as to immune status by three clinicians (classification 1-3). Overall classification
was assigned based on independent classifications as shown.
2.1.4 Other Transcription Factors
Data for NF-kB binding sites was obtained from Kasowski et al31 (Geo Acces-
sion = GSE19486). The authors had performed ChIP-Seq on cross-linked cells
from different lymphoblastoid lines generated by the HapMap project. Data
had been processed through the Illumina pipeline and peaks called through the
PeakSeq pipeline. We combined all files for NF-kB binding in all the different
lines tested and merged intersecting peaks using Galaxy. We then analysed the
resulting dataset. Data for STAT4 binding was obtained from Liao et al308 (Geo
accession = GSE27158). The authors had sorted CD4+, CD45RA+ cells from hu-
man buffy coats, pre-activatedwith aCD3 and aCD28 and stimulatedwith IL-12
prior to cross-linking and ChIP-Seq. Reads had been mapped to the genome us-
ing the Illumina pipeline. Files were available as tag coordinate bed files which
we ran through the MACS analysis as with the methylation data but using a
p-value cut-off of 1⇥ 10 5. Data for ER-a binding was obtained from Stender
et al.309 Authors had performed ChIP-Seq in human breast cancer cells. Pro-
cessing of the peaks had been performed by authors using ELAND and peak
identification was by authors using HOMER.
2.2 Mice
Wild-type BALB/c and C57BL/6 mice were obtained from Charles River Labo-
ratories International (Margate, UK). T-bet-/- mice on both BALB/c (for adop-
tive transfer experiments) andC57BL/6 (for all other experiments) backgrounds
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were from Taconic (Ejby, Denmark). IFN-g-/- mice were on BALB/c back-
ground and were from Charles River Laboratories. Rag2-/- mice on BALB/c
background were from Harlan Laboratories (Indianapolis, USA) and Rag1-/-
mice on C57BL/6 background were a kind gift from R. Noelle. Mice were kept
at Charles River Laboratories and then transferred to in-house facilities at Kings
College London for experiments. Mice were kept in Specific Pathogen Free con-
ditions and in accordance with home office protocols under a laboratory wide
project license (reference number PPL70/6792). Mice were female except for
three recipient mice in the coeliac experiment which were male due to mouse
availability. Mice were between 4 and 12weeks of age at start of experiment and




Cells were cultured in High Glucose (4.5g/l) Dulbecco’s Modified Eagle
Medium (DMEM) (PAA) or Roswell Park Memorial Institute 1640 (RPMI)
medium (PAA). Both were purchased without L-Glutamine but then supple-
mented with 50 units/ml Penicillin, 50 µg/ml Streptomycin (obtained as com-
bined Pen-Strep fromGibco), 10 mMHEPES buffer solution (Fisher Scientific), 1
mM Sodium Pyruvate (Gibco), 1 ⇥Minimum Essential Medium-Non Essential
Amino Acids (Gibco), 2 mML-Glutamine (Gibco) and 10% Foetal Bovine Serum
(PAA). For culture of mouse cells, 50 µM 2-Mercaptoethanol (Gibco) was also
added. All cells were maintained at 37°C in 5% CO2. Centrifugation of cells
in preparation and analysis steps was at 652g for five minutes at either room
temperature (when preparing cells for culture) or 4°C (when preparing cells for
analysis) unless otherwise stated.
Phosphate Buffered Saline (PBS) without Ca2+ and Mg2+ was made in house
from tablets (Oxoid) dissolved in water and autoclaved as appropriate except
for coeliac model experiments where premade PBS (Gibco) was used.
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2.3.2 Isolation and Culture of Cells fromMice
Mouse CD4+ for culture and for in vivo models were obtained from spleen.
Spleens were forced through mesh (SEFAR, reference number 3053-1000-676-
00) to produce a single cell suspension. Red blood cells were lysed with
ACK Lysis Buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM Na2EDTA (all from
Sigma)). CD4+ cells were enriched from total population using CD4 (L3T4)
MACS beads (Miltenyi Biotec) according to manufacturers protocol. Naïve or
effector/memory CD4+ cells were then sorted by FACS based on markers for
CD4, CD25, CD62L and CD44 as detailed in text and in table 2.2. Purity in
post-sort analysis was typically 98% of live cells.
For cell culture experiments cells were activated in tissue culture treated 48 well
plates (Corning) that had been pre-coated at 4°C overnight with 2 µg/ml aCD3
(clone 145-2C11 from BioXCell) and 2 µg/ml aCD28 (clone 37.51 from BioXCell)
in PBS. To skew cells towards a Th1 phenotype, cells were plated at 1 ⇥ 106
per well in 0.5 ml RPMI supplemented as detailed above plus 20 ng/ml IL-12
(eBioscience, reference number 14-8121-62), 5 µg/ml aIL-4 (clone 11B11 from
BioXCell) and 20 ng/ml IL-2 (BioLegend, reference number 589102). For Th2
conditions, cells were cultured in RPMI plus 20 ng/ml IL-4 (eBioscience, refer-
ence number 14-8041-62), 20 ng/ml aIFN-g (clone XMG1.2 from BioXCell) and
20 ng/ml IL-2 (as for Th1). Cells were left for 36 hours and then a further 0.5 ml
RPMI containing the same cytokine and antibody cocktail was added per well.
Cells were removed from activation into new 48 well plates approximately 72
hours after initial plating depending on activation state and split as appropri-
ate. RPMI plus 20 ng/ml IL-2 was added whenever cells were split. Times for
IL18R1 expression timecourse were measured from time of removal from acti-
vation.
For in vivo experiments cells were resuspended in 250 µl PBS and injected in-
traperitoneally as detailed below.
For analysis, spleens were harvested as for cell culture and in vivo models but
either surface stained after red blood cell lysis with appropriate antibodies (as
detailed in table 2.2) or stimulated with Phorbol 12-myristate 13-acetate (PMA)
and Ionomycin prior to intracellular staining (as detailed below). Lymph nodes
were also harvested for some experiments. Single cell suspensions were made




2.3.3 Isolation and Culture of Cells from Human
Human CD4+ cells were obtained from buffy coats that had been obtained
through the National Blood Service or from whole blood from healthy vol-
unteers under REC reference number 10/H0804/65. CD4+ cells were isolated
using RosetteSep Human CD4+ T cell Enrichment Cocktail (STEMCELL Tech-
nologies) according to manufacturers instructions. Briefly, blood was incubated
with RosetteSep Mix and then layered over LSM 1077 Lymphocyte Separation
Medium (PAA). Sample was then placed in centrifuge and run at 652g for 30
minutes at room temperature with acceleration set to half of maximum and
with no break. CD4+ cells migrated to a central layer in the sample from which
they were removed by pasteur pipette and washed with PBS. CD4+ cells were
then activated in tissue culture treated 48 well plates that had been precoated
at 4°C overnight with 2 µg/ml aCD3e (clone UCHT1 from R&D systems) and 2
µg/ml aCD28 company (clone 37407 from R&D systems) in PBS.
To skew cells towards a Th1 phenotype, cells were plated at 1⇥ 106 per well in 1
ml supplemented RPMI plus 10 ng/ml IL-12 (R&D Systems, reference number
219-IL) and 10 µg/ml anti IL-4 (clone 34019 from R&D systems). After approx-
imately 48 hours, cells were activated and were removed from activation into
fresh 48 well plates. Cells were split as appropriate and wells were maintained
at a volume of 1 ml by addition of RPMI containing 10 ng/ml IL-2 (BioLegend,
reference number 589102). Cells were harvested to make lysate for OligoFlow
after seven days of culture.
2.3.4 Cell Lines
YT cells were a kind gift from S. Johm, EL-4 cells were a kind gift fromH. Stauss
and Jurkat cells were a kind gift from G. Lombardi. YT cells were maintained
in RPMI supplemented as described above. EL-4 and Jurkat cell lines were
maintained in DMEM supplemented as described above. All cell lines were
passaged every two to three days to a density of 1 ⇥ 106 per ml for YT cells,





Antibodies used for flow cytometry are detailed in (table 2.2.) All samples
were acquired on Canto, LSR II or Fortessa machines (BD Biosciences) using
Diva software. Multi-colour experiments were automatically compensated us-
ing One Comp eBeads (eBiosciences). Results were analysed in FlowJo version
7.6.3 (Tree Star Inc.)
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Table 2.2: Antibodies. Antibodies used for flow cytometry experiments.
Reagent Conjugation Clone Company Catalogue
Number
Dilution Used
Anti-Mouse CD62L eFluor450 MEL-14 eBioscience 48-0621-82 1:100 (for analysis)
or 1:20 (for sorting)
Anti-Human/Mouse CD44 FITC IM7 eBioscience 11-0441-82 1:100 (for analysis)
or 1:20 (for sorting)
Anti-Mouse CD4 PE-Cy7 GK1.5 eBioscience 25-0041-82 1:100 (for analysis)
or 1:20 (for sorting)
Anti-Mouse CD25 PE PC61.5 eBioscience 12-0251-81 1:100 (for analysis)
or 1:20 (for sorting)
Anti-Mouse CD25 Alexa700 PC61.5 eBioscience 56-0251-82 1:200
Anti-Human/Mouse T-bet PE eBio4B10 eBioscience 12-5825-80 1:150
Anti-Mouse IFN-g eFluor450 XMG1.2 eBioscience 48-7311-82 1:150
Anti-Mouse IFN-g FITC XMG1.2 eBioscience 11-7311-82 1:150
Anti-Mouse IL18Ra Alexa647 BG/IL18RA BioLegend 132903 1:40
Anti-Mouse CD4 APC-
eFluor780
RM4-5 eBioscience 47-0042-82 1:200
Anti-Mouse CD4 FITC GK1.5 eBioscience 11-0041-85 1:100
Anti-Mouse CD4 PE H129.19 BD
Biosciences
553652 1:200
Anti-Mouse CD3e PE-Cy7 145-2C11 eBioscience 25-0031-82 1:200
Anti-Mouse CD4 APC GK1.5 eBioscience 17-0041-82 1:20
Anti-Mouse CD25 APC-
eFluor780
PC61.5 eBioscience 47-0251-80 1:20
Anti-Human/Mouse CD44 PE-Cy7 IM7 eBioscience 25-0441-82 1:200 (for analysis)
or 1:20 (for sorting)
Anti-Mouse/Rat IL-17A PE eBio17B7 eBioscience 12-7177 1:150
Anti-Mouse IFN-g PE XMG1.2 eBioscience 12-7311-82 1:100
Anti-Human GATA3 Alexa488 L50-823 BD
Biosciences
560163 12.5 ng per Oligo-
Flow Sample
Anti-Human/Mouse T-bet eFlur660 eBio4B10 eBioscience 50-5825-80 0.1 µg per Oligo-
Flow Sample
Anti-Human/Mouse T-bet Alexa647 4B10 BioLegend 644803 Titrated to 0.25 µg
per OligoFlow Sam-
ple (see text)
2.4.2 Surface and Intracellular Staining
Any samples to be analysed for intracellular cytokines were incubated in RPMI
with 50 ng/ml PMA (Sigma) and 1 µM Ionomycin (Sigma) for two hours fol-
lowed by addition of 3 µM monensin (Sigma) for a further 2.5 hours. Samples
to be analysed were washed twice in PBS and incubated in 50 µl of 1:100 FcR
Blocking Reagent (Miltenyi Biotec) in PBS for 10 minutes at 4°C. The surface
stain consisted of 150 µl PBS containing surface antibodies (as detailed in text
and in table 2.2) and 0.5 µl Live/Dead Fixable Aqua stain (Invitrogen, reference
number L34957). Samples were incubated in the dark at room temperature for
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20 minutes. Samples were washed twice in PBS and then either resuspended
in PBS and acquired directly or fixed by resuspending in PBS and adding 37%
paraformaldehyde dropwise to a concentration of 4% and a final volume of 1
ml. Cells were incubated in the dark for 10 minutes at room temperature then
washed once in PBS. For surface stain experiments, cells were then resuspended
in PBS and kept at 4°C in the dark until acquisition not more than 48 hours after
fixation. For intracellular staining, after fixing, cells were washed once in Per-
meabilization Buffer (purchased as 10⇥ concentrate from eBioscience and di-
luted to 1⇥ with H2O) and then resupended in 150 µl Permeabilization Buffer
plus antibodies for intracellular components as detailed in text and in 2.2. Sam-
ples were incubated in the dark at room temperature for 20 minutes and then
washed twice in Permeabilization Buffer. Centrifugation of cells prior to per-
meabilization was at 652g for five minutes at 4°C. All washes after permeabi-
lization were at 887g for five minutes at 4°C. Samples were then resuspended
in PBS and acquired.
2.5 Array data
Array data on IL18R1 and IL18RAP expression in T-bet-/-, IFN-g-/- double
deficient cells transduced with T-bet or empty retrovirus was from Jenner et
al.158.
Data on IL18R1 and IL18RAP expression across T helper cells subsets in mice
had been generated in house.310,311 Briefly, naïve CD4+ cells from Balb/c or
C57BL/6 mice had been sorted by FACS based on expression of CD4+, CD25-,
CD62Lhi, CD44low. Cells for Th1, Th2 and Th17 had then been activated and
skewed to appropriate conditions for seven days before cell harvest and RNA
extraction for array. Balb/c cells for Th0 condition had been activated and cul-
tured inmedium plus IL-2 only for seven days. C57BL/6 cells for Thp condition
were sorted directly into TRIzol reagent (Invitrogen) for RNA extraction.
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2.6 In Vivo Disease Models
2.6.1 Coeliac Model
For the coeliac model, wild-type or T-bet -/- mice on C57BL/6 background
were injected with 200 µg gliadin (Sigma) which had been sieved through a
100 µm cell strainer (Fisherbrand) to create a fine powder, suspended in 2 µl
of 100% ethanol and then added to 100 µl Complete Freund’s Adjuvant (CFA)
(Sigma). Mice were then injected again 14 days later with 100 µg gliadin in 1 µl
of 100 % ethanol in 100µl Incomplete Freund’s Adjuvant (IFA) (Sigma). Spleens
were harvested 28 days after first injection. Effector/memory CD4+ cells were
then sorted by FACS as CD4+, CD25-, CD62Llow and CD44high. Cells were
resuspended in PBS and 4⇥ 105 effector/memory cells in 250 µl PBS were in-
jected intraperitoneally into Rag1-/- mice on C57BL/6 background. All mice
were maintained on RM3(E) pellets (Special Diet Services) which contains ap-
proximately 3-4% gliadin. Recipient mice were weighed once a week for eight
weeks and then sacrificed. Spleen and lymph nodes were harvested for analy-
sis by intracellular stain as detailed above and in results. Sections of proximal
small bowel were harvested and fixed in 10% paraformaldehyde for histology
staining or flash frozen in liquid nitrogen and stored at -80°C for RNA extrac-
tion and qPCR. Fixed histology sections were embedded in paraffin, cut and
stained with Haematoxylin and Eosin as detailed by Powell et al.245 For pheno-
typing the effector/memory cells used in the coeliac model, control mice were
injected with 100 µl CFA only and then 100 µl IFA only 14 days later or 100 µl
PBS followed by another 100 µl PBS 14 days later.
2.6.2 Adoptive TransferModel of Inflammatory BowelDisease
For the adoptive transfer model, naïve cells were prepared and sorted as above
and 5⇥ 105 cells in 250 µl PBS were injected into Rag2-/- hosts on Balb/c back-
ground. Recipient mice were sacrificed after 2 weeks or 4 weeks and spleen and
mesenteric lymph nodes were harvested and analysed by intracellular staining





Annealing buffer at 10 ⇥ concentration was 500 mM Tris pH8 (Fisher), 70 mM
MgCl2 (Fisher) and 10 mM Dithiothreitol (DTT, Sigma) and was diluted to 1 ⇥
with H2O as appropriate. Hypotonic buffer was 20 mM HEPES pH8 (Sigma),
10 mM KCl (Sigma), 1 mM MgCL2 (Fisher), 0.1% Triton-X (Sigma), 5% Glyc-
erol, (Fisher) 1 mM DTT and 1 ⇥ Protease inhibitors (made from Complete
Protease Inhibitor Cocktail tablets, Roche, reference number 11697498001). Hy-
pertonic buffer was 20 mM HEPES pH8, 400 mM NaCl (Fisher), 1 mM EDTA
(Sigma), 0.1% Triton (Sigma), 5% Glycerol, 1 mM DTT and 1 ⇥ protease in-
hibitors. Oligo buffer was 100 mM NaCl, 10 mM Tris pH8, 0.1 mM EDTA,
1 mM DTT, 5% Glycerol, 1 mg/ml Bovine Serum Albumin (BSA) Fraction V
(PAA), 20 µg/ml dI/dC (Sigma, reference number P4929) and 1 ⇥ protease in-
hibitor. Sodium Dodecyl Salt (SDS) loading buffer was made at 5 ⇥ concentra-
tion as 312.5 mM Tris pH 6.8, 50% glycerol, 2.5% SDS (Fisher) and bromophenol
blue (Sigma). Buffers were made fresh for each experiment except SDS loading
buffer which was stored at 5 ⇥ and then diluted to 1 ⇥ and supplemented with
2% 2-Mercaptoethanol (Sigma) immediately prior to use.
2.7.2 Oligonucleotides Used
Table 2.3: Oligonucleotides. Forward and reverse oligonucleotides used for
















































































































































































































































































A sequence of 52bp around each allele of each SNP to be tested was obtained
from dbSNP and this sequence was ordered with 5’ biotinylation (Integrated
DNA Technologies). The reverse complement of each sequence was also or-
dered unmodified (see table 2.3). Oligonucleotides were resuspended to a con-
centration of 100 µM and stored at -20°C. Complementary sequences were an-
nealed to produced double stranded oligonucleotides by mixing 10 µl of the
forward oligonucleotide with 10 µl of its reverse complement, 5 µl of 10 ⇥ an-
nealing buffer (described above) and 25 µl of DNase free water and incubating
in a thermocycler for the following cycle: 94°C for 5 minutes, 65°C for 10 min-
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utes, 25°C for 10 minutes and 4°C thereafter. Double stranded oligonucleotides
were kept at 4°C until same-day use or stored at -20°C for long term use. For
pulldown and Western blot, 20 µl of Streptavidin Agarose beads (Sigma) were
used per sample. For OligoFlow, 50 µl of Sphero Streptavidin Polystyrene Par-
ticles (Spherotech, reference number SVP-100-4) were used per sample. Beads
were washed twice in PBS and then once in 1⇥ anneal buffer. For each wash,
beads were centrifuged for three minutes at 7000g at room temperature, super-
natant was removed and beads were resuspended in 500 µl. Beads were then
incubated for one hour with oligonucleotides at 4°C. Beads were then washed
twice in oligo buffer and resuspended in 450 µl oligo buffer. Lysate was pre-
pared from between 10 and 30 million cells per sample. Cells used were YT or
human CD4+ cells cultured to Th1 in vitro for T-bet pulldowns or Jurkat cells
for GATA3 pulldowns. Cells were washed twice in PBS and then resuspended
in 1 ml hypotonic buffer and incubated on ice for five minutes. Lysed cells were
pelleted at 4700g for five minutes, resuspended in 150 µl hypertonic buffer and
vortexed vigorously for 12 minutes at 4°C. Debris was pelleted by centrifuga-
tion at 16000g for five minutes and 180 µl of supernatant containing nuclear
extract was added to each sample. Samples were incubated on a rotor for one
hour at 4°C. For Western blotting, samples were then washed three times in
Oligo Buffer, resuspended in 25 µl SDS loading buffer and stored at -20°C until
Western blot. For OligoFlow, antibody was added as appropriate (see text and
table 2.2) and samples were covered and incubated for a further 1hr at 4°C. Sam-




















Firefly luciferase SNP testing constructs were based on PGL4.13 plasmid
(Promega). All PCR programmes used in the construction of luciferase assay
constructs were: 95.0°C for 5 minutes followed by 35 cycles of 95°C for 30s, ap-
propriate annealing temperature for 30s and 72°C for 1 minute. PCR was then
held at 72°C for 10 minutes and 4°C thereafter. Annealing temperature varied
for different amplifications and is specified in each case below. IFNG promoter
region from -456 to +68, relative to TSS was amplified using primers contain-
ing restriction sites for BglI (forward primer) or HindIII (reverse primer). PCR
reaction mix was 1 µM IFNG promoter forward primer, 1 µM IFNG promoter
reverse Primer, 1 µl template DNA and 22 µl Accuprime Pfx SuperMix (Invit-
rogen) in a final volume of 25 µl. Annealing temperature for PCR was 55°C.
PCR product was gel purified and excised band was extracted with QIAquick
Gel Extraction Kit (Qiagen). Resultant DNA product was digested with HindIII
and BglII (both from New England Biolabs) and digested product was cleaned
using QIAquick PCR Purification kit (Qiagen). PGL4.13 vector was digested
with HindIII and BglII which removed unwanted SV40 promoter sequence. Re-
sulting PGL4.13 backbone was gel purified as above. PGL4.13 backbone and
IFNG promoter were ligated using T4 ligase (New England Biolabs). A 441
bp region around the SNP rs1465321 was amplified from genomic DNA using
primers containing restriction sites for NheI and XhoI. PCR reaction mix was as
for IFNG promoter region except primers were ’Amplifying rs1465321’ primers
detailed in table 2.4. Annealing temperature for amplification was 54°C. Once
IFNG promoter had been successfully placed into PGL4.13 then vector was di-
gested further with NheI and XhoI (both from New England Biolabs) and the
region around rs1465321 was inserted using same method as for insertion of
IFNG promoter region detailed above. Mutation of SNP to opposing allele
was performed as previously described.312 Briefly, two primers were designed
against the region containing the rs1465321 SNP with base pair mismatch at
the SNP itself. These ’Altering rs1465321’ primers (as detailed in table 2.4)
were paired with the ’Amplifying rs1465321’ such that the forward ’Altering
rs1465321’ primer was used in reaction with the reverse ’Amplifying rs1465321’
primer and vice versa to produce two half regions containing the opposite allele
of the SNP. Remainder of PCR reaction mix was as before. Annealing temper-
ature was 53°C. Products were gel purified as before and used as template for
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a further round of PCR with ’Amplifying rs1465321’ primers to produce full
length DNA with the required mutation. Annealing temperature for final step
was 53°C. DNAwas digested and ligated into IFNG promoter containing vector






















Figure 2.1: Luciferase construct for testing functional effect of altered T-bet bind-
ing at rs1465321. - Construct was based on PGL4.13 backbone with IFNG promoter
and region surrounding rs1465321.
Human cDNA sequence for T-bet was digested from TOPO vector (Invitrogen)
using XhoI and HindIII restriction enzymes (both New England Biolabs). Ex-
pression construct was based on pcDNA3.1 (+) (Invitrogen) and was also di-
gested using XhoI and HindIII. T-bet sequence was ligated into construct as
described for IFNG construct. All constructs were sequence checked before use
and T-bet expression was tested by flow cytometry (fig. 2.2). Renilla luciferase






























Figure 2.2: T-bet expression from T-bet expression construct. - EL-4 cells were
electroporated with T-bet expression plasmid and then stained for T-bet. Cells were
also stained with Live/Dead Aqua to allow for gating on live cells as seen in (a).
(b) EL-4 cells from culture showed no T-bet expression. (c) Electroporated cells
showed some T-bet expression.
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2.8.3 Cell Transfection
EL-4 cells were triple transfected with 3 µg promoter construct, 6 µg expression
construct and 0.3 µg renilla construct using the Nucleofector 4D system (Lonza).
Transfection was as per manufacturers protocol except buffer used was manu-
facturers SG buffer and programme was CM-150 based on troubleshooting to
improve viability and transfection efficiency. Each transfection was with 2⇥ 106
cells. Following electroporation, cells were rested for five minutes at 37°C in
500 µl RPMI before transfer to well of 24 well plate containing 1 ml pre-warmed
DMEM. Cells were cultured for 20 to 30 hours before stimulation for 4.5 hrs
with 50 ng/ml PMA and 1 µM Ionomycin. Cells were then harvested, washed
once in PBS and luciferase assay was performed using Dual Luciferase Reporter
Assay (Promega) as per manufacturers instructions. Luminescence was read on
a Lumat LB9507 luminometer (Berthold Technologies).
2.9 Timecourse of IL-18 Signalling
Naïve cells from wild-type or T-bet-/- mice were harvested, FACS sorted, acti-
vated and cultured in Th1 skewing conditions for six days as described above.
Cells were then harvested, washed once in PBS, once in X-Vivo 20 medium
(Lonza, reference number BE04-448G) and then replated at 2⇥ 106 in 1 ml X-
Vivo 20 medium. Cells were incubated for 90 minutes at 37°C and then 200
ng/ml of recombinant mouse IL-18 (R&D Systems, reference number B002-5)
was added to one well at a time at 5 or 10 minute intervals over 40 minutes.
Cells were then immediately harvested into ice cold PBS and centrifuged to
wash. PBS was fully removed and cells were resuspended in 150 µl ice cold
RIPA buffer (Sigma) which had been supplemented with 1 tablet of Complete
Protease Inhibitor Cocktail per 10 ml RIPA and 1⇥ Phosphatase Inhibitor Cock-
tail 1 (Sigma, reference number P2850) and 1 ⇥ Phosphatase Inhibitor Cocktail
2 (Sigma, reference number P5726). Cells were incubated on ice for 30 minutes
and then spun at 20,000g to pellet debris. Supernatant was snap frozen in liquid




Gels were precast 4% to 15% gradient gels (BioRad). Running buffer was 25
mM Tris-base, 200 mM Glycine, 0.1% SDS. Transfer buffer was 48 mM Tris-
base, 39 mM Glycine (Fisher), 0.037% SDS (Fisher) and 20% Methanol. Tris-
Buffered Saline supplemented with Tween 20 (TBS-T) was made from 10⇥ Tris-
Buffered Saline stock (G-Biosciences) and supplemented with 0.1% Tween-20
(Sigma).
Oligonucleotide pulldown samples had been frozen in SDS loading buffer as
detailed above and were denatured by heating from frozen at 95°C for 15
minutes before loading onto gel. Samples from IL-18 timecourse were left to
thaw on ice and then 10 µl of 5 ⇥ SDS loading buffer, supplemented with 2-
Mercaptoethanol, as described above, was added to 40 µl of sample and sam-
ples were heated at 95°C for fiveminutes. Gels were run in running buffer at 100
volts for approximately one hour before transfer to nitrocellulose membrane us-
ing transfer buffer. Transfer was conducted on ice at 60 volts for 1 hour 15 min-
utes. For oligonucleotide pulldown, samples were blocked in 5% milk in TBS-T
and primary incubation was with 1:1000 aT-bet antibody (clone eBio4B10 from
eBioscience) in 4% milk in TBS-T. For IL-18 timecourse samples, samples were
blocked in 5% BSA in TBS-T and primary incubation was with 1:1000 app38
antibody (clone 12F8 from Cell Signalling Technology) in 5% BSA in TBS-T.
For all experiments, blocking was for one hour at room temperature and pri-
mary incubation was at 4°C overnight. All incubation and wash steps were per-
formed under gentle agitation. Blots were washed for 3⇥ 5 minutes in TBS-T at
room temperature before addition of secondary antibody. Secondary antibody
was 1:2500 anti mouse linked to Horse Radish Peroxidase (HRP) (GE Health-
care, reference number NA931) in 4% milk for oligonucleotide pulldown sam-
ples. Secondary antibody was 1:5000 arabbit HRP (GE Healthcare, reference
number NA934) in 5% BSA for IL-18 signalling timecourse samples. All sec-
ondary incubations were for one hour at room temperature. All blots were then
washed three times with TBS-T before addition of Enhanced Chemiluminescent
Substrate (PerkinElmer Inc, reference number NEL100001EA) as per manufac-
turers instructions and exposure to film. After development, timecourse blots
were stripped with Restore stripping buffer (Thermo Scientific) for 25 minutes
at room temperature under gently aggitation, washed three time in TBS-T, re-
developed to check for complete removal of signal and then reblocked as previ-
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ously. Blots were then reprobed overnight at 4°C using 1:1000 a beta-actin an-
tibody (polyclonal from Cell Signalling Technologies, reference number 4967S)
in 5% BSA. Secondary incubation and redevelopment was as before. Blots were
then restripped and reprobed for total p38 using 1:1000 a p38 antibody (poly-
clonal from Cell Signalling Technologies, reference number 9212P) in 5% BSA
and using same procedure as already used for pp38 and beta-actin.
2.11 qPCR
Small bowel tissue sections from coeliac model were homogenised in 1 ml
TRIsure (Bioline) using a TissueLyser (Qiagen) set to 25 Hz/s for five minutes.
RNA was extracted by adding 200 µl chloroform to 1 ml TRIsure in tube, vor-
texing and incubating for 15 minutes at room temperature. Mixture was then
centrifuged at 12,000g for 15 minutes at 4°C. After centrifugation, 500 µl Iso-
propanol and 0.5 µl GlycoBlue (Invitrogen) were added to the aqueous phase
and this was transferred to a clean tube. The supernatant was vortexed briefly
and then left at room temperature for 10 minutes. The sample was then cen-
trifuged for eight minutes at 12,000g and 4°C to pellet the RNA. The RNA was
washed twice in ice cold 75% ethanol and then left to air-dry fully. RNA was
then resuspended in RNase free water and stored at -80°C until use. RNA con-
centrationwasmeasuredwith nanodrop. cDNAwasmade fromRNAusing Re-
vert Aid First Strand cDNA Synthesis Kit (Thermo Scientific) according to man-
ufacturers instructions. Reaction was performed using 1 µg of RNA and resul-
tant cDNAwas stored at -20°C until use. cDNAwas diluted 1 in 2 prior to qPCR
analysis. qPCR was performed using TaqMan probes in 384 well plate. Mixture
was 5 µl Maxima Probe/ROX qPCR Master Mix 2 ⇥ (Thermo Scientific), 1 µl
cDNA, 3.5 µl water and 0.5 µl gene specific probemix (all from TaqMan). Probes
incorporating the FAM dye were used for IL18R1 (Mm00515178_m1), IL18RAP
(Mm00516053_m1), IFN-g (Mm01168134_m1) and IL-17A (Mm00439619_m1).
Probes incorporating the VIC dye were used for b-actin (4352341E). qPCR
was performed on an ABI Prism 7900HT Sequence Detection System (Applied
Biosystems) using a programme of 10 minutes at 95°C followed by 60 cycles
of 95°C for 15 seconds and 60°C for 1 minute. Data was acquired and anal-
ysed on Sequence Detection Software version 2.4 (Applied Biosystems) Reac-
tions were performedwith one probe per tube based on preliminary data which
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showed cross reaction between IL18RAP and b-Actin probes in multiplex reac-
tions.
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3Trait-Associated SNPs in Binding
Sites for the Transcription Factors
T-bet and GATA3
3.1 Introduction
The recent development of large scale genomic analyses have demonstrated the
importance of non-coding regions of the genome and some of the ways in which
those regions can be analysed and annotated. In terms of understanding dis-
ease mechanisms, GWAS has provided many examples of DNA variation that
fall outside of protein coding regions but that fall in other regulatory regions.
Work to trace causal SNPs that alter disease risk and to understand the molecu-
lar mechanisms by which they exert their effect is ongoing. However, although
large scale efforts such as the ENCODE3 project have yielded vast amounts of
information they have also highlighted the limitations of any such projects: we
now understand the importance of context in genomic regulation and down-
stream effect. Possible connections between genetic variation, transcription fac-
tor binding, downstream biochemical effect and consequential clinical outcome,
in terms of disease or increased risk of disease, have been postulated and ex-
plored. However, in many cases only partial explanations have been found or
connections remain based on statistical association and lack detailed molecular
mechanisms. To fully connect genetic variation with molecular mechanism and
clinical outcomewe need to search for the appropriate regulatory features in the
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appropriate cell type and at the appropriate time. This combination is logisti-
cally daunting if not impossible in the broad-scope analyses of projects such as
ENCODE. However by focusing a project, based on knowledge from other ar-
eas such as immunology, we can hope to narrow down the question sufficiently
that appropriate cellular and kinetic contexts can be studied.
One mechanism by which a SNP can exert an effect is by altering binding of a
transcription factor. To examine whether such altered binding can exert suffi-
cient effect to alter the risk or course of a disease and to understand the mech-
anism by which it might do so, it makes sense to choose a transcription fac-
tor known to have a role in disease and immunity. Furthermore, we want to
choose a cell type known to rely on the transcription factor for full function.
The T helper cell lineages and their master regulators provide examples of this.
Our laboratory has previously obtained ChIP-Seq data for the binding of T-bet
in Th1 cells and GATA3 binding in Th1 and Th2 cells. T-bet is not expressed in
Th2 cells. We decided to examine whether disease-associated SNPs fromGWAS
could be found in binding sites for T-bet in Th1 cells (hereafter just referred to
as T-bet binding sites) or for GATA3 in Th1 or Th2 cells.
3.2 Generating a List of Binding Site SNPs
The NHGRI GWAS catalogue was accessed on 4th November 2011 and all SNPs
listed in this catalogue (hereafter referred to as trait-associated SNPs) were
downloaded. We used the snpMatrix package300 to compile a list of all SNPs
in high LD (r2 > 0.8) with these trait-associated SNPs as given by the data in
HapMap 3 for the CEU (Utah residents with Northern and Western European
ancestry) population. Although not all GWAS in the NHGRI catalogue were
performed in populations of European ancestry the prevalence of studies in
this population made it an appropriate population for the first-pass analysis.
We used HapMap data over whole sequence data because data from the 1000
Genome Project was not readily available at the time of establishing our in sil-
ico analysis. We had already moved on to examining further avenues of work
when the 1000 Genome Project was published and chose to focus on functional
analysis of the SNPs that we had already found rather than redoing our in silico
analysis. We examined whether any of the trait-associated SNPs or the SNPs in
high LD were in binding sites for T-bet or GATA3 as found by ChIP-Seq stud-
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ies.234 For the purposes of this work, strong LD is defined as r2 > 0.8 unless
stated otherwise. We defined strong LD as r2 > 0.8 as a compromise. Using a
higher r2 value might have led us to miss potential hits, especially from ear-
lier GWAS that were conducted across smaller numbers of SNPs. These earlier
GWAS had a greater reliance on imputation through LD. By contrast, using a
lower r2 value might have generated too many false positives, increasing the
number of hits to test in downstream analyses. Of note, r2 > 0.8 was also used
as a cut-off in one of the recent ENCODE publications.107
Our preliminary analysis generated 113 hits for T-bet (appendix table 7.1), 123
hits for GATA3 in Th1 cells (appendix table 7.2) and 89 hits for GATA3 in Th2
cells (appendix table 7.3). We considered a hit (hereafter referred to as a hit-
SNP) to be any SNP in a binding site for the transcription factor under inves-
tigation that was in strong LD with a trait-associated SNP as taken from the
NHGRI GWAS catalogue. We performed our initial systematic analysis on the
autosomal chromosomes only.
3.3 Functional Genomic Annotation of Binding Site
SNPs
3.3.1 Local Genomic Architecture - Histone Modifications and
DNase Hypersensitivity
As discussed in the introduction, gene transcription is regulated at multiple lev-
els and work on understanding those multiple levels is still ongoing. However,
to start investigating whether any of these hits were likely to be biologically
meaningful, we looked at whether any of the transcription factor binding sites
that we found to contain a hit overlappedwith any sites of histonemodification.
As previously discussed, H3K4me3 is a marker for transcriptionally permissive
promoter regions, while H3K27me3 is a mark for regions that are transcription-
ally repressed. Typically H3K4me1 is used as a mark for enhancer elements313
but it also seen downstream of the TSS.10 We downloaded published data on
tag locations of the histone modifications H3K4me1, H3K4me3 and H3K27me3
from previously published work10 and used this to call peaks of histone mod-
ification enrichment using the Model-based Analysis of ChIP-Seq (MACS) al-
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gorithm. This algorithm uses a sliding window to calculate peak width and
then searches for regions of peak-width that are enriched relative to a control
sample or to local background.302 We then found any T-bet or GATA3 sites that
intersected with a peak of histone modification (table 3.1).
The number of transcription factor binding sites that overlapped with
H3K27me3 was surprisingly small. However, we note that there were only 728
regions called for H3K27me3 in our analysis versus 28,074 for H3K4me3 and
45,913 for H3K4me1 (see table 3.1). Given that extra data was later released
for H3K27me3 by the same group,9 this would suggest that the small numbers
result from technical reasons relating to the original H3K27me3 histone modifi-
cation data rather then reflecting underlying biological mechanisms. Since the
new data was not readily available in a standard .bed file format we were un-
able to incorporate the extra peaks into our analysis at this time. We reran the
initial analysis to search for hit-SNPs that were just in the binding sites detailed
in table 3.1. Unsurprisingly, we did not find any hits in the transcription factor
sites that overlapped theH2K27me3modification for either T-bet or GATA3 and
we decided not to pursue this analysis any further. Hit-SNPs in transcription
factor binding sites that overlapped the H3K4me1 or H3K4me3 modifications
are described as Enhancer (for H3K4me1), Promoter (for H3K4me3) or Both (for
both modifications present) in appendix table 7.7, column five.
We also examined whether any of our hits were located in sites of DNase hy-
persensitivity as this would highlight regions where the chromatin was looser
andmore accessible, possibly indicating that the region was being actively tran-
scribed. To make the analysis as biologically relevant to our own data as pos-
sible, we downloaded peaks for DNase hypersensitivity in Th1 and Th2 cells
which had been found byDNase-Seq as part of the ENCODEproject.3 The num-
ber of overlapping peaks is shown in table 3.1. Our analysis showed that over
half (9,336/14,835) of the T-bet binding sites overlapped a region of DNase sen-
sitivity: the numbers were also high for GATA3 binding in Th1 and Th2 cells
(7,112/14,169 and 6,314/12,926 respectively). This is unsurprising given that
the cell types were well matched and that loose chromatin is generally required
for a transcription factor to bind and to mediate transcription. These results are
also in agreement with previously published work on T-bet and GATA3 bind-
ing.234 Hit-SNPs that were in transcription factor binding sites that overlapped
a region of DNase hypersensitivity are annotated in appendix table 7.7, column
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six).
H3K4me1 H3K4me3 H3K27me3 DNase Total Number of
Peaks for Tran-
scription Factor
T-bet 3,709 4,217 26 9,336 14,835
GATA3 in
Th1 cells
4,623 4,889 18 7,112 14,169
GATA3 in
Th2 cells





45,913 28,074 728 77,773(Th1)
92,923(Th2)
Table 3.1: Number of transcription factor binding sites that overlapped sites
of histone modification and DNase hypersensitivity. The number of transcrip-
tion factor binding sites for each of T-bet, GATA3 in Th1 cells and GATA3 in Th2
cells that overlapped with regions of H3K4me1, H3K4me3, H3K27me3 and DNase
hypersensitivity are shown. Last column of table shows total number of binding
peaks for each transcription factor. Last row shows total number of DNase hyper-
sensitive sites.
3.3.2 Proximity to Genes
We then used dbSNP to compile information on the location of our binding
site SNPs relative to the nearest gene. As discussed in the introduction, en-
hancers may act on their nearest gene and/or they may act on genes many kbps
away and even on different chromosomes. However, in general, a good cor-
relation is seen between enhancer activity and the expression of genes up to
50kbp away.314 Promoter elements, by contrast, are much closer to the gene on
which they act. Therefore, we compiled three lists of genes. The first was a list
of genes where a hit-SNP was in the transcribed region of the gene (either 5’
UTR, 3’ UTR, intron or exon), the second was a list of genes within 2kbp of each
hit-SNP and the third was a list of genes within 50kbp of each hit-SNP. Results
for each of the transcription factors are shown in appendix tables 7.4 (T-bet), 7.5
(GATA3 in Th1 cells) and 7.6 (GATA3 in Th2 cells). Because we were predom-
inantly interested in immune mediators, the function of which we could assay
in vitro and in vivo, the lists include only established protein coding genes and
open reading frames as well as miRNAs and some other established noncod-
ing RNAs. Pseudo, hypothetical or partial genes were not included and neither
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were tRNAs. Validated and established protein coding genes with a LOC clas-
sification were included but all other LOC regions were not. The classification
LOC is used by dbSNP and other NCBI databases when no other published
symbol for a gene is available and prefixes the Gene ID as given by NCBI.
3.3.3 Proximity to other SNPs
GWAS examine a selection of SNPs across the genome and infer knowledge on
SNPs in high LD with those SNPs that are studied. Thus a GWAS rarely guar-
antees to find causal SNPs but instead finds a collection of SNPs, all of which
will be in high LD and one of which might be causal. We allowed for this in
our preliminary analysis. However, because of the use of LD, we cannot con-
clude, without further investigation, that our hit-SNPs are any more likely to
be causal than the trait-associated SNPs from the GWAS catalogue. The most
important SNP might be another SNP in the same LD block as the hit-SNP and
trait-associated SNP. SNPsmay act through any of several different mechanisms
including altering transcription factor binding but also including the alteration
of a coding region. Many nonsynonymous SNPs do not alter protein function
(see introduction). It is conceivable that a neutral nonsynonymous SNP could
be in LD with a disadvantageous regulatory SNP. However, the presence of a
nonsynonymous SNP in the same LD block as a hit-SNP would suggest that
the hit-SNP was less likely to be causal. Therefore, we decided that we wanted
to prioritise SNPs that were not in LD with nonsynonymous SNPs for the first
rounds of our subsequent analyses. To do this, we generated a list of all the
SNPs in strong LD with the GWAS SNPs and downloaded information on the
functional class of all these SNPs from the SNP Function Portal.315 Any SNPs
in LD with SNPs causing nonsynonymous coding mutations are shown in ap-
pendix table 7.7 column eight.
3.3.4 Presence and Alteration of Motifs
We then examined whether any of the hit-SNPs were in or near a consensus
sequence for the transcription factor under study. Although a PWM had been
created for both T-bet and GATA3 from the original ChIP-Seq data, this does
not mean that every ChIP-Seq peak contains a motif for reasons discussed in
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the introduction. Our preliminary analysis had been performed by searching
for SNPs in 200bp regions centred on the ChIP-Seq peak summit as called by
the MACS peak finding algorithm. As such, our preliminary analysis was inde-
pendent of underlying sequence. We had refrained from using PWMs for our
initial search because of the caveats as to their use as discussed in the intro-
duction. However, while the lack of a consensus sequence might not necessary
rule out a binding site as not containing a relevant hit-SNP, the presence of a
sequence might increase the likelihood of an already listed hit-SNP being gen-
uine. We examined the presence of motifs using two methods.
In the first method, we obtained FASTA format sequences for the 20bp either
side of each hit-SNP.We then chose two potential consensus sequences based on
the PWM for T-bet234 and the standard GATAmotif for GATA3 and searched for
these using the dreg tool316 from the European Molecular Biology Open Soft-
ware Suite (EMBOSS). For T-bet we searched for either TTxxCAC or CACAC
and their complements. For GATA3, we searched for the standard GATA motif
and its complement. In each case, we analysed the sequences as they had been
obtained and then altered the nucleotide at the hit-SNP position to the opposite
allele to check for the creation or deletion of a motif by the hit-SNP. A workflow
for this analysis can be seen in figure 3.1. Hits are annotated in appendix table
7.7 column six.
Of note, the majority of our sequences did not contain a match to one of the
motifs (fig. 3.2). There are two potential explanations for this. Firstly, we were
not examining the 200bp of binding site sequence itself but a region 40bp long
and centred on the hit-SNP which was somewhere within the binding site. A
motif could have been present in the binding site sequence but outside the range
of the sequence used to search for a consensus motif. Secondly, there may not
have been a consensus sequence present even in the binding site sequence. The
dreg tool searches for one or more given strings of DNA sequence similar to a
standard text search but with the ability to input strings with degenerate bases.
Although we picked TTXXCAC and CACAC based on conservation within the
published PWM we may have lost important information in moving from a
PWM to a search string. This highlights a further issuewith the use of consensus
sequences. Furthermore, not all sequences will contain a match to the motif in
the first place.
We reran our analysis with all of the actual MACS-called binding site sequences
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that contained a hit-SNP to test how many did contain a matching sequence,
even if it was not near the hit-SNP. Our results showed that most but not all the































































Figure 3.1: Work-flow for searching for consensus sequence or PWM around hit-
SNPs. - Sequences around each hit-SNP were searched for a T-bet or GATA3 con-
sensus sequence using the dreg tool (a) or for significant matches to PWM for T-bet
or GATA3 PWM using FIMO (b). Workflow shows sequences tested relative to
binding sites sequences.
In the second method, we obtained FASTA format sequences for the 100bp re-
gion either side of each of our hit-SNPs. Although these sequences were the
same length as the binding site sequences, they did not correspond exactly
to the binding site sequences that contained the hit-SNPs, because they were
centred on the hit-SNP rather than the MACS peak summit (see fig. 3.1). We
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Figure 3.2: Majority of sequences around each hit-SNP did not contain amatch to
transcription factor consensus sequence. - Sequences around each hit-SNP were
examined for consensus sequences taken from the PWM for T-bet and GATA3. Se-
quences around each hit-SNP in a T-bet binding site was examined for presence of
TTXXCAC, CACAC or both (a). Sequences surrounding each hit-SNP in a GATA3
binding site in Th1 cells (b) or Th2 cells (c) were examined for GATA.
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Figure 3.3: Most but not all binding site sequences containing a hit-SNP contain
a consensus sequence as found by dreg. - Sequences of the binding sites contain-
ing each hit-SNP were examined for consensus sequences taken from the PWM for
T-bet and GATA3. Sequences of T-bet binding sites were examined for presence of
TTXXCAC, CACAC or both (a). Sequences of GATA3 binding sites in Th1 cells (b)
or Th2 cells (c) were examined for GATA.
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then used the PWMs generated for the T-bet and GATA3 binding sites from the
ChIP-Seq data234 and applied these to our sequences these using the Find In-
dividual Motif Occurrences (FIMO) tool available through the EMBL Australia
MEME Suite305,306 (see materials and methods). This programme returned any
sequences that matched the motif matrices with a p-value of less than 1⇥ 10 4
as calculated by amixture of log likelihood ratios and dynamic programming as
described by Grant et al.305 The matches for the hit-SNP sequences are shown in
appendix table 7.7 column six. Again, we noticed that not all of our sequences
contained a significant match to the PWM. We tested how many of the bind-
ing site sequences containing a hit-SNP contained a match to the PWM. Again,
we found that not all of the binding sites matched the PWM. Indeed, in this
case, not even the majority of binding sites returned a significant match (fig.
3.4). However, there was enrichment of matches compared to a selection of se-
quences of the same length that were chosen randomly from the genome (fig.

































































Figure 3.4: Percentages of sequences with significant matches to transcription
factor PWM. - Sequences around hit-SNPs and sequences of actual binding sites
containing hit-SNPs were examined for matches to the PWM for the transcription
factor tested using FIMO. Enrichment for hits was tested by analysing with respect
to random sequences.
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3.4 Transcription Factor Co-binding
As we were performing the analyses, we noticed that nearly 30% of our hit-
SNPs for T-bet were also in a binding site for GATA3 in Th1 cells. (fig. 3.5).
This observation agrees with previous observations158,234 that T-bet and GATA3
binding sites often overlap. The overlap in total binding sites on the autosomal
chromosomes, independently of the presence or absence of a SNP, is shown
in figure 3.6. The percentages of total binding sites that overlap with respect
to total number of sites for each transcription factor are broadly similar to the
percentages of SNPs found in multiple binding sites (fig. 3.7). The overlap
between binding sites and hit-SNPs for GATA3 in Th1 and Th2 indicates that
GATA3 binds to these locations in both cell types. Of more interest are those
sites bound by GATA3 in Th1 but not Th2 and vice versa as these highlight re-
gions of differential regulation involving GATA3 in the two different lineages.
Kanhere et al have shown that T-bet can physically redistribute GATA3 in Th1
compared to Th2 cells.234 Some of the overlapping regions between T-bet and
GATA3 in Th1 cells could represent co-binding within the same cell. The over-
lap between T-bet binding sites and GATA3 binding sites in Th2 cells does not
represent co-binding as T-bet is not expressed in Th2 cells. These sites may point
towards differentially regulated loci within the two different cell lineages.
We wanted to examine whether any of the regions surrounding our hit-SNPs
had, in common, the binding of any transcription factors other than T-bet and
GATA3. To examine the possibility that other transcription factors might bind
in the regions around our hit-SNPs and might be affected by the presence of
the SNP, we searched for other consensus sequences in our sequences using the
Multiple Em for Motif Elicitation (MEME) tool available through the MEME
suite.306 This analysis is not ideal as consensus motifs are usually built on thou-
sands of sequences and we had a maximum of 123 sequences. However, we did
find a Runx motif in the T-bet sequences and a weaker Runx motif in the se-
quences for GATA3 binding sites in Th2 cells (fig. 3.8). The motif was found
in 21 (19%) of the sequences around a hit-SNP in a T-bet site and 42 (52%)
of the sequences around a hit-SNP in a GATA3 site in Th2 cells. In the T-
bet sequences, this motif was altered by the presence of SNP rs13333528. In
the sequences for GATA3 binding in Th2 cells, this motif was altered by SNPs
rs1775312, rs2058622, rs40452, rs7171233, rs1596017.
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Figure 3.5: Hit-SNPs are found in multiple transcription factor binding sites. -
Some of our hit-SNPs were found in binding sites for two or more of T-bet, GATA3
in Th1 cells and GATA3 in Th2 cells. Numbers of SNPs found in more than one
transcription factor binding site are shown.
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Figure 3.6: Transcription factor binding sites overlap. - Number of overlapping
transcription factor binding sites for T-bet and for GATA3 in Th1 and Th2 cells out
of total number of binding sites on the autosomal chromosomes.
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Figure 3.7: Overlap of hit-SNPs and transcription factor binding sites. - Over-
lap of total binding sites (purple) or hit-SNPs (blue) for each transcription factor
condition (transcription factor 1) with each of the remaining transcription factor
conditions (transcription factor 2). Percentages are out of total number of binding
sites or hit-SNPs for transcription factor 1.
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    
      
      
      
      
      
      
      
      
      
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      
      
      
     
      
      
      
      
      
      
      
      
      
      
      
      

Figure 3.8: Runx motif found in some regions around the hit-SNPs for T-bet
binding and GATA3 binding in Th2 cells. - The 200bp sequences around our hit-
SNPs were analysed for motifs for other transcription factors and a Runx motif was
found in the sequences around the hit-SNPs for T-bet (a) and GATA3 in Th2 cells
(b). Sequences contributing to the motif are shown on the left and motif built from
those sequences is shown on the right.
108
3.5 Immunological Annotation of Binding Site SNPs
We also examined whether any other transcription factors might bind near our
hit-SNPs using Transcription Factor Affinity Prediction (TRAP), amethodwhich
ranks transcription factor binding based on estimated binding affinities rather
than searching for specific motifs.307 For the sequences around the hit-SNPs for
GATA3 binding in Th2 cells, the highest rankingmotif was for GATA1, although
the motif for GATA3 still reached significance above a control analysis using
random sequences. GATA3 was also significant for the list of sequences around
the hit-SNPs for GATA3 in Th1 cells. Because we were searching for DNA bind-
ing proteins against the JASPAR database, which does not contain information
for T-bet, we were not expecting to see this motif returned as significant for the
sequences surrounding the T-bet hit-SNPs. However, the T protein which is,
like T-bet, a T-box protein and the homologue of Xenopus brachyury was sig-
nificant. These results suggested that our hits were plausible. The significant
binding events found are summarised in table 3.2.































Table 3.2: Potential transcription factors binding around hit-SNPs. The se-
quences around our hit-SNPs for T-bet binding, GATA3 binding in Th1 cells and
GATA3 binding in Th2 cells were analysed for other potential transcription factor
binding events using TRAP. Transcription factors that scored more highly than the
highest score assigned to a transcription factor binding event at a set of randomly
generated control sequences are listed.
3.5 Immunological Annotation of Binding Site SNPs
We noticed that our hit-SNPs seemed to be enriched for binding site SNPs that
were either associated with immune mediated diseases or had been generated
because they were in high LDwith SNPs that were associated with immuneme-
diated diseases. To test this further, we divided the traits in the database into
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three categories, traits which were definitely immune driven (such as coeliac
disease and T1D), traits which were definitely non immune driven (such as
mathematical ability) and traits which may or may not be immune driven (in-
cluding various cancers). We performed this three- way classification as we
wanted to analyse all SNPs but, at the same time, appreciated that not all
traits can be split cleanly and definitely into immune and non-immune driven
conditions. From this, we constructed a list of ’strictly’ immune related trait-
associated SNPs (hereafter referred to as strictly immune related SNPs) that
were only associated with traits that were definitely considered immune medi-
ated. We also generated a list of ’loosely’ immune related trait-associated SNPs
(hereafter referred to as loosely immune related SNPs) that were associatedwith
at least one condition that might be immune mediated. We then counted how
many SNPs from the list of strictly immune related SNPs had generated a hit-
SNP. In other words, how many of the trait-associated SNPs from the strictly
immune related SNP list were in high LD with a SNP in a binding site for T-bet
of GATA3. We compared this number to the total number of strictly immune
related SNPs in the entire GWAS catalogue. If there was no enrichment for im-
mune mediated disease among those traits that had generated a hit-SNP then
we would expect the proportion of strictly immune related SNPs that gener-
ated a hit-SNP to be similar to the proportion of strictly immune related SNPs
in the entire NHGRI GWAS catalogue. However, we saw an enrichment of both
strictly and loosely immune related SNPs that had generated a hit-SNP com-
pared to the entire database (table 3.3). In the case of T-bet, for example, 40.1%
of hit-SNPs were in LD with a strictly immune related SNP compared to only
13.9% in the entire database.
This data suggested that our results might have functional relevance given the
important roles of both T-bet and GATA3 in the immune system. However,
we might expect to see an enrichment even if the SNPs do not exert mechanis-
tic effect through altering transcription factor binding for the following reason.
There is an enrichment of T-bet and GATA3 binding sites at immune genes.158
Furthermore, for those GWAS traits that are immune mediated we would ex-
pect an enrichment of SNPs associated with immune related genes. The enrich-
ment we saw may simply reflect these two enrichments without being biologi-
cally relevant.
In addition, the above analysis was performed by counting trait-associated
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T-bet 147 59 40.1% 68 46.2%
GATA3 in
Th1 cells
153 64 41.8% 84 54.9%
GATA3 in
Th2 cells
98 30 30.6% 41 41.8%
Total
Database
5222 724 13.9% 1249 23.9%
Table 3.3: Enrichment of immune related trait-associated SNPs. Trait-associated
SNPs from the GWAS catalogue that had generated (were in strong LD with) our
hit-SNPs were classed as strictly, loosely or not immune related and proportions
of immune related SNPs relative to all SNPs were calculated. Bottom line shows
values for total database.
SNPs, which does not completely reflect the number of hit-SNPs, as our prelim-
inary analysis found some hit-SNPs tagged by multiple trait-associated SNPs
and some trait-associated SNPs taggingmultiple binding site SNPs. This would
have given us duplications in our counting given that it is the function of the
binding site SNPs that we are interested in. This is why, for example, the total
number of trait-associated SNPs for T-bet is 147 rather than the 113 hit-SNPs
that we found for T-bet. It is also why we did not feel it relevant to subject
the numbers given in table 3.3 to extensive statistical testing. Table 3.3 repre-
sents a quick analysis which was done to determine whether further analysis
was worthwhile. Given that the data used in table 3.3 does not completely and
accurately reflect the biological question being asked, we felt it would be mis-
leading to start trying to determine statistical significance. It should be noted
that table 3.3 suggests, rather than conclusively demonstrates, that there is an
enrichment for immune related SNPs in T-bet and GATA3 binding sites. En-
richment within the data presented in table 3.3 could be analysed as immune
related versus non immune related SNPs by chi-squared test but this would
still fail to address some of the underlying biological issues that are discussed
above. These issues are addressed in the following sections.
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3.5.1 Randomisation of Binding Sites
We used two different methods to address some of the issues with our first anal-
ysis and to test the significance of the enrichments we saw. In the first method,
we made lists of all SNPs that were strictly or loosely immune related and all
the SNPs in strong LD with those SNPs and counted how many of these SNPs
were in a binding site for T-bet. In silico, we then shifted each T-bet binding site
in our list of binding sites along the chromosome by a random number of base
pairs between 500bp and 5000bp either up or downstream of the actual binding
site. We then examined how many of our immune related SNPs and their LD
counterparts were in the newly shifted T-bet sites. By shifting between 500bp
and 5000bp, we had created new sites that were associated with the same genes
but not in the actual biological binding sites. If the enrichment in our initial
T-bet hits was purely due to pre-enrichments based on proximity to immune
related genes, we would expect to see a similar enrichment for immune related
SNPs in the shifted T-bet sites. We repeated the binding site shifting and re-
analysis through 10,000 random re-assignments of binding site position to test
for significance of the enrichment. We then repeated for GATA3 in Th1 and Th2
cells.
This analysis did suggest that the enrichment for immune related SNPs in T-bet
binding sites is biologically relevant and suggested strongly that the enrichment
was also relevant for GATA3 in Th1 cells (table 3.4). Significant enrichments
were not seen for GATA3 in Th2 cells (p > 0.05 for Th2Gata3 binding site ran-
domisations in both cases.)
There are two potential issues with this analysis. The first is potential bias due
to unequal coverage of traits in the GWAS catalogue. There is bias in the traits
that have been studied and this is reflected in a bias in traits listed as associ-
ated with SNPs in the catalogue. In particular common traits that gave many
hits in preliminary GWAS such as Crohn’s disease have been further studied
with larger cohorts and better statistical power than other traits, which have
received less attention. In addition, some traits that are harder to study func-
tionally, such as various psychological conditions, have been extensively subject
to GWAS. These could be overrepresented in the GWAS catalogue as a result.
Furthermore, in some conditions it is possible that the population in the initial
GWAS was heterogeneous for whether their condition was immune mediated.
Some cancers, for example, can give the same clinical result but may be driven
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by different biological processes (inflammation, environmental exposure etc).
This level of detail may not always be reflected in the original GWAS paper or
our subsequent meta-analysis through the NHGRI GWAS catalogue. Because
our in silico experiments were broad, we may have not captured finer details
from individual papers.
3.5.2 Permutation of SNPs
As another way to assess the biological relevance of our analyses, we reassigned
the immune status of our SNPs but used the real transcription factor binding
sites. We counted the number of trait-associated SNPs from the NHGRI GWAS
catalogue that we had called strictly or loosely immune related. We then chose
this number of SNPs at random from the entire list of SNPs in the GWAS cat-
alogue. The number of these permuted SNPs, or SNPs in high LD with these
permuted SNPs, that were within the actual binding sites for each of our tran-
scription factors was then counted and averaged over 200 permutations. Be-
cause this analysis was more computationally intensive than the analysis of
shifted binding sites we were not able to test the significance of our results
by standard permutation testing. Instead, we checked that the number of hits
obtained over 200 permutations was approximately normally distributed and
then checked for significance of our enrichment using a standard z-test over the
200 permutations. The results are shown in table 3.4. This analysis found sig-
nificant enrichment of strictly immune related SNPs for all three transcription
factor conditions (p < 0.05 in all cases.) Graphs showing the normal distribution
are shown in figure 3.9.
Testing for significance by permuting the immune status of the SNPs is, we
could argue, more statistically robust than shifting the transcription factor bind-
ing sites. The lists of permuted SNPs are chosen independently of their actual
immune status. By contrast, the shifted binding sites are chosen to be a certain
distance away from their actual location. The distance by which each site is
shifted is random each time but within the constraints that it must be within
500 to 5000bp of the original location and on the same chromosome - the new
location is not chosen at random from the entire genome. Furthermore, as a
result of this, we noticed that we would sometimes pick up the same LD block
and same disease-associated SNP for the shifted transcription factor binding
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site as for the actual transcription factor binding site. However, the purpose
of shifting the binding sites was to test whether the enrichment was specific to
the binding sites and not to the genomic locations in which they were found.

















T-bet (Strict) 42 31 (p = 0.0359)
(s.d = 5.6)
25 (p = 0.0006)
(s.d = 5.3)
T-bet(Loose) 50 39 (p = 0.0543)
(s.d = 6.3)




48 27 (p = 0.0002)
(s.d = 5.2)




62 34 (p = 0.0001)
(s.d = 5.9)




28 24 (p = 0.2026)
(s.d = 4.9)




37 30 (p = 0.1284)
(s.d = 5.6)
30 (p = 0.1382)
(s.d = 6.5)
Table 3.4: Hit-SNPs are enriched for immune related SNPs. Enrichment of im-
mune related SNPs was tested by randomly shifting transcription factor binding
sites and by permuting immune status of GWAS SNPs. Actual number of strictly
and loosely immune related SNPs in transcription factor binding sites is shown
in column two. Column three shows mean and standard deviation of strictly and
loosely immune related SNPs in shifted transcription factor sites. P-value was ob-
tained over 10,000 randomisations. Column four shows mean and standard devi-
ation of strictly and loosely immune related SNPs in transcription factor sites over
200 permutations of immune status reassignment. P-value obtained by z-test over
200 permutations.
3.5.3 Application to other Transcription Factors
To examine whether enrichment for immune related SNPs could be seen in
other transcription factors, we obtained data on the binding sites of NF-kB,
STAT4 and Oestrogen Receptor alpha (ER-a) and subjected these to our anal-
yses. NF-kB was chosen as our positive control, a transcription factor known to
be involved in immune responses. ER-a was chosen to be our negative control
as this is not thought to be heavily involved with immune response. STAT4 is a
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   

Figure 3.9: Number of permuted hit-SNPs followed approximately normal dis-
tribution. - Number of hits recorded for each re-assignment of immune related
SNPs was plotted as a histogram for each transcription factor and for choosing
a number of SNPs corresponding to the number of strictly immune related SNPs
(strict) and number of loosely immune related SNPs (loose). Vertical line indicates




very general transcription factor which has functions in the immune system as
discussed in the introduction. The results of our testing on these transcription
















NF-kB (Strict) 429 293 (p < 0.0001)
(s.d = 16.7)
247 (p < 0.0001)
(s.d =27.6)
NF-kB(Loose) 573 407 (p < 0.0001)
(s.d =20.0)
425 (p < 0.0001)
(s.d =30.5)
STAT4 (Strict) 67 52 (p = 0.0172)
(s.d = 7.1)
32 (p < 0.0001)
(s.d = 6.5)
STAT4 (Loose) 81 63 (p = 0.0187)
(s.d = 8.0)
55 (p = 0.0003)
(s.d = 7.5)
ER-a (Strict) 14 9 (p = 0.0965)
(s.d =3.2)
11 (p = 0.2435)
(s.d = 3.7)
ER-a (Loose) 20 14 (p = 0.0764)
(s.d = 3.8)
21 (p = 0.5630)
(s.d = 4.5)
Table 3.5: Summary of immune related SNPs in binding sites for other transcrip-
tion factors. Summary of immune related SNPs in binding sites for NF-kB, STAT4
and ER-a. Data obtained and presented as for T-bet and GATA3.
Our results showed a strong enrichment for our positive control NF-kB. By con-
trast our negative control ERa showed no significant enrichment supporting the
methods we had used and the classification we had made. Of interest, STAT4
also showed significant enrichment of actual immune related hit-SNPs in actual
sites versus permuted SNPs or SNPs in shifted immune sites.
3.6 Algorithm Comparison
Although most of our analysis was done using T-bet and GATA3 binding site
peaks as called by the MACS algorithm, we also had data on the binding site
peaks for the same ChIP-Seq experiments as called by the Site Identification
from Short Sequence Reads (SISSRs) algorithm317 which calls peaks based on
the directionality of aligned reads. In general, most peaks called by SISSRs will
also be called by MACS but only around 50% of peaks called by MACS will
be called by SISSRs.22 Therefore, although MACS is considered by many as the
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gold standard, we ran a comparison. Peaks called by both algorithms are highly
likely to represent real transcription factor binding events which would give us
increased confidence in any hit-SNPs in these binding sites. However, such a
comparison would also allow us to examine whether either of the algorithms
was better for calling binding sites that might contain hit-SNPs. SISSRs tends
to call fewer peaks. However, if these are the peaks of strong binding that are
more likely affected by a single base pair change, then using this algorithm,
for our purposes, would save effort in downstream analyses. However, if SIS-
SRs missed peaks containing hit-SNPs that were later validated then this would
confirm the usefulness of MACS.
As can be seen from figure 3.10, the overlap between hit-SNPs when the bind-
ing sites are called by SISSRs and hit-SNPs when the binding sites are called by
MACS is not very strong. This is in agreement with the work byWilbanks et al22
discussed above. Without an independent way of verifying which peaks repre-
sent true binding sites we cannot be certain as to whether the SISSRs algorithm
is not sensitive enough andmisses peaks or whether the MACS algorithm is not
specific enough and returns many false positives.
3.7 Specific Analyses of the X Chromosome
We conducted most of our analysis on the autosomal chromosomes. How-
ever, binding regions on the X chromosome were also found in our ChIP-Seq
data for all three datasets, T-bet, GATA3 in Th1 cells and GATA3 in Th2 cells.
The chromosome harbours important genes including the Treg master regula-
tor FoxP3 and mutations on this chromosome are known to cause diseases such
as haemophilia and, in relation to the FoxP3 gene in particular, Immunodys-
regulation Polyendocrinopathy and Enteropathy X-linked (IPEX). Furthermore,
GWAS hits have been reported on the X chromosome associatedwith a wide va-
riety of traits including height, smoking behaviour, coronary heart disease and
prostrate cancer. We repeated our basic analysis to look for SNPs that were in
a binding site and either in the GWAS catalogue or in high LD with a SNP in
the catalogue but found no hits. Therefore, we did not pursue analysis on this
chromosome any further.
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Figure 3.10: Overlap between SNPs in binding sites called by SISSRs and SNPs
in binding sites called byMACS. - Binding site peaks for T-bet and GATA3 in Th1
and Th2 cells as called by the SISSRs algorithm were analysed for hit SNPs and the




We have found multiple disease or trait-associated SNPs that are either in a
binding site for T-bet or GATA3 or in high LD with a SNP in a binding site.
Many of these hit-SNPs are found in regions marked as functionally relevant
by genomic features such as histone modification or DNase hypersensitivity.
Some of our hit-SNPs are near or in a motif for T-bet or GATA3 and some are in
or near motifs for other transcription factors. Furthermore, some of our SNPs
are in binding sites for both T-bet and GATA3.
It is unlikely that all of our hit-SNPs alter transcription factor binding and ex-
ert an effect on disease risk. However, we have some confidence in our results
from the observation that our hit-SNPs were generated by traits that were en-
riched for immune mediated conditions. Hit-SNPs for T-bet were significantly
enriched for strictly immune related SNPs as tested both by randomly shifting
the T-bet binding sites and by randomly permuting the SNPs tested (p < 0.05
in both cases). Hit-SNPs for GATA3 in Th1 cells were significantly enriched for
both strictly and loosely immune related SNPs. Of note, there was a far weaker
enrichment of immune related SNPs in GATA3 binding sites in Th2 cells. This
may reflect the biological differences in specificity of the two transcription fac-
tors. While T-bet is immune restricted, GATA3 has a broader role in biological
processes.
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4In Vitro Testing of SNPs Found by In
Silico Analysis
4.1 Introduction
Our in silico analysis revealedmultiple SNPs that were in a binding site for T-bet
or GATA3 or both and either associated with or in high LD with a SNP associ-
ated with a trait or disease in the NHGRI GWAS catalogue. However, although
our genomic annotation and statistical testing of these hit-SNPs are encourag-
ing, we have done no more than make associations at this time. To make causal
links between our hit-SNPs and altered transcription factor binding and down-
stream mechanistic effect, we need to assess the function of our SNPs both in
vitro and in vivo.
4.2 Some SNPs Show Altered Binding
4.2.1 Oligonucleotide Pulldown
Having found many hit-SNPs for both T-bet and GATA3 in silico, we started to
investigate whether any of these SNPs altered transcription factor binding us-
ing oligonucleotide pulldown assays. We started by testing the effects of SNPs
found in T-bet binding sites because a high affinity antibody is available for T-
bet.229 Biotinylated double stranded DNA oligonucleotides (hereafter referred
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to just as oligonucleotides) containing each allele of the SNP of interest were
bound to streptavidin beads. These beads were then incubated with lysate from
YT cells which constitutively express T-bet. Bound protein was eluted from the
beads and probed for T-bet byWestern blot. We also designed a positive control
(T-bet +), which contained a T-bet consensus sequence as recently determined
from ChIP-Seq data on T-bet binding in Th1 cells.234 We designed a negative
control (T-bet -) in which this T-bet consensus sequence was mutated at two
key residues. Using this technique, we tested hit-SNPs near or in the genes
for IL18R1 (rs1465321), CCR1 (rs3181080) and RGS1 (rs2984920). We quanti-
fied the Western blots and found differential binding between the two alleles of
rs1465321 (fig 4.1 (a) and (b)), with the G allele consistently binding T-bet more
strongly than the A allele. We tested this SNP further by using lysate from bead
enriched human CD4+ cells that had been cultured in vitro in Th1 conditions for
seven days. This was because transcription factor binding often depends on the
presence of other transcription factors and on post-translational modification of
the transcription factor such as phosphorylation. It is possible that the YT cell
line, of NK lineage, does not represent Th1 cells in one of these aspects. Again,
we saw stronger T-bet binding to the G allele of rs1465321 than to the A allele.
By contrast, we found very little T-bet binding at the other hit-SNPs rs3181080
(fig. 4.1 (c)) and rs2984920 (fig. 4.1 (d)). Of note, figure 4.1 shows bars for in-
dividual experiments as the inter-assay variability was high between replicates.
As such, weweremore interested in consistency of differential binding (seen for
rs1465321 but not rs3181080 or rs2984920) than in numbers for absolute band in-
tensity. However, for rs1465321, if we try and control for inter-assay variability
by normalising values for band intensity of the G allele to (band intensity of A
allele =1), then a significant difference is seen across the combined experiments
(p = 0.049, paired samples t-test).
4.2.2 OligoFlow
From the in silico analysis there were many SNPs that we wanted to test for dif-
ferences in transcription factor binding, most of which were likely to be subtle.
However, a conventional pulldown assay does not directly measure transcrip-
tion factor binding to the beads but presence of the transcription factor in the fi-
nal sample. This can introduce experimental error in the procedure. If the beads
are not thoroughly washed or they are washed to different levels in different
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Figure 4.1: Consistent differential binding at rs1465321 but not rs3181080 or
rs2984920. - Hit-SNPs for T-bet were tested for differential T-bet binding by
oligonucleotide pulldown assay. (a) Example Western blot showing T-bet eluted
from streptavidin beads prepared with positive control (T-bet +) or negative con-
trol (T-bet -) oligonucleotides, or oligonucleotides for the DNA region around
rs1465321. (b) Quantification of Western blots from three separate pulldown ex-
periments with rs1465321 and cell lysate from YT cells and one pulldown with
rs1465321 and lysate from CD4+ cells cultured in Th1 conditions in vitro. Results
are normalised to (T-bet -) = 1 for each experiment. (c) Example Western blot and
quantification of Western blots from two separate pulldown experiments with the
DNA region around rs3181080. Data analysed as for (b). (d) Example Western blot
and quantification of Western blots from two separate pulldown experiments with
the DNA region around rs2984920. Data analysed as for (b).
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samples or if any of the beads are lost during the wash steps then this will skew
the results. This is especially problematic given that, unlike most other West-
ern blotting procedures, there is no accepted internal control for which we can
reprobe on theWestern blot. In addition, a conventional pulldown assay is time
consuming because it requires two steps, the assay itself and then the Western
blot to analyse the results. This makes it difficult to scale up the assay to analyse
SNPs in a medium to high throughput way. The issue of potential experimental
variability is addressed in part by running the experiment multiple times but,
in order to screen our hit-SNPs with better accuracy, we decided to develop a
flow-based method for analysing pulldown samples. Flow cytometric analysis
is a one step process that could easily be added onto the end of the pulldown
assay, yielding data in approximately one hour versus the two day process of a
Western blot. We reasoned that we could perform the pulldown assay as stan-
dard but, after the lysate incubation step, we could add a fluorescently labelled
antibody for the transcription factor of interest instead of washing the beads,
eluting protein and Western blotting. We could then measure the relative Me-
dian Fluorescence Intensity (MFI) as a readout of strength of transcription factor
binding in each individual sample. An outline of this approach in comparison
to a standard pulldown followed by Western blotting is shown in figure 4.2. A
broadly similar idea has been used to study interactions between RNA binding
proteins and their RNA target.318 However, this previous work used GFP la-
belled protein which had to be synthesised from an appropriately constructed
plasmid and then purified. In our case, we wanted to test whether we could
achieve a signal using cell lysate containing the transcription factor of interest
in its native form and an appropriate antibody. We reasoned that, if we were
able to do this, then this would broaden the applicability of the technique. The
technique could be applied easily to test differential binding of a range of tran-
scription factors. Furthermore, we wanted to examine whether the assay was
sensitive enough to detect differences in binding as a result of single base pair
changes in the oligonucleotide used.
To test this technique of running a pulldown assay and then analysing by flow
cytometry (hereafter referred to as OligoFlow), we first used oligonucleotides
for just the positive and negative controls for T-bet binding (T-bet + and T-bet-).
We found that we needed to use streptavidin coated polystyrene beads rather
than the standard agarose beads that are used when Western blotting as the
agarose beads could not withstand the pressure of a flow cytometer fluidics
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Figure 4.2: Overview of OligoFlow method. - Steps required for assessing dif-
ferential transcription factor binding to DNA by OligoFlow in comparison to pull-
down assay followed by Western blotting.
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system. We were unsure as to whether the various available fluorochromes
would be able to tolerate the buffer that is used for incubating the pulldown
beads with cell lysate (the oligo buffer). Therefore, we performed a side by side
comparison. We attached our positive or negative control oligonucleotides to
beads and incubated with lysate. We then either added the antibody directly,
incubated and acquired or washed the beads and resuspended them in PBS
before incubation with the antibody. At the same time, we acquired FacsComp
beads that had been added either to PBS or to an aliquot of the cell lysate and
oligo buffer prior to incubation with the antibody. For our first analyses, we
chose the Alexa647 fluorochrome as it is relatively stable and bright.
Incubating the FacsComp beads in the buffer used for oligonucleotide pull-
down did decrease the signal intensity from our aT-bet Alexa647 antibody com-
pared to FacsComp beads in PBS (fig. 4.3 (a) and (b)). However, it did not
completely abrogate the signal and two peaks for positive and negative beads
could still be seen (fig. 4.3 (b)) . When we compared the positive and negative
control beads incubated in oligo buffer, we could see a marked increase in T-bet
Alexa647 fluorescence on the beads made with positive control oligonucleotide
(T-bet + beads) versus beads made with the negative control (T-bet - beads) (fig.
4.3 (e)) and versus background of polystyrene beads only (fig. 4.3 (d)). When
we mixed the positive and negative control beads, we could distinguish signals
from the two different populations and the histograms for the two different
populations produced peaks that overlapped only slightly (fig. 4.3 (e)). By con-
trast, we could not see signal from the T-bet + beads that were washed in PBS
prior to antibody addition (fig. 4.3 (f)), suggesting that this washed off the tran-
scription factor bound to the beads. This was most likely because the PBS wash
destabilised the interaction between the transcription factor and the oligonu-
cleotide, whereas the oligo buffer was designed to stabilise this interaction. The
dissociation constant between a transcription factor and its DNA binding site is
generally in the µM range. This is compared to a dissociation constant on the
order of ⇥10 14 for the interaction between biotin and streptavidin. Since, we
were trying to avoid having to wash the beads in the first place, this was not an
issue.
In flow cytometry, if we do not wash the beads after incubation, this should
not overly affect the results as the antibody size is below the limit of detection
and will not register as an event. However, free antibody in the buffer will
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Figure 4.3: Establishing antibody stability in OligoFlow - Positive and negative
control T-bet oligonucleotides were used to test antibody performance in buffer
used for oligonucleotide pulldown protocol. (a) Plots showing brightness of aT-
bet Alexa647 antibody on FacsComp beads in PBS or in cell lysate and buffer used
for oligonucleotide pulldown. (b) Overlay of histograms for data shown in (a). (c)
Gating strategy for polystyrene beads in OligoFlow experiments. (d) Plot showing
fluorescence level of polystyrene beads without addition of antibody. (e) Plots for
T-bet on beads made with positive control (T-bet +), negative control (T-bet - ), in
vitro combination of beads for positive and negative control (Combined) and in
silico overlay of histograms for positive and negative controls (Overlay). Numbers
on histogram denote MFI for the correspondingly coloured peak. Beads gated as
in (c). Histograms normalised to total events for FSC-A, FSC-H gate. (f) T-bet on
beads made with positive control oligonucleotide but washed and resuspended in
PBS before incubation with aT-bet antibody.
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give a certain level of background fluorescence to all samples. This background
should vary less between experimental samples within an experiment than the
variation introduced by washing beads in a standard oligonucleotide pulldown
assay. However, if the background is too high, it will decrease sensitivity of
the experiment. Given that the variations in binding strength caused by a SNP
might be quite small we wanted the lowest background (and so most sensitiv-
ity) possible while still achieving high signal in the positive control. We were
able to achieve this by titrating the antibody dose, which decreased the MFI
of the negative control (fig. 4.4 (a)) without affecting the MFI of the positive










































Figure 4.4: Increase in OligoFlow sensitivity by decreasing antibody concentra-
tion. - OligoFlowwas performed with T-bet + beads and T-bet - beads and decreas-
ing volumes of antibody. (a) Histograms showingMFI of OligoFlow samples using
T-bet - beads with 1 µg per test (orange line), 0.5 µg per test (blue line) or 0.25 µg per
test (red line) of aTbet antibody. (b) Histograms showing MFI of OligoFlow sam-
ples using T-bet + beads with 0.5 µg per test (blue line) or 0.25 µg per test (red line)
of aT-bet antibody. Numbers on histogram denote MFI for the correspondingly
coloured peak.
We also tested another fluorochrome, eFluro660which is brighter thanAlexa647
but, like Alexa647, is read on the APC channel. We found that this antibody
gave decreased sensitivity in this assay because the unbound antibody from the
unwashed beads was too bright for the sensitivity required (fig. 4.5).
To get good discrimination between the positive and negative control and thus
good sensitivity, we also found that we needed lysate from a high number of
cells. Using a high number of cells to prepare the lysate (typically 30⇥ 106 cells
per sample) gave both a lowerMFI for the negative control and a higherMFI for
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Figure 4.5: Very bright fluorochrome caused high background and low sensitiv-
ity in OligoFlow. - We tested T-bet + beads and T-bet - beads in OligoFlow with
eFluro660 labelled aT-bet. Histograms for MFI of T-bet+ beads (blue) and T-bet -
beads (red) are shown.
the positive control than when the number of cells was lower, thus increasing





















































Figure 4.6: High OligoFlow sensitivity with lysate prepared from high cell num-
ber. - We prepared lysate from 15⇥ 106 cells per sample (a) or 30⇥ 106 cells per
sample (b) and used these lysates for OligoFlow with T-bet+ and T-bet- beads. (c)
Overlay of MFI of each sample tested. Numbers on histogram denote MFI for the
correspondingly coloured peak.
Having optimised the assay on the basis of the positive and negative control
oligonucleotides, we were able to run the assay with the rs1465321 oligonu-
cleotides that had shown differential binding in the original pulldown andWest-
ern blotting. As before, we found that the SNP rs1465321 showed differential
binding between the A and G alleles and this was consistent across multiple
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experiments with lysate from both YT cells and CD4+ cells cultured in Th1 con-
ditions. The experiment was repeated with a new lot of oligonucleotides to
validate the method and check that the differential binding did not result from


























































Figure 4.7: rs1465321 alters T-bet binding in OligoFlow assay. - Summary of
OligoFlow results for rs1465321. (a) Example plot showing MFI values for T-bet
on positive and negative controls and A and G alleles of rs1465321. (b) MFI values
for A and G alleles over several experiments (Exp) using YT and Th1 cells and with
new batch of rs1465321 oligonucleotide (denoted ’new’ under appropriate columns
on graph). Values normalised to negative control = 1. p values are for comparison
of the two MFI distributions obtained for each allele within each replicate experi-
ment.
4.2.3 Testing other Hit-SNPs
We used the OligoFlow technique to analyse some of the other SNPs that we
had found in a T-bet binding site. Since we could not test all the binding site
hits from our computational analysis, we chose SNPs based on other data from
our in silicowork. For example, we chose some SNPs because they disrupted the
T-bet motif and we might expect that this would impact on binding. However,
rs1465321 does not disrupt a T-bet motif - rs1465321 is three base pairs away
from a motif, suggesting a slightly more complex situation and implying that
we couldmiss hits if only restricting ourselves to SNPs in a motif. Therefore, we
also chose some SNPs that were within 20bp of, but not directly in, a binding
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site motif. We also chose SNPs based on the presence of histone modifications
or DNase hypersensitivity that might suggest the site was functionally relevant.
The SNPs chosen and the reasons for choosing them are outlined in table 4.1.
We tested all of these SNPs at least once using lysate from YT cells and/or Th1
cells.
SNPs that did not appear to show differential binding were not tested any fur-
ther due to time constraints (fig. 4.8). In cases where the first test suggested
that there was or might be differential binding, the experiments were repeated
with lysate fromYT and/or Th1 cells to examinewhether a consistent difference
could be seen across experiments (fig. 4.9).
Table 4.1: Summary of SNPs chosen for OligoFlow. Hit-SNPs in T-bet binding
sites chosen for OligoFlow assay and reasons for choosing them.
Hit-SNP Associated-Trait Reasons for Choosing
rs1006353 Body Mass Index Consensus motif altered
rs10152590 Height Consensusmotif altered. H3K4me3mark present.
DNase sensitive region
rs11135484 Crohn’s Disease Near consensus motif. In intron for ERAP2which
has a role inMHCpeptide loading. H3K4me1 and
H3K4me3 marks present. DNase sensitive region.
rs13333528 Colorectal
Cancer
Near consensus motif. In intron for CDH1. Alters
RUNX motif. DNase sensitive region.
rs1420106 Coeliac Disease,
Crohn’s Disease
Near 5’ end of IL18RAP which is involved in sig-
nalling in immunity. H3K4me3 mark present.
DNase sensitive region.
rs2106346 Psoriasis H3K4me1 mark present. In intron for TSC1
rs2387397 Rheumatoid
Arthritis
Consensusmotif altered. H3K4me3mark present.
DNase sensitive region.
rs2703078 Coeliac Disease Consensusmotif altered. H3K4me1mark present.
DNase sensitive region.
rs2984920 Coeliac Disease Near 5’ end of RGS1. H3K4me3 mark present. Al-
ready tested in pulldown assay and Western blot.
Near T-bet consensus sequence.
rs3091310 Coeliac Disease Within locus for CCR3. H3K4me3 mark present.
DNase sensitive region.
rs5778 Body Mass Consensus motif altered. Within 2kbp of TRHR.
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Hit-SNP Associated-Trait Reasons for Choosing




Consensus motif altered. Within 50kbp of IL2RB




Consensus motif altered. DNase sensitive region.
rs8008961 Primary Biliary
Cirrhosis
H3K4me3 mark present. In intron for RAD51B.
rs8062727 Leprosy Consensusmotif altered. H3K4me1mark present.
DNase sensitive region.
Due to the novelty of the assay, there was no pre-defined cut-off point for dif-
ferential binding. In cases of no differential binding, we would expect the MFI
values for the two alleles to be equal and, thus the ratio of the two alleles to be
one. Therefore, to test for significance in the differential binding between the A
and G alleles of rs1465321, we took the natural logarithm of each MFI value and
analysed by paired t-test. This showed the differential binding to be significant
(p = 0.003). We performed the same analysis on all SNPs tested (table 4.2).
Table 4.2: Significance testing for differential binding in OligoFlow assay. Dif-
ference between ln(MFI) values of the two alleles for each SNP were tested and
ranked in order of significance.
Hit-SNP Number of replicates
performed
Mean of MFI values p value
rs1465321 5 0.263 0.003
rs11135484 3 0.172 0.080
rs1006353 3 0.091 0.129
rs2703078 2 0.118 0.172
rs1015290 2 0.055 0.276
rs2984920 2 0.130 0.431
rs13333528 2 0.037 0.450
rs8008961 2 0.023 0.742
rs142016 2 -0.012 0.753
rs2106346 1 0.020 n/a
131
4.2 Some SNPs Show Altered Binding
Hit-SNP Number of replicates
performed
Mean of MFI values p value
rs2387397 1 0.008 n/a
rs3091310 1 0.033 n/a
rs5778 1 0.013 n/a
rs6784841 1 0.062 n/a
rs743776 1 0.020 n/a
rs7441808 1 0.063 n/a
rs8062727 1 0.039 n/a
By this analysis, only rs1465321 reached significance. This was possibly be-
cause we were examining very small differences in binding and three replicates
is not enough to find a significant difference. Due to time constraints, we were
not able to repeat the assays further. Furthermore, throughout data acquisition,
the protocol was optimised to increase the difference between the MFI of the
negative and positive controls to try and detect small differences in binding.
There was large variability in the MFI of our positive control (T-bet +) between
experiments due to variations in number of cells used and efficiency of cell ly-
sis in each experiment. Although we examined the effect of cell number on
the experiment, cell number was sometimes suboptimal due to number of cells
available. In those experiments where cell number was suboptimal then our
experimental range would have been decreased and we would expect to see
smaller differences between two alleles of any ’hit’ SNP for technical reasons.
Likewise, in conditions of ample lysate, we might see small experimental vari-
ations amplified enough to give a false positive. In addition to increasing cell
number and optimising antibody concentration, as already discussed, we also
varied the voltage for the fluorescence channel. As such, there is wide inter-
assay variability in the experiments which is unideal for comparing MFI values
across experiments. Now that the protocol is established, moving it towards
a robust medium to high throughput assay might include the standardisation
of settings across all experiments using Cytometer Setup and Tracking beads
to set a standard baseline on the cytometer, combined with a fixed voltage in
the fluorescence channel. This would allow cleaner comparison across replicate
experiments for the same SNP.
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Figure 4.8: Some hit-SNPs did not show differential binding in OligoFlow. - MFI
values normalised to the negative control (T-bet -) = 1 are shown for those hit-SNPs
that did not show differential binding in OligoFlow.
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Figure 4.9: Some hit-SNPs were tested more than once to search for consistent
differential binding. - MFI values normalised to the negative control (T-bet - ) =
1 for hits which showed possibility of differential binding in first OligoFlow as-
say and were repeated. Each pair of bars represents one experiment (Exp). YT
denotes experiment performed with lysate from YT cells. Th1 denotes experiment
performed with lysate from in vitro cultured human Th1 cells.
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Moreover, this assay was a screening step and it would be more biologically
relevant to test for altered binding of these hit-SNPs from the OligoFlow as-
say in vivo. To gain some idea of where a cut-off for differential binding might
lie we plotted the difference in ln(MFI) values (fig. 4.10). This suggests that
a cut-off of approximately 0.1 for ln(MFI of allele1) - ln(MFI allele2) would be
appropriate. However, more work is needed to validate this, including repe-
tition of rs1006353, rs11135484 and rs2703078 to check whether the differences
for these are significant if we perform more replicates. Moreover, the results of
the assay need validation by a further method such as ChIP followed by allele-
specific qPCR. Based on the results from the OligoFlow, we took our top three
hits rs1465321, rs111354854 and rs1006353 to be of interest in further analysis










































































































Figure 4.10: Difference in ln(MFI) values for all replicates of all SNPs tested. -
Natural logarithm of each MFI value was taken and difference between the two
alleles for each experiment is shown. Data is as used in table 4.2. Difference of 0
(MFI values the same) is shown as solid line across graph.
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We tried as well to test some of the binding site hits that we had found for
GATA3 by OligoFlow. We made positive and negative control oligonucleotides
as we had for T-bet and incubated these with lysate from the Jurkat cell line,
which expresses GATA3. However, we found that we could not get the same
level of separation between positive and negative controls as we could for T-
bet, just by changing two residues. We tried two separate positive and negative
control pairs (V1 and V2, fig. 4.11) but found that, although we could obtain a
range of MFI values across the two pairs, the MFI values of each pair depended
heavily on the surrounding sequence (which differed between V1 and V2 and
is given in materials and methods table 2.3). The MFI values between the pos-
itive and negative control of each pair showed a small separation in MFI (fig.
4.11 (c)). This may demonstrate the relative promiscuity of GATA3 binding rela-
tive to DNA sequence versus T-bet and raises questions over whether the assay




























































Figure 4.11: Separation for GATA3 positive and negative controls. - Oligonu-
cleotides containing either the complete GATA3 consensus motif (Gata3+) or the
GATA3 consensus motif with two residues mutated (Gata3-) were designed. (a)
and (b) each show a pair of control oligonucleotides where Gata3+ and Gata3 -
differ by only two base pair changes in the consensus motif. (a) shows result for
version 1 of oligonucleotides (as labelled in materials and methods). (b) shows re-
sults for version 2 oligonucleotides. Surrounding sequence for the consensus motif
differs between (a) and (b) and shifts the MFI of the pair as can be seen by overlap-
ping results for the two pairs (c).
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4.3 Further In Silico Analysis of In Vitro Hits
4.3.1 rs1465321
One of our biggest ’hits’ from the binding studies was a SNP in the second
intron of the IL18R1 gene. This SNP, rs1465321, is in an LD block associated
with coeliac disease214, Crohn’s disease319 and, to a lesser extent, ulcerative
colitis.279 T-bet binds across this locus both at IL18R1 and IL18RAP and, indeed,
our in silico data also showed another potential binding site SNP, rs1420106 just
upstream of IL18RAP. GATA3 also binds across this locus. The SNP rs1465321
is also in a binding site for GATA3 in Th1 cells and rs1420106 is in a binding site
for GATA3 in both Th1 and Th2 cells. Furthermore, two SNPs in between the
IL18R1 and IL18RAP genes are also in a GATA3 binding site in both Th1 and Th2
cells (though they are not in a T-bet binding site.) These SNPs are rs12991737
which is in LD with rs3771180, a SNP associated with Asthma320 and rs3732123
which is in LD with rs17027258 a SNP associated with white blood cell sub-
types321. Another SNP rs2058622, also found in a GATA3 binding site in both
Th1 and Th2 cells, is found downstream of rs1465321, in the same intron of
IL18R1. Although not itself in a called T-bet binding site, rs2058622 sits between
two called T-bet peaks in a region of high T-bet binding. The rs2058622 SNP is
in the same LD block as rs1465321 and is also, therefore, associated with coeliac
and Crohn’s disease and ulcerative colitis. Alignments of T-bet and GATA3
binding in addition to histone marks and regions of DNase hypersensitivity
across the locus are shown in figure 4.12. T-bet also binds across the region in
mouse both in Th1 cells and Treg cells. Our lab also has data on the binding of
another master regulator, FoxP3, in the Treg cell lineage in mouse cells and this
also shows binding across the locus (figure 4.13.)
To investigate whether anything was already known about correlation of our
SNP with gene expression we checked the original papers for the disease-
associated SNP as lodged in the NHGRI GWAS catalogue and also searched
for our SNPs in the Gene Expression Variation (Genevar) tool from the Well-
come Trust Sanger Institute. The SNP rs1465321 is in LD with three published
GWAS hits rs13015714, rs2058660 and rs917997. In the original papers, the hap-
lotype at both rs13015714 and rs917997 were shown to be associated with ex-
pression of IL18RAP but not IL18R1 in whole blood in coeliac cases.214 Genevar
can be used to analyse ’in-house’ data but also provides published information
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Figure 4.12: Genomic annotation of region surrounding rs1465321. - UCSC
genome browser plot showing T-bet binding at the IL18R1/IL18RAP locus. GATA3
binding in Th1 cells and Th2 cells and called peaks for histone marks and DNase
hypersensitivity as used in results chapter one are also shown. Bottom track shows
location of other SNPs in the region that are trait-associated SNPs in the NHGRI
GWAS catalogue. The first and second SNPs (from left to right) in the this track
are not labelled to maintain clarity of figure but are rs9807989 and rs13015714 re-
spectively. The location of rs1465321 is shown as a red line across the figure. The
locations of other binding site SNPs are shown as blue lines across the figure. Be-
cause rs12991737 and rs3732123 cannot be resolved at the scale shown, they are
indicated by one line.
Figure 4.13: T-bet and FoxP3 binding at Il18r1/Il18rap in mice - UCSC genome
browser plot showing T-bet binding at the Il18r1/Il18rap locus in Th1 and Treg cells
in mouse and FoxP3 binding in Treg cells across the locus in mouse.
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on eQTLs from cell lines from the HapMap3 project,322 the Gencord collection46
and the MutHER project.323 These projects contain a variety of cells lines im-
mortalised from various cell types (including T cells, B cells and non-immune
cells) originally donated from a variety of people across a variety of ethnicities.
However, neither rs1465321 nor rs142016 were present in the database for this
resource.
When we looked back at the TRAP data for the sequences around each of our
binding site SNPs, we found that the sequence around rs1465321 was suggested
to have potential binding sites for AP1, FEV, ELV5, NFE2L2 and RORA_2. TRAP
also has a tool for predicting whether a SNP alters the binding of a transcription
factor in the JASPAR database. This tool did not return any significant hits but it
is important to remember that the JASPAR database is not exhaustive and does
not, for example, include a PWM for T-bet.
4.3.2 rs11135484
The SNP rs11135484 is in an intron of the ERAP2 gene and is in LD with
rs2549794, a SNP associated with Crohn’s disease.319 It is within a binding site
for T-bet but also GATA3 in both Th1 and Th2 cells (fig. 4.14) and is in LD with
rs2549794, a SNP associated with Crohn’s disease319. As its full name, Endo-
plasmic Reticulum Aminopeptidase 2 suggests, ERAP2 is involved in peptide
trimming: it is required for the generation of most MHC class I peptides in hu-
man but is not found in mouse.
When we searched for eQTL data using Genevar, we found that rs11135484 was
associated with altered ERAP2 expression in the HapMap collections (figure
4.15). The TRAP data suggested that the sequence around rs11135484 could
have potential binding sites for Runx1, SpI1, IRF1, FEV, ELV5 and IRF2 and that
the SNP could interfere with an Egr1 binding site.
4.3.3 rs1006353
As seen in results chapter one, rs1006353 is not within 2kbp of a gene. It is, how-
ever, within 50kbp of Mitochondrial Translational Initiation Factor 3 (MTIF3)
and General Transcription Factor 3A (GTF3A). As can be seen from figure 4.16,
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Figure 4.14: Genomic annotation of region surrounding rs11135484. - UCSC
genome browser plot showing T-bet binding at the ERAP2 locus. GATA3 bind-
ing, methylation marks and DNase hypersensitivity as used in analysis in results
chapter one is also shown. The location of rs11135484 is shown as a red line across
the figure.
Figure 4.15: rs11135484 is an eQTL. - Expression of ERAP2 by genotype at
rs11135484 in lymphoblastoid cell lines from HapMap 3 project as analysed by
Genevar.
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it is in a binding site for T-bet but also for GATA3 in both Th1 and Th2 cells.
Interestingly, it is also approximately 70kbp from LNX2 an E3 ligase which reg-
ulates the cellular location of CD8a.324 Another SNP, rs17753121, which is also
found between the genes for MTIF3 and LNX2, is in a GATA3 binding site in
Th2 cells. The SNP rs17753121 is associated with obesity while rs1006353 is
in LD with rs4771122, a SNP associated with Body Mass Index in a separate
study.325
Figure 4.16: Genomic annotation of the region surrounding rs1006353 - UCSC
genome browser plot showing T-bet binding around rs1006353. GATA3 binding,
methylation marks and DNase hypersensitivity as used in analysis in results chap-
ter 1 is also shown. The location of rs1006353 is shown as a red line across the
figure. The location of rs17753121, a SNP in a GATA3 binding site in Th2 cells is
shown as a blue line across the figure.
Although found in the Genevar databases, rs10006353 was not significantly as-
sociated with gene expression as an eQTL. In the original study, some associ-
ation was found between rs4771122 and expression of GTF3A in lymphocytes
and blood but this was best explained by another SNP, rs7988412, which is also
in LD with rs4771122. The SNP rs7988412 is located on the other side of the
trait-associtaed SNPs rs4771122 to our hit-SNP, rs1006353, on the chromosome.
Our TRAP analysis suggested potential binding sites for Runx1 and SpI1 in the
200bp region around rs1006353. Reflecting the gained GATA motif, as shown
in results chapter one, our TRAP analysis suggested that the SNP may alter
GATA1 binding. The analysis also suggested the SNP may interfere with an
Evi1 motif.
141
4.4 Functional Testing of OligoFlow hits
4.4 Functional Testing of OligoFlow hits
We wanted to test whether hit-SNPs that showed differential binding in our
OligoFlow assays would show differential gene activation in a luciferase assay.
Many of our hit-SNPs were outside of promoter regions. We reasoned that the
regions containing these SNPs must exert their effect by acting on a promoter
region and that we would need to include a promoter region in our luciferase
constructs in order to see any effect from differential binding at the SNP under
investigation. Since the best know promoter target of T-bet is the IFNG pro-
moter, we decided to make a general construct with this promoter upstream of
the firefly luciferase gene into which we could then insert a region containing a
SNP of interest from the OligoFlow assay. Therefore, we cloned the promoter re-
gion from -456 to +86 relative to the IFNG TSS into the PGL4.13 firefly luciferase
construct. (The PGL4.13 vector contains an SV40 promoter but the IFNG pro-
moter was inserted in such a way as to disrupt this promoter so that only the
IFNG promoter was controlling luciferase expression.) The region from -456 to
+86 was chosen based on the -445 to +64 construct used by Soutto et al and in-
cludes the -445 to -410 region shown to be critical for T-bet responsive promoter
activation by that group.180 We cotransfected this construct into EL-4 cells with
a renilla luciferase transfection control and tested for firefly luciferase expres-
sion that was increased when a T-bet expressing plasmid was also cotransfected
(fig. 4.17).
Of all the SNPs tested by OligoFlow, rs1456321 showed one of the most consis-
tent and biggest differences in T-bet binding. It is also not in a promoter region.
Therefore, we decided to test this SNP in our luciferase construct. We cloned
a region of 447 bp around rs1465321. The size of this region was designed
to be large enough to try and recapitulate some of the genomic environment
around rs1465321 but small enough not to include any other common SNPs as
determined from HapMap and from pilot phase 1000 genome data. We made
two separate constructs, one with the A allele at rs1465321 and one with the G
allele. We cotransfected this construct into EL-4 cells with a plasmid that ex-
pressed T-bet or an empty expression plasmid. We also transfected a renilla
luciferase expressing transfection control into all samples. After 24 hours, we
stimulated the cells and assayed for luciferase expression. To control for trans-
fection efficiency we divided firefly luciferase expression by renilla luciferase
expression. To standardise across experiments, we normalised each experiment
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Figure 4.17: T-bet responsive luciferase construct. - Firefly luciferase expression
normalised to renilla transfection control from IFNG promoter construct when co-
transfected with T-bet expressing plasmid or empty expression vector control. Re-
sults are averaged over three separate experiments. Error bars show standard de-
viation across three different experiments.
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to (firefly/renilla) expression for IFNG promoter alone =1. We found a slight
increase in firefly luciferase signal from the construct containing the G allele of
rs1465321 versus the construct containing the A allele (fig. 4.18) and this was
consistent across three experiments. This was not significant (p = 0.061, 2 tailed
paired t-test), most likely becausewe are looking at very small differences in sig-
nal across only three experiments. Because of the small differences, we would
need to further repeat the assay before we could draw any firm conclusions
and it is possible that the luciferase assay system introduces too much experi-
mental noise to assay the differences in binding properly. Furthermore, while
the region around rs1465321 does seem to act to enhance transcription of the
luciferase gene slightly, it does not show the strong enhancer activity typically
seen in luciferase assays. This may imply that this particular region is not, in
fact, functionally relevant. However, the presence of the T-bet binding site, in
addition to other genomic marks as seen in our computational analysis, would
suggest otherwise. Alternatively, the region may interact with other parts of the
IL18R1 locus to exert its full biological function and this is missed in a luciferase
assay that extracts the region from its full genomic context.
4.5 Conclusion
We have found three SNPs that are in a binding site for T-bet, alter binding
of T-bet in vitro and are in high LD with SNPs associated with coeliac dis-
ease, Crohn’s disease, ulcerative colitis or Body Mass Index. These SNPs are
in regions of genomic and immunological importance. We have developed
a luciferase construct to test the functional effect of altered binding at non-
promoter hit-SNPs. We found increased binding of T-bet at one of our hit-SNPs,
rs1465321. However, we did not find this to be significantly associated with
increased transcriptional activity at this time. This may indicate issues with
our approach or suggest that rs1465321 has no causal effect. Alternatively, it
could, indicate that the luciferase assay is not the most appropriate tool for
assaying such small differences in binding. Recent work from the ENCODE
project found that luciferase assays are more useful for verifying transcription
factor function at regions close to the TSS. Presumably, binding is more depen-
dant on sequence close to the TSS and is less dependant on the other chromatin


































Figure 4.18: Small but non significant increase in luciferase expression with G
versus A allele of rs1465321. - Expression of firefly luciferase from constructs con-
taining region around rs1465321 upstream of IFNG promoter. Expression is nor-
malised to renilla transfection control and then IFNG promoter alone = 1. Results
are shown for three separate experiments. Lines connect results from each allele for




flect the same issue and further work needs to be done before fully confirming
or discounting an effect at rs1465321 or any other of our hit-SNPs.
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5Functional Studies of the IL-18
Receptor
5.1 Introduction
One of the largest and most consistent hits from our in silico and in vitro work
was a SNP, rs1465321, in an intron of IL18R1. This SNP is in a binding site both
for T-bet and for GATA3 in Th1 cells and is found near a motif for T-bet. FoxP3
also binds at this region in mouse Treg cells: we can hypothesise that the same
is true in human Treg. The gene for IL18R1 neighbours the gene for IL18RAP
and disease-associated SNPs are found across the region. IL-18 signalling has a
key role in Th1 function: IL-18 stimulation can induce production of IFN-g, the
canonical Th1 cytokine and full IL18R1 expression is, at least in part, dependant
on T-bet. Despite its importance in immunology, data on the kinetics of IL18R1
and IL18RAP expression is conflicting on some key points. There is disagree-
ment over the level of IL18R1 expression on unstimulated cells and over the
extent to which T-bet is required for IL18R1 expression under different circum-
stances. If we are to functionally connect altered transcription factor binding
to downstream mechanistic effects and downstream disease risk then we need
a better understanding of the fine details of IL18R1 expression and the role of
IL-18 in disease mechanisms. To try and examine some of these fine details, we
moved to mouse studies. The IL18R1/IL18RAP locus is highly conserved be-
tween mouse and human and assays in mice have two important advantages.
Knockout models including the T-bet knockout mouse, are available and we
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can induce and manipulate disease mechanisms in such studies.
5.2 Kinetics of IL18R1 Expression
5.2.1 IL18R1 Expression on Wild-Type and T-bet-/- Cells
The kinetics of IL18R1 expression have been followed both in C57BL/6 and
BALB/c mice by Yu et al.204 This group show that intermediate levels of IL18R1
are expressed on unstimulated CD4+ cells and that this expression is then down-
regulated on activation. IL18R1 is then reexpressed or further downregulated
as a cell commits to the Th1 or Th2 lineage respectively. At the mRNA level, Yu
et al observe co-regulation of IL18R1 and IL18RAP during the process of lineage
commitment. However, Yu et al use the entire CD4+ population, as isolated by
magnetic beads, for their starting population. Therefore, they cannot exclude
effects of effector and memory cells in the population. As for the role of T-bet,
in previous reports the absence of T-bet either diminishes or completely abro-
gates the upregulation of IL18R1 in the Th1 condition.170,213
To determine whether T-bet deficient cells can upregulate IL18R1 at all and to
examine the kinetics of IL18R1 expression relative to CD3+ stimulation in a pure
population of naïve cells, we sorted naïve cells from wild-type and T-bet -/-
mice to very high purity. Sortingwas based on CD62Lhi and CD44lo expression
which defines a naïve population.326 The ligand of CD62L is expressed on the
high endothelial venules of peripheral lymph nodes: the expression of CD62L
on naïve cells targets them to the peripheral lymph nodes where they may meet
their cognate antigen. CD44 is also involved in cell migration and its expression
on CD4+ cells is a mark of an effector/memory phenotype. We then cultured
these cells in Th1 or Th2 conditions and examined the kinetics of IL18R1 expres-
sion. We found that, even starting from this pure population, the wild-type Th1
cells upregulated IL18R1 over the length of the timecourse. By contrast the Th2
cells rapidly downregulated IL18R1 such that expression of this molecule was
never seen even at early timepoints (fig. 5.1). We found that IL18R1 upregula-
tion was defective in T-bet deficient cells: expression of IL18R1 was noticeably
reduced in T-bet-/- Th1 cells versus wild-type Th1 cells at all timepoints (fig.
5.1). However, expression of IL18R1 was higher on T-bet-/- cells cultured in
Th1 conditions than either wild-type or T-bet-/- cells in Th2 conditions (figs.
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5.1 and 5.2). This result suggested, in contrast to Thieu et al,213 that T-bet -/-
cells can express some IL18R1 when cultured under Th1 conditions. Of interest
was a small reduction in IL18R1 between 24 and 48 hrs post-activation in the
T-bet-/- cells unlike the wild-type cells, where the proportion of IL18R1 posi-
tive cells increased with each timepoint. This could illustrate the instability of
IL18R1 expression in the absence of T-bet and may suggest why some reports
find IL18R1 in T-bet -/- cells and some do not depending on timepoint of assay.
Of note, samples from 0 and 12 hours post activation were acquired during the
same flow cytometry session. Samples from 24 and 48 hours post activation
were also acquired during the same session as each other but during a different
session to those samples for 0 and 12 hours post activation. Therefore, care must
be taken in directly comparing data from 12 hours and 24 hours. However, gat-
ing with respect to the unstained samples in both sessions is similar allowing
broad trends to be noted.
In light of our timecourse results we decided to test whether IL-18 could sig-
nal in T-bet -/- cells. We cultured T-bet-/- cells in Th1 conditions for six days
and then washed the cells and incubated them for 90 minutes in serum free
medium. We then added IL-18 to the cultures and measured response to IL-18
by phosphorylation of p38. Phosphorylation of p38 is a downstream effect of
IL-18 signalling in CD4+ cells.199 Both wild-type and T-bet-/- cells were able
to respond to IL-18 by phosphorylating an already available supply of p38 (fig.
5.3).
5.2.2 IL18R1 Expression on Wild-Type IFN-g-/- Cells
T-bet acts to stabilise the expression of IFN-g, the production of which is re-
duced in T-bet deficient cells. We examined whether the reduced capacity for
IL18R1 expression in T-bet-/- cells might be mediated through the resultant re-
duction in IFN-g expression rather than the loss of T-bet itself. To do this, we
assessed IL18R1 expression in IFN-g deficient mice. We found reduced IL18R1
expression in IFN-g-/- mice compared to a parallel wild-type control but sub-
stantial IL18R1 was still seen in these cells (71% positive cells in IFN-g -/- cells
versus 95.8% inwild-type, fig. 5.4). Therefore, we can conclude that IFN-g is not
essential for IL18R1 upregulation. This contrasts with work by Smeltz et al206
which suggests that IFN-g is required for the induction of high level IL18R1 ex-
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Figure 5.1: T-bet deficient cells are impaired but not unable to express IL18R1
in Th1 conditions. - Naïve CD4+ cells were sorted from wild-type and T-bet-/-
mice and activated using aCD3 and aCD28 in Th1 or Th2 conditions. IL18R1 ex-
pression was assessed by flow cytometry at varying timepoints after removal from
activation.
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Figure 5.2: T-bet deficient cells have deficient upregulation of IL18R1. - His-
tograms of IL18R1 expression on wild-type and T-bet-/- cells that have been acti-





              
 
Figure 5.3: T-bet deficient cells can phosphorylate p38 in response to IL-18. - Cells
from wild-type and T-bet-/- mice were cultured in Th1 conditions, serum starved
and then IL-18 was added for varying lengths of time. Cells were harvested and
signalling response was measured by Western blot for pp38. UN denotes unstimu-
lated condition in which cells were serum starved but did not receive IL-18. Num-
bers denote time in minutes between addition of IL-18 and harvest of cells.
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pression by IL-12. However, although Smeltz et al do find a substantial reduc-
tion in IL-12 driven IL18R1 expression in IFN-g-/- cells they do observe some
IL18R1 expression in these conditions. The differences in our data most likely
reflect differences between our experiments. Smeltz et al used splenic CD4+
cells, activated these for 48 hours and then removed them from activation and
cultured for a further 48 hours. We used CD4+ cells that had been sorted naïve
and activated these for a longer period of time prior to running our timecourse.
Furthermore, Smeltz et al do not consider a role for T-bet and do not attempt to
separate out the direct effects of IFN-g loss versus the indirect effects of IFN-g
loss through reduced T-bet expression. Our data supports the idea that IFN-
g is less necessary than T-bet for stable IL18R1 expression given that IFN-g-/-
cells reach 71% IL18R1 positive cells versus a maximum of 42.9% in the T-bet
-/- cells. However the timecourse experiments are not directly comparable as
the IFNg-/- was on a BALB/c background. From Yu et al,204 we would expect
BALB/c and C57BL/6 strains to have similar kinetics of IL18R1 expression and
so this should not affect the results substantially.
To better address the direct contribution of T-bet and IFN-g to IL18R1 expres-
sion, we used data generated by Jenner et al158 on mRNA levels in T-bet-/-,
IFN-g-/- double deficient cells that were then transduced with constitutive T-
bet before assayingmRNA levels by array (stored at ArrayExpress, Accession E-
TABM-759). Transduction of T-bet into these cells was able to upregulate IL18R1
and IL18RAP expression even though IFN-g was still absent, demonstrating
the independence from IFN-g of T-bet in IL18R1 and IL18RAP expression (fig.
5.5).
5.2.3 IL18R1 and IL18RAP Expression Across CD4+ Subsets
and Mouse Strains
IL-18 signals through a heterodimer consisting of both IL18R1 and IL18RAP.
There is conflicting data as to whether and under what conditions these two
proteins are co-regulated. To assess relative levels of IL18R1 and IL18RAP in
different CD4+ cell subsets, we used data generated in house for mRNA lev-
els across Th1, Th2, Th17 and Th0/Thp subsets in BALB/c and C57BL/6 mice.
Cells had been sorted as naïve, polarised for seven days and then reactivated
with aCD3 and aCD28 for four hours. It should be noted that Balb/c Th0 cells
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Figure 5.4: IFN-g deficient cells are able to express IL18R1 in Th1 conditions.
- Naïve CD4+ cells were sorted from wild-type and IFN-g-/- mice and activated
using aCD3 and aCD28 in Th1 conditions. IL18R1 expression was assessed by flow
cytometry at varying timepoints after removal from activation.
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Figure 5.5: T-bet can upregulate both IL18R1 and IL18RAP independently of
IFN-g. - Data from expression arrays on cells from T-bet-/-, IFN-g-/- double
knockout mice which had been retrovirally transduced with empty retrovirus
(Empty) or with constitutively active T-bet (T-bet) was analysed to calculate fold
change in expression of IL18R1 and IL18RAP upon addition of constitutively ac-
tive T-bet. Fold change is normalised to cells transduced with empty retrovirus for
each of IL18R1 and IL18RAP. Error bars show standard deviation of two biological
array replicates.
154
5.2 Kinetics of IL18R1 Expression
had been cultured with just IL-2 for seven days. By contrast, C57BL/6 Thp
cells had been sorted as naïve cells directly into TRIzol for RNA extraction.
Fold change of mRNA for IL18R1 and IL18RAP across subsets and in wild-type
and T-bet-/- cells was calculated relative to mRNA in wild-type Th0 cells (for
BALB/c) or wild-type Thp cells (for C57BL/6) (fig. 5.6). Because the neutral
(Th0 or Thp) condition is different between each dataset and because datasets
were acquired on different types of array, we cannot draw direct comparisons
between the two datasets. However, we can examine trends within the datasets
for the two strains.
As expected, IL18R1 expression is upregulated in Th1 cells compared to
Th0/Thp and although upregulation is seen in the T-bet-/- Th1 cells, this up-
regulation is less in the T-bet deficient cells than wild-type. IL18RAP expres-
sion follows a similar pattern. It is higher in Th1 cells than in Th0/Thp and
an increase is still seen but is smaller in T-bet-/- Th1 versus Th0/Thp than in
wild-type Th1 versus Th0/Thp. In Th2 cells IL18R1 expression is lower than
in Th0/Thp cells but IL18RAP is upregulated both in wild-type and T-bet-/-
cells. This suggests that IL18R1 and IL18RAP are not always co-regulated.
IL18RAP expression is also upregulated in cells skewed to Th17, whereas
IL18R1 expression is either not upregulated (C57BL/6) or very slightly upregu-
lated (BALB/c).
Taken together, these data indicate that IL18R1 and IL18RAP might be co-
regulated in Th1 lineage conditions but not in other conditions. The one po-
tential caveat to this is that if IL18R1 is downregulated by CD3, as has been
suggested,190,204–206 stimulation of these cells prior to RNA extraction for the
arrays may have affected the results. However, since we do see high levels of
IL18R1 in wild-type cells, this does not seem to have been the case.
The two strains of mice that we examined, Balb/c and C57BL/6 are geneti-
cally different. To check whether there was any genetic variation between the
two strains at either the Il18r1/Il8rap locus or the Il18 locus, we used the Mouse
Genome Informatics Resource (http://www.informatics.jax.org/) to search for
SNPs on chromosome one (the chromosome on which Il18r1 and Il18rap are lo-
cated) and chromosome nine (the chromosome on which Il18 is located). There
were no SNPs reported between C57BL/6 and Balb/c in any of the loci exam-
ined. The nearest SNP to the Il18r1/Il8rap locus was over 470kbp away and the
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Figure 5.6: Expression of IL18R1 and IL18RAP across CD4+ cell subsets. -
Data from expression arrays on different CD4+ cell subsets in both BALB/c and
C57BL/6 mice was analysed for expression of IL18R1 and IL18RAP. Data was nor-
malised to expression for wild-type (WT) cells in Th0 or Thp condition. Data for
C57BL/6 is averaged over two replicate arrays. Data for Balb/c is from one array
only.
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nearest SNP to the Il18 locus was over 170kbp away.
5.3 IL18R1 Expression In Vivo
The above work demonstrates some key principles of IL18R1 regulation but in
optimized in vitro culture conditions where populations can be neatly defined
and tightly controlled. As discussed in the introduction and elsewhere, while
the CD4+ lineage subset paradigm is a useful concept and broadly applicable,
the in vivo context is not always quite as well delineated or as fixed. To investi-
gate the role of IL18R1 in vivo in a disease context, we used two mouse models.
Because our interest in the IL18R1 locus stemmed from an observation of dif-
ferential T-bet binding at a SNP in a region highlighted by GWAS for coeliac
and Crohn’s diseases, we used a model of general Inflammatory Bowel Disease
(IBD) and a model of coeliac disease.
5.3.1 Naïve T Cell Transfer Model of Inflammatory Bowel Dis-
ease
For the IBD model, we sorted naïve cells from wild-type or T-bet -/- mice and
injected 500,000 of these cells per mouse into Rag2-/- hosts. We sacrificed half
of the recipient mice at two weeks after injection and the remaining mice at
four weeks after injection. We harvested spleen and mesenteric lymph nodes to
examine kinetics of IL18R1 upregulation across disease timepoints in addition
to across genotypes. We stimulated the cells with PMA and Ionomycin and
assayed for IL18R1 and IFN-g by intracellular staining and flow cytometry (fig.
5.7). Despite low cell counts in some conditions, this model shows that T-bet-/-
cells can express IL18R1 during an in vivo model, as well as in optimised in
vitro culture. Interestingly, in the T-bet-/- cells we saw a decrease in IL18R1
expression from two weeks to four weeks suggesting that IL18R1 expression
is less stable with time in the absence of T-bet which agrees with our in vitro
findings. This experiment needs repeating to confirm these results.
157























































Figure 5.7: IL18R1 expression with progression of naïve adoptive transfer model
of IBD. - Rag2-/- mice were injected with naïve CD4+ cells as shown in (a). Cells
were recovered at two weeks or four weeks and CD4+ cells were examined for
expression of IFN-g and IL18R1 as shown in (b). Results are shown in (c).
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5.3.2 Primed Effector/Memory CellModel of CoeliacDisease
For the coeliac model, we used the model published by Freitag et al.327 We im-
munized wild-type and T-bet-/- mice with gliadin in adjuvant and then trans-
ferred the effector/memory CD4+ cells from these mice into Rag1 deficient
hosts (fig 5.8). If maintained on a diet containing high levels of gluten thesemice
develop symptoms resembling coeliac type disease. Similar to its human coun-
terpart, the model is milder than most models of IBD. However, administration
of wild-type effector/memory cells to Rag1-/- recipients has been shown to
slow subsequent weight gain by the mice compared to controls and to result in

























Figure 5.8: Coeliac disease model. - Schematic of coeliac disease model used.
In agreement with Frietag et al, we found that, although all mice gained weight
during the eight week timecourse, mice given effector/memory CD4+ cells did
tend to gain less weight as a percentage of starting body mass than mice given
PBS control (fig. 5.9). However, in our hands, this was not significant.
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    
Figure 5.9: Weight gain in coeliac model. - Mice were injected with effec-
tor/memory CD4+ cells from wild-type or T-bet-/- mice that had been primed
with gliadin injection or with PBS as control. Weight was measured over eight
weeks and is shown relative to mouse weight at time of injection. Error bars show
standard deviation in percentage weight change relative to starting weight for all
mice in group. Group sizes were as follows: three mice received wild-type ef-
fector/memory cell, four mice received T-bet-/- effector/memory cells, two mice
received PBS.
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After eight weeks, we sacrificed the mice. We weighed the spleen and small
intestine of each mouse (fig. 5.10). We saw no correlation between mass of



















































Figure 5.10: Mass of spleen and small intestine showed no trend between exper-
imental and control animals. - Spleen mass is shown in (a). Mass of small intestine
is shown in (b). Error bars represent standard deviation across experimental group.
We stained a section of the proximal small intestine for histology. This showed
some disease in somemice. We saw partial villous atrophy in some sections (fig.
5.11 (a) and (b)) and fat villi and eosinophil infiltrate were also seen in some
mice. However, crypt hyperplasia (as measured by number of mitotic cells in
five adjacent crypts) and inflammation (as scored by an external assessor from
0 to 3 for Lamina Propria Chronic Inflammation (LP CI)) did not correlate with
receipt of wild-type or T-bet-/- cells or PBS control (fig 5.12). As previously
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mentioned, the model is relatively mild. Furthermore, the mice are monitored
over an eight week period after receipt of cells. This constituted sufficient time
for one of our PBS controls to develop inflammation despite having not received
cells, possibly from reaction to a microbe not screened out by our in-house Spe-
cific Pathogen Free conditions and in the context of an immunodeficient state.
This mouse had a small spleen, partial villus atrophy and scored the maximum
LP CI score of three. These findings strongly suggests that we had too few mice
to draw strong conclusions about overall disease at this time. Of note, Freitag et
al also find duodenal inflammation in their control group, although it is not as
great as in their experimental groups.
 
 
Figure 5.11: Histology of small intestine sections showed some evidence of dis-
ease in coeliac model. - Sections of small intestine were harvested and stained for
each mouse in coeliac model. (a) Normal small intestine from PBS control mouse.
(b) Example of partial villous atrophy in small intestine of mouse injected with
T-bet-/- cells. (c) Example of fat villi in mouse injected with wild-type cells. (d) Ex-
ample of eosinophil infiltration in mouse injected with wild-type cells. Eosinophils
circled in black.
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Figure 5.12: Histology scores for coeliac model. - Sections of small intestine were
examined for presence of mitotic cells (a) and scored for presence of inflammation
(b). Error bars indicated standard deviation for experimental group.
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5.3 IL18R1 Expression In Vivo
To examine the cytokine production of the cells injected, we harvested themesen-
teric lymph nodes and analysed IL18R1 and IFN-g expression on the CD4+ cells
found in both spleen and mesenteric lymph node by intracellular staining. We
also examined the expression of IL-17A on these cells because the research by
Frietag et al327 suggests that IL-17 has a role in the disease in addition to IFN-g.
Unsurprisingly, we found fewer IFN-g producing cells in the T-bet-/- samples.
We found a high number of IL-17A producing cells and this number was fur-
ther increased in the T-bet-/- samples (fig. 5.13). In the mesenteric lymph node,
the difference in percentage of IFN-g producing cells between the two groups
was significant (p = 0.02).The differences in the other populations was not. In
the spleen, the difference in percentage of IFN-g producing cells was also sig-
nificant (p = 0.01), as was the difference in double producers (IFN-g+, IL-17A+
(p= 0.03). On closer examination of the plots (fig. 5.13 (b)) we found that one
mouse from the T-bet-/- group had very low numbers of IL-17A producing
cells compared to all others in the group. We checked for any other abnormali-
ties in this mouse and found that it also had a lower small intestine mass than
all other mice receiving T-bet-/- cells. Furthermore, we recovered fewer CD4+
cells from this mouse than the others suggesting that the model may not have
worked properly in this mouse. If we exclude this sample from analysis then,
in the lymph node, the percentage of IFN-g producing cells remains signifi-
cant (p=0.01) and the percentage of IL-17A producing cells become significant
(p= 0.01). In the spleen, percentage of IFN-g producing cells also remains sig-
nificant (p= 0.026) and the percentage of IL-17A producing cells also becomes
significant (p= 0.008). However, when this sample is removed the percentage of
double producing cells is no longer significant (p=0.059).
We then examined IL18R1 expression in the CD4+ population. Most of the
CD4+ population were IL18R1 positive. (fig. 5.14 (a)). To show that this was
not due to unspecific binding, we compared the CD4+ population to the to-
tal live cell population. In the total live cells, we saw a bimodal distribution
of IL18R1 expression as we would expect from the different cells types present
and demonstrating that out results did not result from non specific binding (fig.
5.14 (b)).
Although most CD4+ cells were IL18R1 positive, we did see a few IL18R1 neg-
ative cells (as seen from the negative ’tails’ on the histograms in fig. 5.14 (a)). To
investigate whether these belonged to a specific population of cytokine pro-
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Figure 5.13: Cytokine production in spleen and mesenteric lymph node from
coeliac model. - Spleen and mesenteric lymph nodes were harvested eight weeks
after administration of gliadin primed effector/memory CD4+ cells and stained
to asses IL-17A and IFN-g production by intracellular stain. Gating protocol for
experiment is shown in (a). Percentage of IL-17A producers, IFN-g producers and
IL-17A, IFN-g double producers in mice injected with wild-type or T-bet-/- cells
is shown in (b). Blue crosses represent individual mice and black lines represent
mean for group.
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ducers, we examined IL18R1 expression in the different cytokine producing
populations of the CD4+ population. ((IFN-g+, IL-17A-), (IFN-g+, IL-17A+),
(IFN-g-, IL-17A+) and (IFN-g-, IL-17A-)) (fig 5.15). As can be seen from the fig-
ure, the IL-17A producing populations (red and blue lines) tended to have high
levels of IL18R1 expression independently of genotype. By contrast the IL-17A
negative populations and, particularly the IFN-g+ IL-17A- population showed
a bimodal distribution of IL18R1 expression in the T-bet-/- cells. This second
result demonstrates the need for T-bet to stabilise IL18R1 expression in Th1 type
cells. However, the T-bet independent high expression of IL18R1 on IL-17A sin-
gle producers and IL-17A+, IFN-g+ double producers is more unexpected and
suggests a role for IL18R1 in non Th1 type cells. This result also suggests IL18R1
expression is T-bet independent in non Th1 type cells in this model.
Gating for the above results was based on unstained control (see figure 5.13).
However, some CD4+ cells were seen in mice injected with PBS control.
This was most likely because CD4+ is also expressed at low levels on some
macrophages. To exclude the possibility that low level expression of CD4 on
macrophage were affecting our results, we redid the CD4+ gating based on a
PBS control mouse rather than the unstained control. This affected some of
our percentages but did not affect the overall trends in our data. (Data not
shown.)
We also harvested a small section of the small intestine from each mouse, ex-
tracted the RNA and examined expression of IL18R1, IL18RAP, IFN-g and IL-
17A by qPCR. The results showed a general trend towards more cytokine pro-
duction in those mice that had received cells versus PBS control and this was
significant in IFN-g production between mice given wild-type cells and PBS
(p=0.017). This suggests that the injected CD4+ cells were instigating active
inflammation in the small bowel despite the mixed results from the histology
data. However, no significant differences were found between mice given wild-
type and mice given T-bet-/- cells, although IL18R1 expression tended towards
significance (p=0.089) (see fig. 5.16).
5.3.3 Cells used in Coeliac Model
We also phenotyped the effector/memory CD4+ cells that are generated in the
wild-type or T-bet-/- mice by gliadin priming. We injected wild-type and T-
166

































































Figure 5.14: Most CD4+ cells from coeliac mice are IL18R1 positive. - IL18R1
expressionwas examined in CD4+ cells and total live cells from coeliac model mice.
(a) Example plots for IL18R1 expression in CD4+ cells from spleen and mesenteric
lymph node ofmice injectedwithwild-type cells (blue line) or T-bet-/- cells (orange
line). (b) Example plots for IL18R1 expression in total live cells from spleen and
mesenteric lymph node of mice injected with wild-type cells (blue line) or T-bet-/-
cells (orange line).
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Figure 5.15: Example plots for IL18R1 expression on subsets of cells taken from
spleen and lymph node ofmice in coeliacmodel. - All cells are CD4+ and then fur-
ther gated on IFN-g-, IL17A+ (red line), IFN-g-, IL17- (green line), IFN-g+, IL17A-
(orange line) or IFN-g+, IL17+ (blue line). Two plots are shown per condition and
each plot represents one mouse. All histograms show cell count normalised to total
cells in the gate.
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     
     
 
Figure 5.16: MessengerRNA expression in small bowel of coeliac mice. - Tissue
was harvested from small bowel of mice in coeliac model and extracted RNA was
assayed for expression of IL18R1, IL18RAP, IFN-g and IL-17A
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bet-/- mice with gliadin in Complete Freund’s Adjuvant (CFA) and then Incom-
plete Freund’s Adjuvant (IFA) as before or with CFA and then IFA on its own
or with two rounds of PBS. We then harvested spleens as before. However, in-
stead of sorting effector CD4+ cells and reinjecting into Rag1-/- hosts, we stim-
ulated the cells and examined expression of IL18R1, IFN-g and IL-17A. We also
stained for most of the markers we had used for sorting the cells (CD4, CD44,
and CD25) to test for changes in the number of naïve and effector/memory
CD4+ cells in the mice as a result of gliadin priming. Surprisingly this sug-
gested that the mice primed with PBS had a greater percentage of effector and
smaller percentage of naïve cells as a percentage of total CD4+ than mice given
gliadin in adjuvant or adjuvant alone (fig 5.17).
However, CD62L is downregulated by activation with PMA and Ionomycin
and so gating for effector/memory cells was on CD44 expression alone. Fur-
thermore, CD25 is upregulated by activation with PMA and Ionomycin so we
could not use this as a marker to exclude Tregs from our analysis as excluding
CD25+ cells also excluded many effector cells. Since Treg cells comprise ap-
proximately 5-10% of total CD4+ cells, this was not ideal.328 To address some of
these issues, we examined cells from some of the mice for surface markers only,
as used for cell sorting, without stimulation. This showed that, as expected, the
mice injected with PBS had fewer effector/memory and more naïve cells than
those mice injected with gliadin in CFA/IFA or with CFA/IFA alone. In the
wild-type mice, we saw more effector cells in those mice given gliadin in addi-
tion to CFA versus those mice given CFA alone. In the T-bet-/- mice, we saw
a higher percentage of cells in those mice just given CFA (fig. 5.18). However,
for the surface staining, we only have two mice per group so cannot draw firm
conclusions.
Unsurprisingly, we saw very little cytokine production in our naïve cells (see
fig 5.19 (a) for example data). In the effector/memory population, we found
very few IFN-g producing cells from the T-bet-/- mice, whereas between 10%
and 40% of cells from wild-type mice produced IFN-g. IL-17A producing cells
were seen in the effector/memory population from all mice but were generally
slightlymore numerous from the T-bet-/- mice. These results might be expected
from the role of T-bet in IFN-g production. Less expected was a similar trend to
the effector/memory cell counts in that mice injected with PBS tended to have
more cytokine producing cells than mice from the same genotype injected with
170



































































































Figure 5.17: Phenotype of cells introduced into coeliac model. - Wild-type or
T-bet-/- mice were injected with gliadin, CFA/IFA alone or PBS and percentage
of naïve and effector memory CD4+ cells was measured using CD44 expression.
Gating for populations is shown in (a). Percentage of naïve and effector memory as
percentage of total CD4+ is shown in (b). Blue crosses represent individual mice.
Black lines represent mean for the group.
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Figure 5.18: Phenotype of cells introduced into coeliac model based on CD44 and
CD62L expression in unstimulated population. - Cells were harvested as before
but surface stained only without stimulation based on surface expression of CD44
and CD62L.
gliadin in CFA/IFA or CFA/IFA alone (fig 5.19). However this may be due to
the surface marker gating issues discussed earlier.
We found very few double positive (IFN-g+, IL-17A+) cells in the effec-
tor/memory fraction of our cells. (For one wild-type PBS treated mouse we
found 3.08% and, for another, 2.33% but all others were under 2%.). However,
we did find cells that stained positive for IL18R1 and also expressed IFN-g
which is somewhat expected and cells that were positive for IL18R1 and also
expressed IL-17A which was less expected, although consistent with the results
from the full coeliac model. Percentages of the effector/memory population
that were double positive for IL18R1 and IFN-g or double positive for IL18R1
and IL-17A are shown in figure 5.20.
The surface stain experiment also allowed us to examine the difference in IL18R1
expression between effector/memory and naïve CD4+ cells. Our analysis sup-
ported previous reports that, in naïve T cells, there is a basal level of IL18R1 but
this is either up- or downregulated on activation depending on local conditions
to give a bimodal distribution in effector/memory cells (fig. 5.21). We have
yet to determine whether IL-18 signalling can occur through this basal level of
IL18R1 on naïve CD4+ cells and whether cytokines other than IFN-g can be
produced as a result.
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Figure 5.19: Cytokine production by cells used in coeliac model. - Cells from
gliadin primed mice were analysed for IFN-g and IL-17A production. Gating
for naïve and effector memory cells and example plots for cytokine production
are shown in (a). Percentages of IFN-g producers and IL-17A producers in effec-























































































Figure 5.20: IL18R1 expression across IFN-g and IL-17A producing cells. - Cells
were analysed for expression of IL18R1 plus production of either IFN-g or IL-17A.
5.4 Conclusion
We have confirmed reports of basal IL18R1 expression on unstimulated CD4+
cells. Because we sorted our cells to high purity of naïve cells, we can conclude
that IL18R1 is expressed on naïve CD4+ cells. Expression seen in previous pa-
pers does not all result from contamination with an effector/memory popula-
tion. Our results suggest that IL18R1 and IL18RAP are co-regulated in Th1 cells
and that T-bet is required for full expression of IL18R1 in these cells. However,
some IL18R1 can be expressed in the absence of T-bet and T-bet-/- cells can
signal in response to IL-18 in vitro.
Our coeliac model shows some interesting data as to cytokine production and
IL18R1 expression with respect to T-bet loss in vivo. However, the model was
generally inconsistent and subject to high experimental variability as seen from
our macroscopic and histology data. Results from this model should therefore
be treated with caution and we cannot draw any firm conclusions about overall
disease pathology at this time. It is possible that larger sample sizes would have
allowed us tomake firmer conclusions. However, this experiment was a prelim-
inary experiment to examine whether we could establish a coeliac model and


















































Figure 5.21: Bimodal distribution of IL18R1 seen on effector/memory cells. -
IL18R1 expression on cells was analysed on naïve and effector memory popula-
tions. Example gating is shown in (a). Example histograms showing IL18R1 ex-
pression in naïve (red line) and effector/memory (blue line) populations, for both
wild-type and T-bet-/- cells, is shown in (b).
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5.4 Conclusion
used were small. Given the high variability in the data and the practicalities of
needing to use different genotypes of mice at different stages of the experiment,
we conclude that this model is not suitable for further use in our work.
However there is some suggestion that, in a disease context, high levels of
IL18R1 can be expressed on IFN-g- cells both in wild-type and T-bet -/- cells
hinting at a distinct T-bet independent mechanism of IL18R1 upregulation in




Recent large scale genomics projects such as ENCODE and the 1000 Genomes
Project have demonstrated the abundance of SNPs across the genome and have
suggested that SNPs in regulatory regions, including transcription factor bind-
ing sites, have the potential to influence downstream phenotype including dis-
ease susceptibility. Such work builds on the increasing quantity of data on
SNPs associated with diseases and other traits by GWAS. At present, most of
the results presented are based on statistical associations. For example, the 1000
Genome Project finds a small but consistent excess of rare variants in binding
sites for the CCCTC-binding factor which they conclude demonstrates a small
deleterious effect for variation in binding sites for this transcription factor.329
The ENCODE project found that 12% of trait-associated SNPs derived from the
NHGRI GWAS catalogue overlapped a previously characterised transcription
factor binding site versus 6% of total SNPs in 1000 genomes. This result sug-
gests some binding site SNPs increase disease risk.3 However, projects such as
ENCODE have undertakenmuch of their work in cell lines. For our information
to be truly disease relevant and to move from statistical association to specific
molecular mechanism, some genomic assays need to be performed in the right
cell type and at the right time. Furthermore, better in vitro and in vivo assays are
needed to move from statistical associations to underlying mechanism.
We have run bioinformatic analysis to find disease-associated SNPs in binding
sites for the Th1 and Th2 lineage master regulators T-bet and GATA3 in Th1
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6.1 Overview
and Th2 cells. We have then established a new medium-throughput assay for
testing these SNPs. We then moved to a mouse model system to try and bet-
ter understand genomic regulation at a region highlighted by our analysis, the
IL18R1/IL18RAP locus. We also investigated the role of one of the transcription
factors, T-bet, in coeliac disease. Coeliac disease is one of the diseases associated
with some of our hit-SNPs. In the course of our analysis, we set up a workflow
for beginning to assay the functional relevance of some of the SNPs found by













































Figure 6.1: Workflow for project analysis. - Overview of the analysis performed
in this thesis. Work performed is written in black. Analysis to be included in the




6.2.1 Histone Modification and DNase Hypersensitivity
We found a total of 238 SNPs that were in a binding site for at least one of T-bet,
GATA3 in Th1 cells or GATA3 in Th2 cells and were also in high LD with a SNP
from the NHGRI GWAS catalogue. Many of these SNPs were found in tran-
scription factor binding sites that intersected other genomic features such as the
histone modifications H3K4me1 and H3K4me3 or regions of DNase hypersen-
sitivity. An overview of features associated with our hit-SNPs can be seen in
figure 6.2.
Our annotation was performed using publicly available datasets10,303,304 and
the intersections were performed on the Galaxy platform.98–100 Therefore, very
little computational expertise was required to annotate our SNPs and provide
some prioritisation as to which SNPs we should test in our further assays. Fur-
ther annotation will be possible when the newest datasets of the ENCODE
project are no longer under embargo. Our annotation is similar to some of
the annotation performed by projects such as ENCODE. However, we have the
advantage that our ChIP-Seq data was generated in cells relevant both to the
transcription factors under investigation and to disease pathology. One of the
ENCODE project publications finds that a gene desert on chromosome 5p13.1
contains three SNPs rs9292777, rs11742570 and rs6451493 which are associated
with Crohn’s disease or ulcerative colitis and are in a binding site for GATA2
in HUVEC cells.3 Of these SNPs, rs11742570 is also in a site of DNase hyper-
sensitivity in both Th1 and Th2 cells. The authors hypothesise that this data
might suggest functionally relevant GATA3 binding in Th1 and Th2 cells. In
our study, we found that GATA3 does indeed bind at rs11742570 but only in
Th1 cells, not in Th2. Closer examination of this region reveals that the peak of
GATA3 binding at this SNP is quite small compared to a larger binding peak
for T-bet and for GATA3 in both Th1 and Th2 which is approximately 20kbp
upstream. Another SNP, rs929777, which is approximately 27kbp upstream of
rs11742570 is in a binding site for T-bet but not GATA3 in either Th1 or Th2 cells.
Both rs11742570 and rs929777 are found in a region of permissive histone mod-
ification. The summary data for these two SNPs can be seen in table 6.1. The
SNP rs6451493 was not in a binding site for T-bet or GATA3. Although some





































































Figure 6.2: Summary of genomic features around hit-SNPs. - Histone modifica-
tionmotifs andDNase hypersensitivity sites found at hit-SNPs for T-bet (a), GATA3
in Th1 cells (b) and GATA3 in Th2 cells (c). Histone modification and DNase hy-
persensitivity also shown for all 238 hit-SNPs as a group (d). Only those SNPs
in a region that matched the motif for the transcription factor under investigation
(TF appropriate) are included in the motif count. Only those SNPs in a region of
DNase hypersensitivity for Th1 cells (in the case of T-bet or GATA3 in Th1 cells) or




binding patterns across different cell lineages was not.
Table 6.1: SNPs from ENCODE in T-bet and GATA3 binding sites. Genomic
annotation of two SNPs that were hypothesised to be in GATA3 binding sites in





Within Binding Site for Th1Gata3 T-bet












Genes within 2kbp none none
Genes within 50kbp none none
Histone Modifications H3K4me3 H4K4me1
DNase Hypersensitivity yes yes




In our case, we wanted to use our genomic annotation to suggest which SNPs
might alter transcription factor binding. We modified the traditional pulldown
protocol to increase the accuracy of the results and decrease the time required
for completion of the assay and make it medium-throughput. We ran com-
parisons between the traditional Western blotting pulldown protocol and our
OligoFlow protocol and found good correlation between the results. However,
due to the complex nature of genomic regulation and the novelty of both our
observations and our technique we must be careful not to overstate our results
at this time and work is ongoing on other ways to validate our findings. We
are currently in the process of examining whether we can detect altered bind-
ing to our hit-SNPs in vivo using ChIP followed by allele-specific qPCR with
TaqMan probes for the SNP of interest. However, we can draw some tentative
conclusions from our work so far. The three hit-SNPs that did show convinc-
ing differential binding for T-bet by OligoFlow were rs1465321, rs1006353 and
























































































































































































































































































































































































































































































































































































































All three SNPs were in binding sites for both T-bet and GATA3 in Th1 cells.
Although rs11135484 was associated with histone modifications and DNase hy-
persensitivity, these were not universal features of all our hit-SNPs and were
not found around either rs1006353 or rs1465321. Given that neither rs1006353
nor rs1465321 are close to a TSS, the lack of histone modification is not surpris-
ing from a genomic perspective. H3K4me3 is known to mark promoter regions.
Although H3K4me1 is often treated as a mark of enhancer regions the paper
from which our data was taken shows that H3K4me1 still tends to be found
within 2kbp of a TSS.10 The anomaly, by this reasoning, is rs11135484 which
is further than 2kbp from the TSS for ERAP2 but yet is associated with both
H3K4me3 and H3K4me1 modifications. This result suggests that the presence
or absence of a modification cannot predict altered transcription factor binding,
although whether it can distinguish those differential binding events that affect
phenotype from those that do not remains to be investigated. It should be noted
that the Barski et al10 paper produces data on resting T cells and not cells that
have been activated and then skewed towards a specific lineage. As such the
cell type used to annotate our data with histone marks is not perfectly matched
with the cell type which we used for our binding site data. However, the data
from Barski et al is the closest data set available. For this reason, we decided
not to repeat the analysis with published acetylation data. As mentioned in the
introduction, methylation is a fairly stable mark that indicates areas that are
generally transcriptionally permissive whereas acetylation is a less stable mark
that indicates active transcription of the gene. Given the differences in active
transcription between resting CD4+ cells and skewed Th1 and Th2 cells we de-
cided that published data did not match our data sufficiently for any analysis
of acetylation marks to be useful. Data on the histone modifications should be
interpreted with this limitation in mind.
The lack of DNase hypersensitivity at rs1006353 and rs1465321 is slightly un-
expected as transcription factor binding tends to loosen DNA and result in
DNase hypersensitive sites. Furthermore, the DNase hypersensitivity data was
as matched as possible to our own in terms of cells studied. Given the biology
of Th1 cells, it is surprising that a SNP in an intron of the IL18R1 locus does
not overlap a region of DNase hypersensitivity. However, if we examine the
genomic location of rs1465321 (fig. 4.12) we find that it is just upstream of a
region of differential DNase hypersensitivity between Th1 and Th2 cells. The
differences in DNase hypersensitivity at this region between the two cell lin-
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eages most likely reflects the different genomic architecture of the locus in Th1
versus Th2 cells. Thus rs1465321 is near an important region but our first pass
analysis for DNase hypersensitivity was too blunt a tool to capture this. This
result highlights the need to narrow down and focus on specific genomic areas
guided by other data and knowledge. Simply overlapping transcription factor
binding sites with other features could miss important sites.
A further finding in the IL18R1 locus is that rs2058622 is in a DNase hypersensi-
tive site in Th2 but not Th1 cells. This SNP is in a binding site for GATA3 in Th1
and Th2 cells and lies between two T-bet peaks. The difference in DNase hyper-
sensitivity patterns at the IL18R1 locus demonstrates the importance of using
the most appropriate cell type possible for genomic annotation. In our analy-
sis, hit-SNPs for bipolar disorder (rs7578035), antipsychotic response (rs507101),
height (rs10152591), ulcerative colitis (rs1886730), schizophrenia (rs2275271),
cardiographic conduction (rs4679048), conduct disorder (rs17103930) and quan-
titative traits (rs3758253) are all found in a binding site for T-bet or GATA3 in
Th1 cells and a binding site for GATA3 in Th2 cells. However, they are only in a
DNase hypersensitive site in Th1 cells. Hit-SNPs for asthma (rs12991737), white
blood cell types (rs3732123) systemic sclerosis, leprosy and chronic lymphocytic
leukaemia (rs9271612 and rs9271613), bone mineral density (rs851984), coeliac
and Crohn’s diseases (rs2058622) and basal cell carcinoma (rs4772190) are all
found in a binding site for T-bet or GATA3 in Th1 cells and a GATA3 binding
site in Th2 cells but only in a DNase hypersensitive site in Th2 cells. It is un-
clear why the DNA around some of these SNPs may be selectively loose in a
lineage specific way. Some of these differences may result from experimental
noise generated at one of the many data acquisition or analysis steps required
to produce the information. For example, it is interesting to find Th1 specific
DNase hypersensitive sites around SNPs associated with various psychologi-
cal conditions. However, while this possibly merits further investigation, it is
also likely that these SNPs are false positives generated by the large number of
GWAS conducted for psychological conditions. The ulcerative colitis associated
SNP, rs1886730, which is in a binding site for GATA3 in Th1 and Th2 cells but
only in a DNase hypersensitive site in Th1 has greater support from evidence
outside of genomics. The interplay between Th1 and Th2 cells in the inflamma-
tory bowel diseases is well known. This SNP is in an intron for TNFRSF14 (also
know as HVEM or LIGHTR) which has been shown to be protective in an adop-
tive transfer model of colitis.330 H3K4me3 and H3K4me1 histone modifications
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are both present and the SNP alters a GATA motif. The Th2 specific DNase hy-
persensitivity at rs9271612 and rs9271613 which are associated with systemic
sclerosis, leprosy and chronic lymphocytic leukaemia also correlates with non
genomic data. Systemic sclerosis is an autoimmune condition and both Th1
and Th2 cells have been implicated in protection from and susceptibility to var-
ious forms of cancer. The link to leprosy is also interesting. Although leprosy
is caused by infection with Mycobacterium leprae, the pathology varies between
individuals and this variation correlates with a type I or type 2 response from
CD4+ and CD8+ cells.331 These SNPs are in a binding site for GATA3 in Th1
and Th2 cells and within 50kbp of the HLA locus suggesting an immediate link
with the immune system.
6.2.2 Genes of Interest- Immune Genes
We found many genes known to be of importance in the immune sys-
tem within 50kbp of our hit-SNPs. SNPs in the region of ERAP2 and the
IL18R1/IL18RAP locus have already been discussed. However, we also found
hit- SNPs in or within 2kbp of TAGAP (rs1738074, T-bet), IL10 (rs3024505, T-bet),
RUNX3 (rs4265380, T-bet), CXCR2 (rs6723449, T-bet), RUNX1(rs8129743, T-
bet), TNFRSF14 (rs1886730, Th1Gata3, Th2Gata3), ICOS (rs4522587, Th1Gata3,
Th2Gata3) GZMB (rs8192917, Th1Gata3) and ICAM4 (rs281438, Th1Gata3 and
Th2Gata3). When we searched for genes within 50kbp of our hit-SNPs, we also
found ATG16L1 (rs10929322, T-bet, Th1Gata3, Th2Gata3), CTLA4 (rs11571293
for T-bet or rs231727 for Th1Gata3, Th2Gata3), IL13 and IL4 (rs12653750, T-bet),
IL12A (rs485499 and rs485789, T-bet), IL2RB (rs743776 and rs743777, T-bet), IL7R
(rs4024110, T-bet, Th2Gata3) and NOD2 (rs8062727, T-bet, Th2Gata3). We also
found many SNPs in binding sites for T-bet and GATA3 that were within 50kbp
of the HLA locus.
For the T-bet binding site hits, rs743776 and rs8062727 have already been tested
and show no altered binding by OligoFlow. From our first round of OligoFlow
results we hypothesise that most of the remaining SNPs will show altered or
even any binding as there is no T-bet consensus sequence present. The excep-
tions are rs485789 and rs743777 which were shown to have a T-bet motif by the
FIMO algorithm. Testing whether these SNPs show altered binding will give us
an indication of the relative capacities of dreg and FIMO to predict SNPs that
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might alter binding. So far, hits in the OligoFlow analysis have arisen from re-
gions containing a T-bet motif present as called by the dreg algorithm. Of the
regions around rs1006353, rs11135484 and rs1465321, only the region around
rs11135484 contained a strong T-bet motif by FIMO analysis.
Inmore general terms, our results provide a convenient way of narrowing down
large scale genomic data to generate specific testable hypotheses. GWAS hits
highlight regions where small genetic variations can influence the immune sys-
tem and disease risk. We could hypothesise that the expression of genes in
these regions would be more easily perturbed than near loci with no GWAS
SNPs. Furthermore, we might suggest that small perturbations in the expres-
sion of these genes would have a greater influence on disease risk than small
perturbations in expression of genes with no GWAS SNPs. We would expect a
causal SNP to alter either transcription product or genomic architecture. In the
case of genomic architecture, we might expect both T-bet and GATA3 to have a
role in shaping any locus to which they bind. Therefore, we could hypothesise
that any hit-SNP implicates a role for T-bet and/or GATA3 acting through that
locus in the GWAS trait, whether the SNP directly alters binding or not. It is
interesting to note, for example, that T-bet binds over a SNP within 50kbp of
IL-4 and IL-13.
6.2.3 Genes of Interest - Non Immune Genes
To focus exclusively on immune system genes would be to neglect other po-
tentially important SNPs. A case in point is the SNP rs1006353 which is not
near any immune genes. However, rs1006353 is within 50kbp of Mitochondrial
Translation Initiation Factor 3 (MTIF3) and is associated with Body Mass In-
dex. The role of mitochondria in energy harvest is well documented and a role
for T-bet in obesity has been published.332 Perhaps T-bet has a role in regulat-
ing MTIF3 expression in some cell types. As we see with the IFN-g locus, it
is possible for genes to be regulated by different mechanisms under different
circumstances.170
Our analysis returned a few coding regions about which very little is known
as highlighted by the use of an ’orf’ or ’LOC’ classification. Given the back-
ground to and rational behind our work we might hypothesise that some of
these regions could be involved in the immune system. In support of this idea,
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a role for C12orf52 in Notch signalling has recently been published.333 C12orf52
is within 2kbp of rs28365932 a SNP in a T-bet binding site. As discussed in the
introduction, Notch signalling has a role in T helper cell lineage commitment.
We could investigate a potential role for this and other regions in CD4+ cells in
a fairly straight forward manner by transduction and cytokine measurement in
cells skewed Th1 or Th2 as appropriate.
Our analysis also returned SNPs near non protein coding genes including
miRNAs and a cluster of small nucleolar RNAs within 50kbp of rs507101
(Th1Gata3, Th2Gata3). Of particular interest is miR-4772 which is lo-
cated within an intron on IL18RAP. This miRNA is within 50kbp of a few
of our hit-SNPs including rs1420106, which is in the promoter region of
IL18RAP. Although mir-4772 is not within 50kbp of rs1465321 it is part of the
IL18R1/IL18RAP locus. Given the dynamic nature of this region and the role of
T-bet in genomic structure of this region, wemight hypothesise that this miRNA
also has a role linked to immunity. To date, very little is published on the role
of this miRNA.
We also found SNPs that were not within 50kbp of any genes. However, the
presence of other features at these SNPs suggest the regions are important in
genomic regulation. For T-bet 18.6% (21 in 113) hit-SNPs were not within 50kbp
of a gene. For GATA3 in Th1 cells 13.0% (16 in 123) hit-SNPs were not within
50kbp of a gene and for GATA3 in Th2 cells 10.1% (9 in 89) SNPs were not
within 50kbp of a gene. Yet, as seen with the SNPs rs11742570 and rs9292777
in the gene desert on 5p13.1, there are other genomic features present at these
SNPs. Figure 6.3 shows the percentage of each set of hit-SNPs that are not
within 50kbp of a gene but have marks. Multiple marks are seen at some SNPs.
The presence of chromatin marks suggests that these SNPs do have a role in
gene regulation. By comparing their associated trait with the known roles of
our transcription factors we could start to form hypotheses as to the regulatory
role served by the regions containing these SNPs.
6.2.4 Co-binding
The importance of co-binding is highlighted by the overlap of SNPs in T-bet
and GATA3 binding sites in Th1 cells. As discussed in the introduction, co-






























































Figure 6.3: Annotation of SNPs not within 50kbp of a gene. - Percentage of hit-
SNPs that are not within 50kbp of a gene (desert SNPs) and percentage of desert
SNPs at locations of histone modification and DNase hypersensitivity.
is an important aspect of control within the immune system. We found many
SNPs that were in a binding site for both T-bet and GATA3 in Th1 cells which
is in agreement with recently published work.234 Our top three hit-SNPs from
the OligoFlow, rs1465321, rs1006353 and rs11135484 were all in a binding site
for T-bet and for GATA3 in Th1 cells. The SNPs rs1006353 and rs11135484 were
also in a binding site for GATA3 in Th2 cells. By contrast, rs1465321 was not
in a binding site for GATA3 in Th2 cells, possibly reflecting the changes at the
IL18R1/IL18RAP locus between Th1 and Th2 cells. Of interest, there are a few
SNPs that are in a T-bet binding site in Th1 cells and a GATA3 binding site in
Th2 cells but not in a GATA3 binding site in Th1 cells. The binding of T-bet
in Th1 and GATA3 in Th2 might suggest that the SNP is in a region that is
differentially regulated in Th1 versus Th2 cells. The five SNPs in this category
are shown in table 6.3.
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Table 6.3: Hit-SNPs for T-bet and Th2Gata3 but not Th1Gata3. Details on SNPs
that are in a binding site for T-bet and for GATA3 in Th2 cells but not in a binding



















RNF145 Promoter Yes none





RGS1 Promoter Yes T-bet(P.D)
All of these SNPs are in DNase hypersensitive sites and most have motifs
and/or are for traits with an immune component. Of note, rs8062727 has al-
ready been tested in OligoFlow and showed no differential binding in the first
experiment. Although the SNP is in a fairly strong consensus motif, we did
not see differential or even any binding above the negative control at this SNP.
This may be for one of two reasons. T-bet may not bind at that location ei-
ther because binding is to another region within the ChIP-Seq peak or because
the peak is a false positive in the ChIP-Seq data. Alternatively, the OligoFlow
result could be a false negative because it does not provide the appropriate co-
binding transcription factors or the appropriate chromosomal context. In sup-
port of the first idea, rs8062727 was not in a T-bet peak as called by the SISSRs
algorithmwhereas rs1465321, rs11135484 and rs1006353 were in peaks called by
both MACS and SISSRs. Furthermore, our experiments suggested that YT cell
lysate would produce the same results as lysate from Th1 cells. In support of
the second idea, rs8062727 is in the Brachyury half site of the T-bet motif which
does suggest that it should alter binding.
The SNP rs2984920 has also been tested in both OligoFlow and pulldown fol-
lowed by Western blotting. In both techniques the results were mixed. One
of the Western blots and one of the OligoFlow experiments showed increased
binding at the G allele of the SNP. However, the other OligoFlow experiment
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showed little differential binding and a secondWestern blot experiment showed
more binding at the A allele (figs. 4.1 and 4.9). It is possible that the differ-
ential binding of GATA3 at this locus between Th1 and Th2 cells highlights a
greater requirement for the correct cofactors to bind at this locus. This SNP
and the other four SNPs listed in table 6.3 would provide a good starting point
for a thorough examination of differences in transcription factor binding in the
OligoFlow assay when using YT cell lysate versus Th1 cell lysate.
The SNPs listed in table 6.3 are mixed with respect to the presence of a T-bet
binding motif. In some contexts, T-bet may bind DNA through other transcrip-
tion factors so the T-bet motif is not seen but other lineage specific transcrip-
tion factors are required. This raises the possibility that OligoFlow with YT cell
lysate might only demonstrate altered binding at SNPs near or within a motif,
not because a motif is always present but because situations where a motif is
not present require other cofactors that are present in Th1 cells and not in YT
cells.
To ultimately resolve these issues, other techniques are needed. In this project,
we established a luciferase construct for testing hit-SNPs and used it to anal-
yse altered gene activation by the two alleles of rs1465321. However, this assay
has several issues. From the small MFI differences seen in the OligoFlow assay,
we expect any difference in luciferase gene activation between the two alleles
of a SNP to be subtle. Given the potential for variability in electroporation ef-
ficiency we could raise concerns over whether the assay is sensitive enough
to detect such subtle variations reliably. Although we used a renilla luciferase
transfection control plasmid, our experiment was based on the assumption that
this plasmid entered the sample with equal efficiency to the promoter construct
and the expression plasmid. Although this assumption is widely made and
broadly accurate in most luciferase assays, it may not be accurate enough for
our purposes. Accuracy could be improved by using a plasmid containing both
renilla and firefly luciferase genes on the same vector. However, this might
then raise issues over whether two genes on the same plasmid are regulated
independently. Furthermore, this method does not remove the assumption that
the efficiency of transfection of expression plasmid is proportional to that of the
luciferase vector. Furthermore the assay, as with the OligoFlow, may not pro-
vide the correct cofactors. The experiments were performed in EL-4 cells which
are derived from a murine lymphoma. EL-4 were used as they do not express
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T-bet and therefore provide a clean background into which T-bet can be trans-
fected in a controlled way. EL-4 cells are also transfected easily to high levels.
However our constructs were based on the human genome and, as previously
discussed, gene activation may require other transcription factors in addition
to T-bet. Some of these factors may not be sufficiently provided by the murine
EL-4 cells. We did try the experiments in CEM cells, in addition to EL-4. CEM
cells are a human T cell lymphoblast cell line. However, the transfection effi-
ciency into these cells, while good, was not good enough to detect the subtle
differences we were expecting.
Furthermore, the luciferase assays provide a larger section of DNA around the
SNP than the OligoFlow assay but still do not test the SNP in a full native
chromatin environment. Luciferase assays have been found, by others, to be
less able to demonstrate transcription factor binding at regions distant from the
TSS.27 Because many of our SNPs were not near a TSS, we decided to make a
construct containing a promoter known to be activated by T-bet, the IFNG pro-
moter. We hoped we could then test for a differential ability of our SNPs to act
as enhancers or otherwise on this promoter. However, this still does not provide
a native context in which to test altered binding and its functional effects.
6.2.5 Motifs
A transcription factor binding motif was found in the region around all three of
our strongest hit-SNPs, rs1006353, rs11135484 and rs1465321, using the dreg
tool (fig. 6.4.) However, this motif is only altered for rs1006353. For both
rs1465321 and rs11135484, the motif is close to but not altered by the hit-SNP.
By contrast, other hit-SNPs that do alter a consensus motif did not show altered
binding by OligoFlow. The sequences around those SNPs that were found to






















Figure 6.4: Surrounding sequence for hit-SNPs. - Sequence around rs1006353,
rs11135484 and rs1465321 is shown. Red text indicates alternative alleles at SNP.




Table 6.4: Summary of OligoFlow for SNPs which altered T-bet motif. Sequence
around hit-SNPs tested in OligoFlow where hit-SNP altered T-bet consensus motif
and summary of results fromOligoFlow. Opposite alleles of each hit-SNP are given
in bold. Match to consensus motif is given underlined.




Differential binding seen but in op-































No differential binding seen in first
experiment.
We could argue that the GTGTG/CACAC motif found around rs10152590,
rs2387397, rs743776 and rs7441808 was not a good representation of the T-bet
motif because it lacks a further A/T at the end of the motif which is highly
conserved in the PWM.234 This could explain why we do not see differential
binding around these SNPs. CACAC is found near rs11135484 but the presence
of the further, highly conserved T (fig. 6.4) may distinguish this site. The SNPs
rs2703078, rs5778 and rs8062727 are better matches to the consensus motif with
both the Brachyury half site and the conserved A/T. In each case, the SNP al-
ters the central nucleotide of the Brachyury half-site (GTG or CAC) which is
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highly conserved in the motif, yet the impact on binding is small or non ex-
istent. By contrast, rs1006353 alters the first nucleotide of the Brachyury half
site which is less conserved and yet rs1006353 does alter T-bet binding in the
OligoFlow assay. This finding highlights the issues with drawing conclusions
about SNP effects from motifs. The situation is not improved by using a PWM
in the bioinformatic analysis: FIMO found a T-bet PWM match in the region
around rs11135484 but not the regions around rs1006353 or rs1465321.
It is possible that some instances where no differential binding is found could
result from using YT cell lysate and not lysate from Th1 cells. It is possible
that in some cases a necessary binding partner is absent in the YT lysate. How-
ever, for our strongest hit-SNPs the trend in results did not differ between using
lysate from YT and lysate from Th1. Our results demonstrate that an altered
motif does not correlate with altered binding in OligoFlow. However, so far our
results do suggest that binding is not seen in DNA sequences that do not match
to any consensus motif. However the region around rs8008961, which does not
contain a consensus sequence has, so far, given conflicting results and needs to
be retested. The SNP rs8008961 is in an intron for RAD51B and is associated
with Primary Biliary Cirrhosis.
6.2.6 Nonsynonymous SNPs
Only 20.6% (49/238) of our hit-SNPs were generated by a trait-associated SNP
that was also in high LDwith a nonsynonymous coding SNP. This result demon-
strates, in agreement with many large scale genomic projects, that many of the
trait-associated SNPs in which we were interested, were not acting through al-
tering protein structure. We prioritised testing those SNPs that were not part of
an LD block containing a nonsynonymous SNP for setting up our in vitro test-
ing. However, we cannot assume that these hit-SNPs do not exert a mechanistic
effect through altering transcription factor binding and, as we establish further
assays, some of these SNPs should be tested.
6.2.7 Future Directions for Genomic Annotation
An obvious extension to our in silico analysis is the inclusion of recently pub-
lished data from the 1000 genomes project.329 For our project we had already
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established the pipeline for our in silico analysis and moved on to establishing
in vitro and in vivo testing before the data from the 1000 Genome Project be-
came readily available. However, the increasing use and availability of whole
sequence data make this an important next step for the type of analysis per-
formed here. The authors of the 1000 Genome publication analyse the number
of SNPs in LD (r2>0.5) with each GWAS signal in the NHGRI GWAS catalogue
and find more than two times as many SNPs using 1000 genome compared to
HapMap. This increase could greatly help us to find other transcription factor
binding SNPs. Many of the novel SNPs found in 1000 genomes are rarer SNPs
(Minor Allele Frequency < 5%) which raises the question of how likely the new
SNPs are to be causal in common diseases. The debate over the relative con-
tributions of rare versus common variation in the common complex diseases is
still active in the genomics community.
In our current analysis, we used the HapMap3 CEU population for all LD cal-
culations even though not all GWAS are performed in a population of CEU-like
ethnicity. Rerunning our analysis with other populations might yield more data
or more appropriate data. For example, we have discussed the disease leprosy:
GWAS on leprosy have often been performed in populations of Asian ethnicity.
If we expand this analysis to include the rarer SNPs of the 1000 genome data,
this issue becomes more important as rarer variations have a greater tendency
to only be found in some ethnicities.329
Moving on from bioinformatic analysis, it is important to be able to test for al-
tered transcription factor binding and downstream effect both in vitro and in
vivo. To this end, we developed the OligoFlow assay. The OligoFlow assay
allows altered binding between two different alleles to be tested quickly and
should, in theory, be easily extendable to other transcription factors. In practice,
it is likely to work better for some transcription factors than others as demon-
strated by our work on GATA3 binding. In the case of GATA3, the strength of
binding was heavily dependant on the sequence surrounding the positive and
negative control motifs making designing positive and negative controls diffi-
cult. By contrast, for T-bet our positive and negative controls worked well. This
difference may reflect the difference in promiscuity between the two transcrip-
tion factors and imply that this assay is more suitable for those transcription
factors with a longer and better defined consensus binding sequence. Exam-
ining the potential use of the OligoFlow assay for other transcription factors
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would be a useful piece of further work. For ease of analysis such work should,
from the outset, use a fixed number of cells and fixed cytometer settings. This
would make replicate experiments, acquired over time, more easily compara-
ble and allow for better statistical analysis of samples. In our case, this was not
possible as we were optimising the assay at the same time as collecting data and
had limited time for repeating measurements.
Another way of testing for altered binding, in addition to the OligoFlow assay
would be desirable. In this project, we used a luciferase assay to investigate
potential differences in binding at rs1465321. However, this assay was not very
sensitive and was subject to large experimental variation due to the use of elec-
troporation. Work to test for differential binding in the appropriate genomic
context is ongoing. We plan to test altered binding by cross-linking Th1 cells
from individuals known to be heterozygous at the SNP of interest. We then
plan to perform ChIP on these cells followed by allele-specific qPCR to exam-
ine for enrichment of one allele over the other in the fragments that are pulled
down. We hope this assay will be sensitive enough and will account for the var-
ious trans and cis acting factors which affect transcription factor binding, but
which may be absent in the OligoFlow assay. Such a technique would allow
independent validation of the OligoFlow assay. Ultimately, we would like to
establish a pipeline in which in silico hit-SNPs are screened by the medium to
high throughput assay of OligoFlow and then SNPs that show differential bind-
ing in OligoFlow are further tested in heterozygotes by ChIP and allele specific
qPCR. The ChIP step is likely to be time consuming as sufficient heterozygotes
for the SNP under investigation must be found. Then cells from each heterozy-
gote would have to be grown and subject to ChIP. Thus, the screening out of
false negatives from the bioinformatic analysis by the OligoFlow assay would
be highly valuable in reducing the number of false negatives from the in silico
analysis prior to further testing.
Another important avenue to pursue further would be to analyse some of our
SNPs for eQTLs in the appropriate cells types. In our case, we should examine
some of our SNPs and their effect on gene expression in skewed and stimu-
lated Th1 and Th2 cells. The importance of this was demonstrated in a recent
IBDmeta-analysis which found that SNPs associated with Crohn’s diseases and
ulcerative colitis are found near genes that show cell specific expression most
notably in DCs but also in CD4+ cells.279 Analysing gene expression with re-
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spect to genotype in the distinct cell populations of CD4+ cells skewed to Th1
or Th2 would be fairly straight forward on the relatively small number of SNPs
and genes identified by our in silico analysis.
6.3 Immune Mediation
T-bet directs aspects of the immune system and its dysregulation results in im-
mune related conditions. We wanted to investigate whether our hit-SNPs were
enriched for SNPs in LD with GWAS SNPs for immune related conditions. The
GO ontology provides a useful means of describing genes and gene products
and classifying them based on their characteristics. No such ontology exists for
phenotypic traits or diseases and for many traits and diseases any classification
system would have controversial elements. As such, it is difficult to objectively
examinewhether a list of traits is enriched for immunemediated conditions. We
attempted to solve this problem by constructing lists of definitely, possibly and
definitely not immune related conditions based on majority clinical judgment.
Although some conditions on each list might be open to debate, this provided a
useful starting point to try and analyse our SNPs for immune enrichment in the
same way that a list of genes might be analysed for enrichment of genes with a
certain GO characteristic.
Our analysis showed significant enrichment for strictly immune related hit-
SNPs in T-bet binding sites and significant enrichment for both strictly and
loosely immune related hit-SNPs in GATA3 binding sites in Th1 cells (p < 0.05 in
all cases.) If we take the average number of strictly immune related SNPs found
in 10,000 randomly shifted T-bet sites versus the actual number of strictly im-
mune related hit-SNPs then this suggests that over 25% (11/42) of our strictly
immune related T-bet hits are functionally relevant over the number of SNPs
expected by juxtaposition of immune related SNPs and immune related genes.
Although we would need to test all hits by other methods to determine how
accurate this prediction was, the result is encouraging. However, we must be
aware that such a classification has the potential to follow a circular argument.
We were interested in whether hit-SNPs for T-bet were enriched in immune re-
lated traits. However, we could argue that the involvement of T-bet implicates
the immune system in a trait. Researchers working on T-bet might be more
likely to judge a borderline condition immune because T-bet is known to have
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role. To avoid this, labels were assigned to each condition by clinicians inde-
pendently from each other and from our project. However, given the research
environment in which the question was asked, we cannot guarantee that such
bias was completely removed. A future direction of this work, might be to seek
consensus from a larger group. It is important to note that such enrichments for
immune related SNPs were weaker for hit-SNPs in GATA3 binding sites in Th2
cells often failing to reach significance. This may reflect the fact that GATA3 has
roles beyond the immune system. Although our ChIP-Seq data was from Th2
cells, it is unlikely that all the binding sites were T cell specific. More general
GATA3 binding sites with a role in other systems could be more common in
Th2 cells than Th1 cells where GATA3 expression is lower and GATA3 is redis-
tributed across the genome by T-bet.234 Alternatively, this could reflect ambigu-
ity in classifying diseases as immune mediated. Aberrant Th1 responses may
produce disease with a more obvious immune component than aberrant Th2
responses.
We could envisage a situation where transcription factors known to have a
prominent role in the immune system might assist in establishing a list of traits
that could then be used in further analysis. To some extent, the merits of the
classification that we made were verified by the permutation and randomisa-
tion testing that we performed. We used data on binding sites for ER-a, a tran-
scription factor with little or no role in the immune system and NF-kB, a tran-
scription factor known to have a key role in the immune system. We showed
that random reassignments of our classification produced significantly fewer
immune mediated hits than our actual classification. This was done indepen-
dently of work on T-bet and GATA3 binding sites. Choosing transcription fac-
tors that are or are not involved in the immune response can be done through
the GO ontology. This could highlight an immune component to conditions not
previously considered immune mediated. A case in point could be the juxtapo-
sition of an established immune component of obesity, the recent publication of
a role for T-bet in obesity332 and the finding that one of our strong hit-SNPs is
associated with BMI.
The enrichment of immune mediated conditions in our hit-SNPs for T-bet pro-
vided a cheap and relatively quick way of gaining some confirmation as to the
validity of our in silico analysis. However, there are issues to consider. Many
complex traits are heterogeneous with respect to the extent and mechanism of
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immune involvement. In some cases this heterogeneity is recognised andmight
be discussed in the GWAS publication. In other cases such heterogeneity is
not fully understood or appreciated. Either way, our analysis was too broad
to capture finer details of each published study. Furthermore, even dividing
transcription factors into immune and non immune related is not a clear cut
process. For example, the data that we used on ER-a was taken from a paper
which demonstrated that, in some cases, ER-a can be tethered to the genome by
Runx1. Our binding site data for ER-a, therefore, would have included cases
of Runx1 binding sites where ER-a was tethered and not just direct ER-a DNA
binding events. Although ER-a is not immune related, Runx1 does have a role
in the immune system. As discussed in the introduction, Runx1 is required for
activation of the Th17 master regulator RORgT and can be sequestered from
this role by physical interaction with T-bet.
6.4 The IL18R1/IL18RAP Locus and rs1465321
6.4.1 Possible Mechanisms
To investigate a potential role for altered binding at one of our hit-SNPs,
rs1465321, we examined the kinetics and T-bet dependence of IL18R1 expres-
sion in vitro and in vivo. Fine mapping data, using the densely covered Im-
munoChIP has been published for coeliac disease and Crohn’s disease, the two
diseases associated with rs1465321.75,279 It is important to note that both of
these studies find other candidate SNPs with greater statistical significance than
rs1465321. For coeliac disease, the highest association in the region was found
at rs990171, a SNP downstream of IL18RAP. For Crohn’s disease, the greatest
significance was found for rs6708413, which is in an intron of IL18RAP. These
results, coupled with eQTL data concerning IL18RAP implicate this locus far
more prominently than the IL18R1 locus. However, it is possible that an eQTL
for IL18R1 might only be observed in the functionally relevant Th1 cells rather
than whole blood or bulk PBMC. Because of the limitations of our OligoFlow
and luciferase assays and because work on other assays is still ongoing, we can-
not conclude any definite role for rs1465321. However, our annotation of the
IL18R1/IL18RAP locus combined with the importance of this signalling path-
way in immunology suggested that a further study of this locus, in the context
199
6.4 The IL18R1/IL18RAP Locus and rs1465321
of T-bet and GATA3 binding and disease mechanism, would be useful. This is
especially the case given that the ImmunoChIP data for IBD demonstrates that
genes near the hits discovered for IBD to date are heavily enriched for genes
involved in cytokine, and in particular IFN-g, production.279
In terms of kinetics of IL18R1 expression, we confirmed that IL18R1 is expressed
on naïve cells at a level intermediate between Th1 and Th2 cells. We also found
that T-bet is not absolutely required for IL18R1 expression and, while the ex-
pression of IL18R1 is decreased on T-bet deficient Th1 cells, it is not lost. T-bet
deficient cells can signal in response to IL-18 in vitro. However, T-bet may be
required for the stability of IL18R1 expression with time both in vitro and in
vivo.
Examination of array data on cells skewed to different T helper cell lineages,
suggests that IL18R1 and IL18RAP are not always co-regulated. As expected,
expression of both IL18R1 and Il18RAP are high on Th1 cells and lower on Th2
cells. However, while IL18RAP expression is lower on Th17 cells than Th2, the
expression of IL18R1 would seem to be intermediate between the two. IL18R1
expression is also seen on IL-17A producing cells in a mouse model of coeliac
disease and the expression of IL18R1 is less affected by the loss of T-bet on this
population than on IFN-g producing cells. This might suggest that IL18R1 is
regulated in two different ways in the two different cell types. However, we
only performed the coeliac model once with small numbers of mice and we
did not examine IL-17A production in the adoptive transfer model of colitis.
Furthermore, we have very little data on the kinetics of IL18RAP expression at
a protein level. Therefore, our conclusions must be treated with caution.
Basic next steps to this analysis would include the examination of IL18RAP ex-
pression on naïve cells and of both IL18R1 and IL18RAP expression on Th17
cells. It would also be helpful to examine the capacity of a pure population of
naïve cells to signal in response to IL-18 as this would link in with studies sug-
gesting a role for IL-18 signalling on naïve T cells in non Th1 like responses and
asthma. The finding of other SNPs in the IL18R1/IL18RAP locus, in binding sites
for GATA3 in Th1 and Th2 cells, and associated with asthma and white blood
cell types, highlights the importance of this examination. The original GWAS
for white blood cell types found that rs17027258, which is in strong LD with
our hit-SNP rs3732123, is specifically associated with Eosinophil count.321 Of
note, our hit-SNPs, rs1465321 and rs373123, are in different LD blocks. The r2
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value between rs1465321 and rs12991737 is 0.0316, the r2 between rs146532 and
rs3732123 is 0.109 and the r2 between rs12991737 and rs3732123 is 0.0544.
We must be careful in interpreting these GWAS in terms of IL-18 signalling
as the locus also contains the gene IL1RL1, also named IL33R which is, in
many respects the Th2 equivalent of IL18R1. IL-33 signalling is similar to IL-
18 signalling but occurs in Th2 cells through a receptor complex of IL1RL1 and
IL1RAP. Therefore, genomic architecture at this region can influence both a Th1
type and Th2 type response and little is known about whether that is indepen-
dent or coordinated. It would seem that, at the IL18R1/IL18RAP locus differ-
ent variants in different LD blocks can alter susceptibility to disease. Some ge-
netic variation increases the Th1 response and thus increases risk of coeliac and
Crohn’s. A separate set of variations can increase Th2 type response and result
in increased risk of asthma or a high eosinophil count. To build up a full picture
of genomic architecture in the region, we would need 3C data on chromosomal
conformation for the region in Th1, Th2 and naïve T cells.
A key transcription factor in IL18R1 regulation that is yet to be discussed is
STAT4 which is needed for full expression of IL18R1 and IL18RAP. Yu et al23
show that transient expression of STAT4 as a cell commits to a Th1 lineage gen-
erates a permissive epigenetic environment for IL18R1 and IL18RAP expres-
sion. They demonstrate that in mice, in response to IL-12, STAT4 becomes ac-
tive, binds to a region upstream of the IL18R1 TSS and promotes histone acety-
lation at both the promoter and first intron of IL18R1. They demonstrate that
STAT4 binding and its effects peak at around 48 hours after addition of IL-12
but then fall over the next five days. They also demonstrate that STAT4 binding
prevents repressive methylation of the DNA and the binding of DNA methyl-
transferases. It is possible that the role of maintaining such a permissive envi-
ronment then falls, later, to T-bet. In mice, strong T-bet binding peaks are seen
in the first, third and fourth introns. One of the peaks seen in the first intron is
present in Th1 but not Treg cells suggesting it is Th1 specific and plays a key part
in IL18R1 remodelling during Th1 lineage commitment. This might explain our
results which suggest that IL18R1 expression is not absent butmight be unstable
over time in T-bet-/- cells. It is possible that the switch from temporarily acti-
vated expression of IL18R1 by STAT4 to stable IL18R1 expressionmaintained by
T-bet is impaired in T-bet-/- mice. This might also explain why we found that
IL18R1 expression on T-bet-/- cells was reduced but still present whereas Thieu
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et al found no IL18R1 expression. The extent of IL18R1 expression in Tbet-/-
cells could depend on the time since IL-12 signal was given which varied be-
tween our two experimental systems.213 Of note, the first intron in the mouse
Il18r1 locus is not present in the UCSC gene schematic of human IL18R1 (as
shown in figures 4.12 and 6.5). However, this region is moderately conserved
between mouse and human204 and human transcripts both with and without
this intron are listed in the Ensembl database. In mice, we find the most no-
ticeable differential T-bet peak between Treg and Th1 cells in this first murine
intron. In Treg cells, this peak corresponds to a peak of FoxP3 binding which
may serve to limit IL18R1 expression in Tregs, although expression of IL18R1
on these cells has not been formally tested.
T-bet binding is seen upstream of the IL18R1 TSS in human. The STAT4 bind-
ing site data that we used for our permutation testing had been obtained from
sorted CD4+, CD45RA+ cells from human buffy coats which had been activated
with aCD3 and aCD28 and stimulated in the presence of IL-12 so this data is a
reasonable approximation to Th1 cells. These cells show STAT4 binding either
side of the second exon at the human IL18R1 locus, overlapping the two large
T-bet peaks seen there. Our hit-SNP rs1465321 is found in a third T-bet peak
just downstream and in a region of moderate homology as aligned in Ensembl.
The regions either side of the second exon also contain histone modifications
and a differential pattern of DNase hypersensitivity between Th1 and Th2 cells.
The genomic marks of this region suggest it could be an enhancer region acting
on the IL18R1 promoter. GATA3 is present at the region in both Th1 and Th2
cells. In Th2 cells, it would seem to play an active part in repressing IL18R1 ex-
pression as retroviral transduction of constitutively expressed GATA3 into Th1
cells reduces expression of IL18R1.204 A schematic of some of the dynamically
changing features found by us and others at the IL18R1 locus in mouse and
human can be seen in figure 6.5.
Another important region is the promoter of IL18RAP. Although we have fo-
cused less on this region, one of our hit-SNPs, rs1420106, is in this location in a
binding site for T-bet and GATA3 in Th1 and Th2 cells and the SNP disrupts a
GATAmotif. As yet, we have not sufficiently established a system to test this for
altered GATA3 binding and functional effect at this SNP but it would be a high
priority once such assays are established. From a statistical genetics perspec-
tive, this SNP is interesting as it achieved a higher p-value in the recent coeliac
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Figure 6.5: Features at the IL18R1 locus. - Some of the features at the IL18R1 locus
in human (top) and mouse (bottom).
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ImmunoChIP than rs1465321 and expression of IL18RAP is part of an eQTL in
whole blood.75,214
6.4.2 Future Directions - The IL18R1/IL18RAP Locus
Although the data obtained so far gives some important indications about the
kinetics of IL18R1 and IL18RAP expression, much of the work needs repeat-
ing before firm conclusions can be drawn. Although we can confidently con-
clude that lack of T-bet results in reduced, but not absent, IL18R1 expression, we
would need to run the timecourse experiment again to confirm whether IL18R1
expression is unstable, peaking and then decreasing with time in T-bet deficient
cells. As already mentioned, an investigation of the kinetics of IL18RAP expres-
sion would also be useful.
6.5 Role of T-bet in Model of Coeliac Disease
Because rs1465321 was in LD with a trait-associated SNP for coeliac disease,
we examined the role of T-bet in a mouse model of coeliac disease. We found
that, in agreement with the original paper and in line with the human disease,
the model was milder than most models of IBD. As a result, it was not possible
to observe any macroscopic effects of T-bet loss in the model. Furthermore, the
model was inconsistent and due to time constraints, our group sizes were small.
It may be that some patterns could be seen if we were to repeat the experiment.
However, there are issues with the model. The disease develops over a long
period of time in Rag1 deficient hosts. During this time, even the hosts given
PBS develop some inflammation, as can be seen histologically. Dissecting out
inflammation caused by the model versus that caused by other means is not
easy.
One crucial finding of the model was the expression of IL18R1 on IL-17A+
single producers and IL-17A+, IFN-g+ double producers. IL18R1 expression
seems to be dependent on T-bet only in those cells producing IFN-g. Again, we
cannot draw firm conclusions from the small numbers used but the examina-
tion of this is the context of coeliac and other disease models would be a useful
next step.
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6.6 Final Conclusions and Future Directions
In this study, we have attempted to combine data on disease-associated genetic
variation with binding site data on transcription factors with known roles in
disease and obtained in cells of appropriate lineage. We have then developed
a medium throughput assay to test our in silico hits and tried to examine one
of the DNA loci in a mouse model of disease. In doing so, we have attempted
both to further investigate the mechanisms behind the regulation of a key im-
mune gene and to evaluate different ways in which the growing datasets from
genetic investigation can be examined with respect to detailed molecular mech-
anism.
Because of the novelty of the work presented it is difficult to draw broad-scale
firm conclusions at this time. Our finding of differential binding at rs1465321,
rs1006353 and rs11135484 suggest that out approach can find important hits for
further investigation. However, there are limitations to the data obtained using
our OligoFlow assay. Because we were simultaneously establishing the assay
and collecting data on altered binding, there is variability between replicates
for any one SNP, in terms of absolute MFI values obtained. Thus we cannot
quantitatively analyse the data across replicates. As previously discussed, now
that optimal parameters for the assay have been established, measures can be
taken to run the assay so that absolute MFI values are comparable across time.
Thus, replicate readings could be analysed quantitatively rather than simply
looking for consistent trends as we have done. Furthermore, work is ongoing to
establish a second assay where altered binding is analysed by ChIP followed by
qPCR in cells that are heterozygous at the SNP of interest. If the results from this
are consistent with those of the OligoFlow assay, it will validate the OligoFlow
assay and provide data on the situation in vivo. As already mentioned our in
silico work could also be improved by incorporation of the recently published
1000 genome data and use of some of the data and tools produced by the EN-
CODE project. (At the time of writing this thesis, certain aspects of ENCODE
were still under embargo.)
Our work suggests that a study of the changing three dimensional structure
of the IL18R1/IL18RAP locus in T helper cell lineage commitment would help
better understand the regulation and role of this locus in different T helper cell
subtypes. The possibility that IL18R1 is expressed on Th17 cells, and that its
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expression is regulated differently in Th1 and Th17 cells, also remains to be ex-
amined. In terms of other hit-SNPs, it would be useful to expand the OligoFlow
assay to other transcription factors. In addition, the role of T-bet at the locations
around our hit-SNPs rs1006353 and rs11135484 remain to be investigated.
Although one of our hit-SNPs, rs1465321, was in the IL18R1/IL18RAP locus,
our examination of IL18R1 expression in a mouse model of coeliac disease did
not produce any significant results. This may be due to limited experimental
group size. However, as discussed previously, there were issues with themodel.
A further direction might be to look at IL18R1 and IL18RAP expression with
progression of disease in a different disease model. In this project, we briefly
examined IL18R1 expression in a model of inflammatory bowel disease. The
adoptive transfer model of inflammatory bowel disease is well established and
gives a strong disease readout. Another next stepwould be to repeat and extend
our work in this model.
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system("awk ’{print $1,$11,$12}’ /Users/claresoderquest/Documents/katrina/AllStudies
Analysis/041111DatabaseWork/Gata3BindingSitesTh2Cells.txt > TransFact_katrina.tab")
TF <- read.table(’TransFact_katrina.tab’, header = TRUE)
for (chrom in my.chroms) {




Chroms <- read.table ( file = my.table, header = TRUE, row.names = 1)
ChromsCurrent <- subset(Chroms, (Chr == chrom))
hapmap.data <- paste(’file://///Users/claresoderquest/Documents/katrina/HapMap3/chr’,
chrom, ’CEU.txt’, sep =”)
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7.1 Script for Determining Binding Site SNPs
hapmap <- read.HapMap.data( url = hapmap.data, verbose = FALSE, save = NULL )
for (j in 1:nrow(ChromsCurrent)) {
snp <- row.names(ChromsCurrent)[j]
if(!(snp %in% dimnames(hapmap$snp.data)[[2]])) {
cat("Cannot find snp", snp, "in hapmap\n")
absent <- c(absent, snp)
} else {
my.ld.results <- ld.with(data = hapmap$snp.data, snps = snp)$rsq2
high.ld.snps <- subset(row.names(my.ld.results), (my.ld.results[, snp] > min.r2)
& !is.na(my.ld.results[, snp]))
my.snps.support <- hapmap$snp.support[ high.ld.snps,]
first <- TRUE
for (i in 1:nrow(my.snps.support)) {
snptoo <- row.names(my.snps.support)[i]
position <- my.snps.support$Position[i]
TableChrom <- paste("chr", chrom, sep = ”)
# TF
TF.intersec <- subset(TF, (Chr == TableChrom) & (position > rStart - window) &
(position < rEnd + window) )
if (nrow(TF.intersec) >= 1) {
cat("Looking at current TF snp", snptoo, "in LD with snp ", snp, "\n")
print(TF.intersec)
if (first) {
print(subset(my.ld.results, (my.ld.results[, snp] > min.r2) & !is.na(my.ld.results[, snp])))
first <- FALSE}
linkage.value.TF <- my.ld.results[snptoo, snp]
print(linkage.value.TF)
TransFact.results.snptoo <- c(TransFact.results.snptoo, snptoo)
TransFact.results.snp <- c(TransFact.results.snp, snp)
TransFact.results.linkage <- c(TransFact.results.linkage, linkage.value.TF)}
TF.results <- cbind(TransFact.results.snptoo, TransFact.results.snp, TransFact.results.linkage)
} } }}}
write.table(TF.results, "/Users/claresoderquest/Documents/katrina/AllStudiesAnalysis
/041111Database Work/ResultsGata3BindingSitesTh2Cells.txt", row.names = FALSE, quote
= FALSE, sep = "\t")
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7.2 Lists of Strictly and Loosely Immune Mediated Conditions
write.table(absent, "/Users/claresoderquest/Documents/katrina/AllStudiesAnalysis
/041111Database Work/AbsentResultsGata3BindingSitesTh2Cells.txt", row.names = FALSE,
quote = FALSE, sep = "\t")
7.2 Lists of Strictly and Loosely Immune Mediated
Conditions









Coeliac disease and Rheumatoid arthritis
Coeliac disease
Crohn’s disease and Coeliac disease




Hepatitis B vaccine response
Inflammatory bowel disease (early onset)
Inflammatory bowel disease
Lupus








7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Rheumatoid arthritis
Sarcoidosis








List of NHGRI GWAS catalogue traits judged as possibly immune mediated:
Acute lymphoblastic leukaemia (childhood)










Carotid atherosclerosis in HIV infection
Carotid intima media thickness
CD4:CD8 lymphocyte ratio






Drug-induced liver injury (amoxicillin-clavulanate)
Drug-induced liver injury (flucloxacillin)
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7.2 Lists of Strictly and Loosely Immune Mediated Conditions
End-stage renal disease


























Monocyte early outgrowth colony forming units
Moyamoya disease
Multiple sclerosis–Brain Glutamate Levels







7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Non-alcoholic fatty liver disease histology (AST)
Non-alcoholic fatty liver disease histology (lobular)
Non-alcoholic fatty liver disease histology (other)
Nonalcoholic fatty liver disease
Periodontitis




Renal function and chronic kidney disease
Response to hepatitis C treatment
Response to interferon beta therapy
Response to TNF antagonist treatment
Response to treatment for acute lymphoblastic leukaemia





Soluble leptin receptor levels




White blood cell count
White blood cell types
List of NHGRI GWAS traits judged as non immune mediated:








7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Adiposity
Adverse response to aromatase inhibitors
Adverse response to carbamapezine
Age-related macular degeneration
Aging
Aging (time to death)




Alcoholism (12-month weekly alcohol consumption)
Alcoholism (alcohol dependence factor score)
Alcoholism (alcohol use disorder factor score)
Alcoholism (heaviness of drinking)
Alzheimer’s disease
Alzheimer’s disease (late onset)
Alzheimer’s disease biomarkers
Amyotrophic lateral sclerosis












Attention deficit hyperactivity disorder
Attention deficit hyperactivity disorder (time to onset)
Attention deficit hyperactivity disorder and conduct disorder
Attention deficit hyperactivity disorder motor coordination
Attention deficit hyperactivity disorder symptoms (interaction)
Autism
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7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Basal cell carcinoma (cutaneous)






Bipolar disorder (age of onset and psychomotor symptoms)
Bipolar disorder and major depressive disorder (combined)
Bipolar disorder and schizophrenia
Birth weight
Bitter taste response
Black vs. blond hair colour
Black vs. red hair colour
Bladder cancer
Bleomycin sensitivity
Blond vs. brown hair colour
Blood lipid traits
Blood pressure
Blue vs. brown eyes
Blue vs. green eyes
Body mass (lean)
Body mass in chronic obstructive pulmonary disease
Body mass index
Body mass index and fat mass
Bone mineral density
Bone mineral density (hip)
Bone mineral density (spine)
Brain imaging








7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Cardiac hypertrophy
Cardiac structure and function
Cardiovascular disease risk factors







Chronic kidney disease and serum creatinine levels
Chronic myeloid leukaemia







Conduct disorder (case status)
Conduct disorder (interaction)
















7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Diabetes (incident)


















Environmental confusion in the home
Episodic memory
















7.2 Lists of Strictly and Loosely Immune Mediated Conditions















Glycemic control in type 1 diabetes (HbA1c)









HDL Cholesterol - Triglycerides (HDLC-TG)
Hearing impairment
Heart failure
Heart rate variability traits
Height
Hematocrit






















































Menarche (age at onset)
Menarche and menopause (age at onset)
Meningioma
Menopause (age at onset)
Metabolic syndrome




Migraine in bipolar disorder
Morbidity-free survival
Mortality among heart failure patients
MRI atrophy measures
Myocardial infarction














7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Non-small cell lung cancer
Nonsyndromic cleft lip with or without cleft palate
Normalised brain volume
Obesity





Oesophageal cancer and gastric cancer
Optic disc parameters
Optic disc size (cup)
Optic disc size (disc)
Optic disc size (rim)
Osteoarthritis












Parkinson’s disease (age of onset)
Parkinson’s disease (familial)








7.2 Lists of Strictly and Loosely Immune Mediated Conditions





Plasma level of vitamin B12
Plasma levels of liver enzymes
Plasma levels of polyunsaturated fatty acids
Plasma levels of Protein C
Plasma Lp (a) levels
Plasma vWF and FVIII levels
Platelet aggregation
Platelet counts
Platelet function and related traits
Polycystic ovary syndrome
Postoperative nausea and vomiting
Postoperative ventricular dysfunction
PR interval
Primary tooth development (number of teeth)


















7.2 Lists of Strictly and Loosely Immune Mediated Conditions
Red blood cell traits
Red vs non-red hair colour
Red vs. non-red hair colour
Refractive error
Renal cell carcinoma
Response to acetaminophen (hepatotoxicity)
Response to antidepressant treatment
Response to antidepressants
Response to antineoplastic agents
Response to antipsychotic therapy (extrapyramidal side effects)
Response to antipsychotic treatment
Response to cerivastatin
Response to citalopram treatment
Response to clopidogrel therapy
Response to diuretic therapy
Response to iloperidone treatment (PANSS-T score)
Response to iloperidone treatment (QT prolongation)
Response to lithium treatment in bipolar disorder
Response to metformin
Response to methylphenidate treatment
Response to platinum-based chemotherapy in non-small-cell lung cancer
Response to platinum-based chemotherapy in small cell and non-small cell lung
cancers
Response to platinum-based chemotherapy in small-cell lung cancer
Response to statin therapy






RR interval (heart rate)
Schizophrenia






















Sickle cell anaemia (severity)
Skin pigmentation






Social and Non-Social Autistic-Like Traits









Suicide attempts in bipolar disorder
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Testicular germ cell cancer
Testicular germ cell tumour












Type 2 diabetes and 6 quantitative traits
Type 2 diabetes and other traits
















7.3 Hit-SNPs in T-bet binding Sites
Waist Circumference - Triglycerides (WC-TG)








7.3 Hit-SNPs in T-bet binding Sites
Table 7.1: SNPs in binding sites for the transcription factor T-bet. SNPs that had
previously been associated with various traits (trait-associated SNPs) were down-
loaded from the NHGRI GWAS catalogue and all SNPs in strong LD with these
trait-associated SNPs were found. Any SNP that was in a binding site for T-bet
was recorded in conjunction with the trait-associated SNP with which it was was
in high LD and the trait with which the trait-associated SNP was associated.









rs1006353 rs4771122 0.810 Body mass index
rs10152590 rs10152591 1.000 Height
rs10152591 rs10152591 1.000 Height
rs10760294 rs10818854 0.861 Polycystic ovary syndrome
rs10808568 rs9792269 1.000 Coeliac disease
rs10850435 rs2338104 0.952 HDL cholesterol
rs10861892 rs8179116 1.000 Conduct disorder (symptom count)
rs10929322 rs10210302 0.975 Crohn’s disease
rs10929322 rs2241880 0.951 Crohn’s disease
rs10929322 rs3792109 0.938 Crohn’s disease
rs10929322 rs3828309 0.963 Crohn’s disease
rs10930310 rs6749447 0.967 Blood pressure
rs10995195 rs10995190 0.953 Mammographic density and breast cancer
rs11009175 rs11009175 1.000 Depression–quantitative trait
rs11082995 rs9635963 0.813 Protein quantitative trait loci
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rs11130317 rs1042779 0.804 Bipolar disorder
rs11130317 rs2251219 0.986 Major mood disorders
rs11135484 rs2549794 0.832 Crohn’s disease
rs11571293 rs3087243 0.940 Type 1 diabetes autoantibodies, Rheumatoid
arthritis, Type 1 diabetes
rs12136874 rs4140564 1.000 Knee osteoarthritis
rs12574073 rs1128334 1.000 Systemic lupus erythematosus
rs12574073 rs6590330 1.000 Systemic lupus erythematosus
rs12653750 rs2040704 1.000 Serum IgE levels
rs12653750 rs2244012 1.000 Asthma
rs12928552 rs16965039 1.000 Coronary heart disease
rs12946510 rs11078927 0.852 Asthma
rs12946510 rs2305480 0.852 Asthma, Ulcerative colitis
rs12946510 rs2872507 0.873 Type 1 diabetes autoantibodies, Ulcerative
colitis, Rheumatoid arthritis, Crohn’s disease
rs12946510 rs907092 0.929 Primary biliary cirrhosis
rs13333528 rs9929218 0.898 Colorectal cancer
rs1335512 rs4636294 1.000 Cutaneous nevi
rs1364340 rs1424233 0.975 Obesity
rs1374910 rs1374910 1.000 Type 2 diabetes
rs1420106 rs13015714 1.000 Coeliac disease
rs1420106 rs2058660 0.980 Crohn’s disease
rs1420106 rs917997 1.000 Coeliac disease
rs1465321 rs13015714 1.000 Coeliac disease
rs1465321 rs2058660 1.000 Crohn’s disease
rs1465321 rs917997 1.000 Coeliac disease
rs149299 rs151181 0.974 Crohn’s disease
rs149299 rs4788084 0.961 Type 1 diabetes autoantibodies, Type I dia-
betes
rs1551398 rs1551398 1.000 Crohn’s disease
rs1551399 rs1551398 0.974 Crohn’s disease
rs1610588 rs3129055 0.918 Nasopharyngeal carcinoma
rs1631457 rs1322512 1.000 Tonometry
rs17032405 rs2292303 1.000 Height
rs17032405 rs5742692 1.000 Height
rs17103930 rs8179116 1.000 Conduct disorder (symptom count)
rs17234657 rs17234657 1.000 Crohn’s disease
rs17234657 rs4613763 1.000 Crohn’s disease
rs1738074 rs1738074 1.000 Multiple sclerosis, Coeliac disease
rs17772411 rs9929218 0.906 Colorectal cancer
244





rs1788183 rs1371867 0.926 Atrioventricular conduction
rs1806689 rs10785581 0.875 Hypertension
rs1806689 rs7960483 0.847 Hypertension
rs1918788 rs12185268 0.959 Parkinson’s disease
rs1918788 rs183211 0.921 Parkinson’s disease
rs1918788 rs199533 1.000 Parkinson’s disease
rs1918788 rs2942168 0.962 Parkinson’s disease
rs1918788 rs393152 0.959 Parkinson’s disease
rs1918788 rs415430 0.958 Parkinson’s disease
rs1918788 rs8070723 0.959 Progressive supranuclear palsy, Parkinson’s
disease
rs2070615 rs2070615 1.000 Bipolar disorder
rs2106346 rs1076160 0.988 Psoriasis
rs216172 rs1231206 1.000 Coronary heart disease
rs216172 rs216172 1.000 Coronary heart disease
rs2179225 rs4140564 0.872 Knee Osteoarthritis
rs2268080 rs4911414 0.970 Burning and freckling, Freckles, Red Vs. non-
red hair colour, Skin sensitivity to sun
rs2273017 rs2273017 1.000 Graves’ disease
rs228599 rs11212617 1.000 Response to metformin
rs2288344 rs8032158 0.922 Keloid
rs2331903 rs1411478 1.000 Progressive supranuclear palsy
rs2387397 rs4750316 0.832 Rheumatoid arthritis
rs2421016 rs6585827 1.000 Height
rs2532234 rs12185268 0.982 Parkinson’s disease
rs2532234 rs199533 0.910 Parkinson’s disease
rs2532234 rs2074404 0.831 Coeliac disease
rs2532234 rs2942168 1.000 Parkinson’s disease
rs2532234 rs393152 1.000 Parkinson’s disease
rs2532234 rs415430 0.893 Parkinson’s disease
rs2532234 rs8070723 1.000 Progressive supranuclear palsy, Parkinson’s
disease
rs264834 rs169082 0.810 Protein quantitative trait loci
rs2703078 rs2762051 1.000 Coeliac disease
rs2706383 rs1016988 0.850 Fibrinogen
rs2706383 rs2522056 1.000 Fibrinogen
rs2720665 rs2608053 0.923 Hodgkin’s lymphoma
rs2762060 rs806321 0.952 Multiple sclerosis
rs28365932 rs8179116 1.000 Conduct disorder (symptom count)
rs2897908 rs10785581 1.000 Hypertension
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rs2897908 rs7960483 1.000 Hypertension
rs2904259 rs7671167 1.000 Chronic obstructive pulmonary disease
rs2984920 rs2816316 0.964 Coeliac disease
rs3024505 rs3024493 1.000 Ulcerative colitis
rs3024505 rs3024505 1.000 Type 1 diabetes autoantibodies, Ulcerative
colitis, Crohn’s disease, Type I diabetes
rs307896 rs307896 1.000 Multiple sclerosis
rs3091310 rs13098911 1.000 Coeliac disease
rs3131096 rs4324798 0.941 Lung adenocarcinoma
rs3181080 rs13098911 1.000 Coeliac disease
rs354042 rs354033 1.000 Multiple sclerosis
rs36594 rs36600 1.000 Lung cancer
rs3733041 rs2251219 0.922 Major mood disorders
rs3752948 rs3814219 0.985 Endothelial function traits
rs3758354 rs3758354 1.000 Schizophrenia, Bipolar disorder and depres-
sion (combined)
rs3784388 rs7178909 0.922 Common traits (other)
rs3789053 rs16832015 1.000 Cognitive performance
rs3810610 rs2283792 1.000 Multiple sclerosis
rs3821383 rs10936599 0.939 Multiple sclerosis, Coeliac disease, Colorectal
cancer
rs3821383 rs12696304 1.000 Telomere length
rs4024110 rs3194051 0.870 Ulcerative colitis
rs4265380 rs10903122 0.951 Coeliac disease
rs4265380 rs11249215 0.928 Ankylosing spondylitis
rs4398410 rs10937405 0.886 Lung adenocarcinoma
rs4432068 rs2669010 1.000 Systemic lupus erythematosus
rs4593512 rs6468544 0.971 Antipsychotic-induced QTC interval prolon-
gation
rs4668070 rs13393173 0.831 Response to TNF antagonist treatment
rs4683205 rs9990343 0.804 Brain structure
rs4713186 rs3129109 0.855 Height
rs4713186 rs4947339 0.940 Platelet aggregation
rs4847378 rs12745968 1.000 Bipolar disorder and schizophrenia
rs485499 rs485499 1.000 Primary biliary cirrhosis
rs485789 rs485499 1.000 Primary biliary cirrhosis
rs4906172 rs4906172 1.000 Menopause (age at onset)
rs4944195 rs10899489 0.859 Menarche (age at onset)
rs4944195 rs2373115 0.887 Alzheimer’s disease (late onset)
rs5778 rs7832552 0.817 Body mass (lean)
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rs631106 rs10889353 0.947 Total cholesterol, LDL cholesterol, Triglyc-
erides
rs631106 rs1167998 0.948 Triglycerides
rs631106 rs1168013 0.974 Triglycerides
rs631106 rs1748195 0.974 Triglycerides
rs6556405 rs1473247 0.982 Mean platelet volume
rs6723449 rs11676348 0.831 Ulcerative colitis
rs6784841 rs6806528 0.975 Coeliac disease
rs7156191 rs10133111 0.910 Brain imaging in schizophrenia (interaction)
rs727263 rs7335046 0.855 Basal cell carcinoma
rs743776 rs743777 1.000 Type 1 diabetes autoantibodies, Rheumatoid
arthritis
rs743777 rs743777 1.000 Type 1 diabetes autoantibodies, Rheumatoid
arthritis
rs7441808 rs10517086 0.947 Type 1 diabetes
rs7441808 rs874040 0.947 Rheumatoid arthritis
rs7787612 rs6943555 0.831 Alcohol consumption
rs7801282 rs875971 0.987 Aortic root size
rs7850707 rs10816533 1.000 Height
rs7859727 rs10757278 0.877 Myocardial infarction
rs7859727 rs1333048 0.951 Coronary heart disease
rs7859727 rs1333049 0.901 Coronary heart disease
rs7859727 rs2383207 0.905 Abdominal aortic aneurysm
rs7859727 rs4977574 1.000 Coronary heart disease, Myocardial infarction
(early onset)
rs7859727 rs944797 0.905 Coronary heart disease
rs7923800 rs11013962 1.000 Common traits (other)
rs8008961 rs911263 1.000 Primary biliary cirrhosis
rs8062727 rs9302752 0.932 Leprosy
rs8129743 rs2014300 0.856 Oesophageal cancer
rs907613 rs907611 0.986 Ulcerative colitis
rs9292777 rs11742570 0.933 Crohn’s disease
rs9292777 rs1373692 0.973 Crohn’s disease
rs9292777 rs1992660 0.923 Crohn’s disease
rs9292777 rs6451493 0.933 Ulcerative colitis
rs9292777 rs6896969 0.949 Multiple sclerosis
rs9292777 rs9292777 1.000 Crohn’s disease
rs9300536 rs7335046 0.844 Basal cell carcinoma
rs9303029 rs9303029 1.000 Protein quantitative trait loci
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rs9393984 rs2523822 0.972 Drug-induced liver injury (Amoxicillin-
Clavulanate)
rs9393984 rs6904029 1.000 Vitiligo
rs9594738 rs9533090 1.000 Bone mineral density (spine)
rs9594738 rs9594738 1.000 Bone mineral density, Bone mineral density
(hip)
rs9909593 rs11078927 0.941 Asthma
rs9909593 rs2290400 0.807 Type 1 diabetes
rs9909593 rs2305480 0.941 Asthma, Ulcerative colitis
rs9909593 rs2872507 0.964 Type 1 diabetes autoantibodies, Ulcerative
colitis, Crohn’s disease, Rheumatoid arthritis
rs9909593 rs7216389 0.803 Asthma
rs9909593 rs8067378 0.860 Ulcerative colitis
rs9909593 rs907092 0.976 Primary biliary cirrhosis
rs9909593 rs9303277 0.886 Primary biliary cirrhosis
rs9944207 rs4886707 1.000 Height
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7.4 Hit-SNPs in GATA3 Binding Sites Th1 cells
Table 7.2: SNPs in binding sites for the transcription factor GATA3 in Th1
cells. SNPs that had previously been associated with various traits (trait-associated
SNPs) were downloaded from the NHGRI GWAS catalogue and all SNPs in strong
LD with these trait-associated SNPs were found. Any SNP that was in a bind-
ing site for GATA3 was recorded in conjunction with the trait-associated SNP with
which it was was in high LD and the trait with which the trait-associated SNP was
associated.








rs1006353 rs4771122 0.810 Body mass index
rs10152590 rs10152591 1.000 Height
rs10152591 rs10152591 1.000 Height
rs10263639 rs10263639 1.000 Breast cancer
rs10267797 rs886774 0.887 Ulcerative colitis
rs10421601 rs10403021 1.000 Diabetic retinopathy
rs10828247 rs11012732 0.828 Meningioma
rs10861892 rs8179116 1.000 Conduct disorder (symptom count)
rs10929322 rs10210302 0.975 Crohn’s disease
rs10929322 rs2241880 0.951 Crohn’s disease
rs10929322 rs3792109 0.938 Crohn’s disease
rs10929322 rs3828309 0.963 Crohn’s disease
rs10930310 rs6749447 0.967 Blood pressure
rs10995195 rs10995190 0.953 Mammographic density, Breast cancer
rs11130317 rs1042779 0.804 Bipolar disorder
rs11130317 rs2251219 0.986 Major mood disorders
rs11135484 rs2549794 0.832 Crohn’s disease
rs11142 rs1933182 0.915 Chronic kidney disease
rs11742570 rs11742570 1.000 Crohn’s disease
rs11742570 rs1373692 0.960 Crohn’s disease
rs11742570 rs1992660 1.000 Crohn’s disease
rs11742570 rs6451493 1.000 Ulcerative colitis
rs11742570 rs6896969 0.974 Multiple sclerosis
rs11742570 rs9292777 0.933 Crohn’s disease
rs12038333 rs1329424 1.000 Age-related macular degeneration
rs12132349 rs11584383 0.855 Ulcerative colitis, Crohn’s disease
rs12132349 rs2297909 0.881 Ankylosing spondylitis
rs12132349 rs296547 0.803 Coeliac disease
rs12132349 rs7554511 0.971 Ulcerative colitis
rs1279750 rs1279750 1.000 Platelet counts
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rs12991737 rs3771180 0.806 Asthma
rs1323292 rs2816316 1.000 Coeliac disease
rs133015 rs738322 0.872 Cutaneous nevi
rs133016 rs738322 1.000 Cutaneous nevi
rs133017 rs738322 1.000 Cutaneous nevi
rs1335512 rs4636294 1.000 Cutaneous nevi
rs13418039 rs1559040 1.000 Sudden cardiac arrest
rs1364340 rs1424233 0.975 Obesity
rs1406069 rs12185268 1.000 Parkinson’s disease
rs1406069 rs183211 0.914 Parkinson’s disease
rs1406069 rs199533 0.957 Parkinson’s disease
rs1406069 rs2942168 0.960 Parkinson’s disease
rs1406069 rs393152 1.000 Parkinson’s disease
rs1406069 rs415430 0.914 Parkinson’s disease
rs1406069 rs8070723 1.000 Progressive supranuclear palsy, Parkinson’s
disease
rs1420106 rs13015714 1.000 Coeliac disease
rs1420106 rs2058660 0.980 Crohn’s disease
rs1420106 rs917997 1.000 Coeliac disease
rs1445899 rs1445898 0.987 Type 1 diabetes
rs1465321 rs13015714 1.000 Coeliac disease
rs1465321 rs2058660 1.000 Crohn’s disease
rs1465321 rs917997 1.000 Coeliac disease
rs1481892 rs900145 0.937 Menarche (age at onset)
rs1551398 rs1551398 1.000 Crohn’s disease
rs1551399 rs1551398 0.974 Crohn’s disease
rs1570069 rs1321535 0.882 Phospholipid levels (plasma)
rs1570069 rs2236212 0.941 Phospholipid levels (plasma)
rs1570069 rs3734398 0.953 Phospholipid levels (plasma)
rs1570069 rs3798713 0.952 Phospholipid levels (plasma)
rs1570069 rs4711171 0.893 Phospholipid levels (plasma)
rs1570069 rs4713103 0.830 Phospholipid levels (plasma)
rs1570069 rs6918936 0.828 Phospholipid levels (plasma)
rs1596017 rs10210302 0.951 Crohn’s disease
rs1596017 rs2241880 0.904 Crohn’s disease
rs1596017 rs3792109 0.877 Crohn’s disease
rs1596017 rs3828309 0.928 Crohn’s disease
rs1610588 rs3129055 0.918 Nasopharyngeal carcinoma
rs17035375 rs17035378 0.985 Coeliac disease
rs17035378 rs17035378 1.000 Coeliac disease
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rs17103930 rs8179116 1.000 Conduct disorder (symptom count)
rs17411033 rs4598195 0.947 Ulcerative colitis
rs17533167 rs10484561 0.894 Follicular lymphoma
rs1859156 rs1859156 1.000 Attention deficit hyperactivity disorder
rs1886730 rs734999 0.906 Ulcerative colitis
rs2016755 rs738322 0.875 Cutaneous nevi
rs2058622 rs13015714 1.000 Coeliac disease
rs2058622 rs2058660 1.000 Crohn’s disease
rs2058622 rs917997 1.000 Coeliac disease
rs2106346 rs1076160 0.988 Psoriasis
rs2145998 rs2145998 1.000 Height
rs216172 rs1231206 1.000 Coronary heart disease
rs216172 rs216172 1.000 Coronary heart disease
rs2267020 rs5751614 1.000 Height
rs2275271 rs7914558 1.000 Schizophrenia
rs2278563 rs4907240 0.936 Event-related brain oscillations
rs2282030 rs8017423 0.927 Mortality among heart failure patients
rs231727 rs1024161 0.829 Graves’ disease, Alopecia areata
rs2532234 rs12185268 0.982 Parkinson’s disease
rs2532234 rs199533 0.910 Parkinson’s disease
rs2532234 rs2074404 0.831 Coeliac disease
rs2532234 rs2942168 1.000 Parkinson’s disease
rs2532234 rs393152 1.000 Parkinson’s disease
rs2532234 rs415430 0.893 Parkinson’s disease
rs2532234 rs8070723 1.000 Progressive supranuclear palsy, Parkinson’s
disease
rs2532296 rs12185268 1.000 Parkinson’s disease
rs2532296 rs183211 0.882 Parkinson’s disease
rs2532296 rs199533 0.959 Parkinson’s disease
rs2532296 rs2942168 1.000 Parkinson’s disease
rs2532296 rs393152 1.000 Parkinson’s disease
rs2532296 rs415430 0.919 Parkinson’s disease
rs2532296 rs8070723 1.000 Progressive supranuclear palsy, Parkinson’s
disease
rs261360 rs261360 1.000 Hair morphology
rs2639186 rs2567426 0.800 Information processing speed
rs2702136 rs6707600 1.000 Working memory
rs2703078 rs2762051 1.000 Coeliac disease
rs2706383 rs1016988 0.850 Fibrinogen
rs2706383 rs2522056 1.000 Fibrinogen
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rs2762060 rs806321 0.952 Multiple sclerosis
rs281438 rs281437 1.000 Soluble ICAM-1
rs2865530 rs2865531 1.000 Pulmonary function
rs286913 rs286913 1.000 Response to antipsychotic treatment
rs3101018 rs3117582 0.962 Lung adenocarcinoma, Lung cancer
rs3101018 rs3131379 0.962 Systemic lupus erythematosus
rs3129763 rs3129763 1.000 Systemic sclerosis
rs3129763 rs602875 1.000 Leprosy
rs3129763 rs674313 0.904 Chronic lymphocytic leukaemia
rs3131096 rs4324798 0.941 Lung adenocarcinoma
rs3213621 rs11130248 1.000 Keloid
rs3732123 rs17027258 1.000 White blood cell types
rs3738398 rs12042938 0.809 Neuranatomic and neurocognitive pheno-
types
rs3758253 rs755109 1.000 Quantitative traits
rs3758354 rs3758354 1.000 Schizophrenia, bipolar disorder and depres-
sion (combined)
rs3788013 rs3788013 1.000 Type 1 diabetes autoantibodies
rs3788013 rs9976767 0.865 Type 1 diabetes
rs3806288 rs6702784 0.852 Diabetic retinopathy
rs3863439 rs10871290 0.814 Breast cancer
rs40452 rs42490 1.000 Leprosy
rs4432068 rs2669010 1.000 Systemic lupus erythematosus
rs4522587 rs4675374 1.000 Coeliac disease
rs460901 rs410644 0.813 Anorexia nervosa
rs4667114 rs1018326 0.927 Ankylosing spondylitis
rs4667114 rs13010713 0.882 Coeliac disease
rs4668070 rs13393173 0.831 Response to TNF antagonist treatment
rs4679048 rs2070488 1.000 Electrocardiographic conduction measures
rs4683205 rs9990343 0.804 Brain structure
rs4686760 rs4686760 1.000 Plasma vWF and FVIII levels
rs4713581 rs6457617 0.952 Graves’ disease, Systemic sclerosis, Rheuma-
toid arthritis
rs4713581 rs6457620 0.952 Rheumatoid arthritis
rs4713582 rs6457617 1.000 Graves’ disease, Systemic sclerosis, Rheuma-
toid arthritis
rs4713582 rs6457620 1.000 Rheumatoid arthritis
rs4772190 rs7335046 0.855 Basal cell carcinoma
rs4888376 rs2865531 0.978 Pulmonary function
rs4917014 rs4917014 1.000 Systemic lupus erythematosus
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rs507101 rs7928794 1.000 Response to antipsychotic therapy (extrapyra-
midal side effects)
rs6441957 rs9990343 0.925 Brain structure
rs6651252 rs10088218 1.000 Ovarian cancer
rs6651252 rs6651252 1.000 Crohn’s disease
rs6686643 rs6686643 1.000 Total ventricular volume
rs6919110 rs12199222 0.865 Height
rs6997 rs3197999 0.867 Primary sclerosing cholangitis, Crohn’s dis-
ease, Ulcerative colitis
rs6997 rs9822268 0.897 Ulcerative colitis
rs6997 rs9858542 0.897 Ulcerative colitis, Crohn’s Disease
rs7004723 rs6984045 1.000 Multiple sclerosis
rs707952 rs3129763 0.815 Systemic sclerosis
rs707952 rs602875 0.815 Leprosy
rs707952 rs674313 0.815 Chronic lymphocytic leukaemia
rs707952 rs9272219 0.836 Rheumatoid arthritis, Schizophrenia
rs707952 rs9272535 0.872 Chronic lymphocytic leukaemia
rs7090445 rs10821936 0.972 Acute lymphoblastic leukaemia (childhood)
rs7090445 rs7089424 0.902 Acute lymphoblastic leukaemia (childhood)
rs7117353 rs10437629 0.852 Suicide attempts in bipolar disorder
rs7283760 rs4819388 0.849 Coeliac disease
rs734252 rs2677744 0.920 Attention deficit hyperactivity disorder
rs738322 rs738322 1.000 Cutaneous nevi
rs7578035 rs7578035 1.000 Bipolar disorder
rs7585265 rs2286963 0.842 Serum metabolites
rs7734434 rs17234657 1.000 Crohn’s disease
rs7734434 rs4613763 1.000 Crohn’s disease
rs7965349 rs7957197 0.835 Type 2 diabetes
rs8014856 rs2119704 1.000 Multiple sclerosis
rs8015102 rs2119704 1.000 Multiple sclerosis
rs8027781 rs6494537 0.962 Haematological and biochemical traits
rs8192917 rs8192917 1.000 Vitiligo
rs851984 rs2941740 0.821 Bone mineral density (hip)
rs859648 rs859637 0.976 Coeliac disease
rs881375 rs1953126 1.000 Coeliac disease and Rheumatoid arthritis
rs881375 rs881375 1.000 Rheumatoid arthritis
rs907613 rs907611 0.986 Ulcerative colitis
rs9271170 rs9271100 1.000 Systemic lupus erythematosus
rs9271612 rs3129763 0.948 Systemic sclerosis
rs9271612 rs602875 0.948 Leprosy
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rs9271612 rs674313 0.948 Chronic lymphocytic leukaemia
rs9271613 rs3129763 0.896 Systemic sclerosis
rs9271613 rs602875 0.896 Leprosy
rs9271613 rs674313 0.895 Chronic lymphocytic leukaemia
rs9303029 rs9303029 1.000 Protein quantitative trait loci
rs9314099 rs17376456 0.949 Diabetic retinopathy
rs9314100 rs17376456 0.948 Diabetic retinopathy
rs9393984 rs2523822 0.972 Drug-induced liver injury (amoxicillin-
clavulanate)
rs9393984 rs6904029 1.000 Vitiligo
rs9442234 rs9442235 0.975 Cognitive performance
rs9909593 rs11078927 0.941 Asthma
rs9909593 rs2290400 0.807 Type 1 diabetes
rs9909593 rs2305480 0.941 Asthma, Ulcerative colitis
rs9909593 rs2872507 0.964 Type 1 diabetes autoantibodies, Ulcerative
colitis, Rheumatoid arthritis, Crohn’s disease
rs9909593 rs7216389 0.803 Asthma
rs9909593 rs8067378 0.860 Ulcerative colitis
rs9909593 rs907092 0.976 Primary biliary cirrhosis
rs9909593 rs9303277 0.886 Primary biliary cirrhosis
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7.5 Hit-SNPs inGATA3Binding Sites in Th2 cells
Table 7.3: SNPs in binding sites for the transcription factor GATA3 in Th2
cells. SNPs that had previously been associated with various traits (trait-associated
SNPs) were downloaded from the NHGRI GWAS catalogue and all SNPs in strong
LD with these trait-associated SNPs were found. Any SNP that was in a binding
site for GATA3 was recorded in conjunction with the trait-linked SNP with which
it was was in high LD and the trait with which the trait-associated SNP was asso-
ciated.








rs1006353 rs4771122 0.810 Body mass index
rs10152591 rs10152591 1.000 Height
rs10267797 rs886774 0.887 Ulcerative colitis
rs10516286 rs16891867 1.000 Conduct disorder (symptom count)
rs10516286 rs1861046 1.000 Conduct disorder (case status)
rs10516286 rs1861050 1.000 Conduct disorder (case status)
rs10899476 rs10899489 0.927 Menarche (age at onset)
rs10899476 rs2373115 1.000 Alzheimer’s disease (late onset)
rs10929322 rs10210302 0.975 Crohn’s disease
rs10929322 rs2241880 0.951 Crohn’s disease
rs10929322 rs3792109 0.938 Crohn’s disease
rs10929322 rs3828309 0.963 Crohn’s disease
rs10930310 rs6749447 0.967 Blood pressure
rs10995195 rs10995190 0.953 Mammographic density, Breast cancer
rs11130317 rs1042779 0.804 Bipolar disorder
rs11130317 rs2251219 0.986 Major mood disorders
rs11135484 rs2549794 0.832 Crohn’s disease
rs11142 rs1933182 0.915 Chronic kidney disease
rs11663558 rs1805081 0.834 Obesity
rs11692725 rs882300 0.976 Multiple sclerosis, Electrocardiographic traits
rs12132349 rs11584383 0.855 Ulcerative colitis, Crohn’s disease
rs12132349 rs2297909 0.881 Ankylosing spondylitis
rs12132349 rs296547 0.803 Coeliac disease
rs12132349 rs7554511 0.971 Ulcerative colitis
rs12252379 rs7913069 1.000 Uterine fibroids
rs1279750 rs1279750 1.000 Platelet counts
rs1285403 rs1285407 1.000 Protein quantitative trait loci
rs12942708 rs12936587 0.841 Coronary heart disease
rs12991737 rs3771180 0.806 Asthma
rs1323292 rs2816316 1.000 Coeliac disease
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rs1327235 rs1327235 1.000 Diastolic blood pressure, Systolic blood pres-
sure, Blood pressure
rs1388387 rs7578597 1.000 Type 2 diabetes
rs1406069 rs12185268 1.000 Parkinson’s disease
rs1406069 rs183211 0.914 Parkinson’s disease
rs1406069 rs199533 0.957 Parkinson’s disease
rs1406069 rs2942168 0.960 Parkinson’s disease
rs1406069 rs393152 1.000 Parkinson’s disease
rs1406069 rs415430 0.914 Parkinson’s disease
rs1406069 rs8070723 1.000 Progressive supranuclear palsy, Parkinson’s
disease
rs1420106 rs13015714 1.000 Coeliac disease
rs1420106 rs2058660 0.980 Crohn’s disease
rs1420106 rs917997 1.000 Coeliac disease
rs1596017 rs10210302 0.951 Crohn’s disease
rs1596017 rs2241880 0.904 Crohn’s disease
rs1596017 rs3792109 0.877 Crohn’s disease
rs1596017 rs3828309 0.928 Crohn’s disease
rs1610588 rs3129055 0.918 Nasopharyngeal carcinoma
rs17103930 rs8179116 1.000 Conduct disorder (symptom count)
rs17753121 rs7336332 0.961 Weight
rs1859156 rs1859156 1.000 Attention deficit hyperactivity disorder
rs1886730 rs734999 0.906 Ulcerative colitis
rs1893447 rs10899489 0.859 Menarche (age at onset)
rs1893447 rs2373115 0.887 Alzheimer’s disease (late onset)
rs1983351 rs7495052 1.000 Inattentive symptoms
rs2045592 rs442177 0.825 Triglycerides
rs2058622 rs13015714 1.000 Coeliac disease
rs2058622 rs2058660 1.000 Crohn’s disease
rs2058622 rs917997 1.000 Coeliac disease
rs2106346 rs1076160 0.988 Psoriasis
rs2145998 rs2145998 1.000 Height
rs2239826 rs3093023 0.803 Rheumatoid arthritis
rs2239826 rs3093024 0.827 Rheumatoid arthritis
rs2275271 rs7914558 1.000 Schizophrenia
rs2278563 rs4907240 0.936 Event-related brain oscillations
rs2287900 rs3194051 0.918 Ulcerative colitis
rs231727 rs1024161 0.829 Graves’ disease, Alopecia areata
rs2408025 rs11958779 0.823 Height
rs281438 rs281437 1.000 Soluble ICAM-1
256





rs286913 rs286913 1.000 Response to antipsychotic treatment
rs2984920 rs2816316 0.964 Coeliac disease
rs3129763 rs3129763 1.000 Systemic sclerosis
rs3129763 rs602875 1.000 Leprosy
rs3129763 rs674313 0.904 Chronic lymphocytic leukaemia
rs34251816 rs10026364 1.000 Coronary heart disease
rs34361 rs2112347 0.848 Body mass index
rs3732123 rs17027258 1.000 White blood cell types
rs3758253 rs755109 1.000 Quantitative traits
rs3758354 rs3758354 1.000 Schizophrenia, bipolar disorder and depres-
sion (combined)
rs3792112 rs10210302 0.975 Crohn’s disease
rs3792112 rs2241880 0.975 Crohn’s disease
rs3792112 rs3792109 0.952 Crohn’s disease
rs3792112 rs3828309 1.000 Crohn’s disease
rs4024110 rs3194051 0.870 Ulcerative colitis
rs40452 rs42490 1.000 Leprosy
rs41156 rs5753037 0.975 Type 1 diabetes
rs4522587 rs4675374 1.000 Coeliac disease
rs460901 rs410644 0.813 Anorexia nervosa
rs4668070 rs13393173 0.831 Response to TNF antagonist treatment
rs4679048 rs2070488 1.000 Electrocardiographic conduction measures
rs4683205 rs9990343 0.804 Brain structure
rs4772190 rs7335046 0.855 Basal cell carcinoma
rs4939490 rs4939490 1.000 Multiple sclerosis
rs507101 rs7928794 1.000 Response to antipsychotic therapy (extrapyra-
midal side effects)
rs6441957 rs9990343 0.925 Brain structure
rs6478486 rs1953126 1.000 Coeliac disease and Rheumatoid arthritis
rs6478486 rs881375 1.000 Rheumatoid arthritis
rs6556405 rs1473247 0.982 Mean platelet volume
rs6604026 rs6604026 1.000 Multiple sclerosis
rs6685472 rs12733856 0.885 Mortality among heart failure patients
rs6936240 rs11968814 1.000 F-cell distribution
rs7004723 rs6984045 1.000 Multiple sclerosis
rs7165988 rs12899449 0.957 Bipolar disorder
rs7165988 rs12912251 1.000 Bipolar disorder, Bipolar disorder and major
depressive disorder (combined)
rs7171233 rs12899449 0.957 Bipolar disorder
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rs7171233 rs12912251 1.000 Bipolar disorder, Bipolar disorder and major
depressive disorder (combined)
rs727263 rs7335046 0.855 Basal cell carcinoma
rs7488228 rs10858945 0.976 Optic disc size (cup)
rs7578035 rs7578035 1.000 Bipolar disorder
rs7585265 rs2286963 0.842 Serum metabolites
rs7602799 rs7602460 1.000 Atrioventricular conduction
rs7705826 rs6596075 0.942 Crohn’s disease
rs7988412 rs4771122 0.858 Body mass index
rs8027781 rs6494537 0.962 Haematological and biochemical traits
rs8062727 rs9302752 0.932 Leprosy
rs809930 rs3774372 0.823 Blood pressure
rs851984 rs2941740 0.821 Bone mineral density (hip)
rs881375 rs1953126 1.000 Coeliac disease and Rheumatoid arthritis
rs881375 rs881375 1.000 Rheumatoid arthritis
rs907613 rs907611 0.986 Ulcerative colitis
rs9271612 rs3129763 0.948 Systemic sclerosis
rs9271612 rs602875 0.948 Leprosy
rs9271612 rs674313 0.948 Chronic lymphocytic leukaemia
rs9271613 rs3129763 0.896 Systemic sclerosis
rs9271613 rs602875 0.896 Leprosy
rs9271613 rs674313 0.895 Chronic lymphocytic leukaemia
rs933672 rs11958779 0.823 Height
rs9869432 rs7631605 0.875 P-tau181p
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Table 7.4: Genes located in or near SNP-hits for T-bet. We recorded any genes
containing a hit-SNP for T-bet in addition to any genes within 2kbp of a hit-SNP








Genes within 50kbp of Hit-SNP
rs1006353 none none MTIF3, GTF3A
rs10152590 none none none
rs10152591 none none none
rs10760294 DENND1A (intron) DENND1A DENND1A
rs10808568 none none none
rs10850435 MVK MVK MVK, MMAB
rs10861892 CMKLR1 (intron) CMKLR1 CMKLR1
rs10929322 none none ATG16L1, INPP5D, SCARNA5,
SCARN6
rs10930310 STK39 (intron) STK39 STK39
rs10995195 ZNF365 (intron) ZNF365 ZNF365
rs11009175 none none ITGB1
rs11082995 OSBPL1A (intron) OSBPL1A OSBPL1A, CABYR, TTC39C
rs11130317 GLT8D1 (intron) GLT8D1 GLT8D1, GNL3, PBRM1, SPCS1,
NEK4
rs11135484 ERAP2 (intron) ERAP2 ERAP2, LNPEP
rs11571293 none none CTLA4
rs12136874 none none none
rs12574073 none none ETS1
rs12653750 RAD50 (intron) RAD50 RAD50, IL13, IL4
rs12928552 NLRC5 (intron) NLRC5 NLRC5
rs12946510 none none IKZF3, GRB7, C17orf37, mir-4728,
ERBB2
rs13333528 CDH1 (intron) CDH1 CDH1
rs1335512 none none MTAP
rs1364340 none none none
rs1374910 IGF2BP2 (intron) IGF2BP2 IGF2BP2
rs1420106 none IL18RAP IL18RAP, IL18R1, mir-4772
rs1465321 IL18R1 (intron) IL18R1 IL18R1, IL1RL1, IL18RAP
rs149299 none none CLN3, APOBR, IL27, EIF3CL
rs1551398 none none none
rs1551399 none none none
rs1610588 none none none
rs1631457 SYNE1 (intron) SYNE1 SYNE1
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rs17032405 none none none
rs17103930 none none none
rs17234657 none none none
rs1738074 TAGAP (5’ UTR) TAGAP TAGAP, RSPH3
rs17772411 CDH1 (intron) CDH1 CDH1
rs1788183 none none RNF19A
rs1806689 none none none
rs1918788 KIAA1267 (intron) KIAA1267 KIAA1267
rs2070615 CACNB3 (intron) CACNB3 CACNB3
rs2106346 TSC1 (intron) TSC1 TSC1, C9orf9, AK8
rs216172 SMG6 (intron) SMG6 SMG6
rs2179225 none none none
rs2268080 RALV (intron) RALV RALV, mir-4755
rs2273017 C6orf10 (intron) C6orf10 C6orf10, BTNL2
rs228599 ATM (intron) ATM NPAT
rs2288344 NEDD4 (intron) NEDD4 NEDD4
rs2331903 STX6 (intron) STX6 STX6, KIAA1614
rs2387397 none none none
rs2421016 PLEKHA1 (intron) PLEKHA1 PLEKHA1, mir-3941, ARMS2
rs2532234 KIAA1267 (intron) KIAA1267 KIAA1267
rs264834 DOCK2 (intron) DOCK2 DOCK2
rs2703078 none none none
rs2706383 C5orf56 (intron) C5orf56 C5orf56, IRF1
rs2720665 PVT1 oncogene PVT1 onco-
gene
PVT1 oncogene, mir-1207





rs2897908 none none none
rs2904259 FAM13A (intron) FAM13A FAM13A
rs2984920 none RGS1 RGS1
rs3024505 none IL10 IL10, IL19, MAPKAPK2
rs307896 SAE1 (intron) SAE1 SAE1, ZC3H4
rs3091310 CCR3 (intron) CCR3 CCR3
rs3131096 TPK1 (intron) TPK1 TPK1
rs3181080 none CCR1 CCR1, CCR3
rs354042 none none none
rs36594 MTMR3 (intron) MTMR3 MTMR3
rs3733041 GLT8D1 (intron) GLT8D1 GLT8D1, GNL3, PBRM1, SPCS1,
NEK4
rs3752948 OBFC1 (intron) OBFC1 OBFC1
rs3758354 none none ANXA1
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rs3784388 AP3S2 (5’ UTR) AP3S2 AP3S2, C15orf38
rs3789053 MDM4 (intron) MDM4 MDM4, PIK3C2B
rs3810610 MAPK1 (3’ UTR) MAPK1 MPAK1, YPEL1
rs3821383 none MYNN MYNN, ARPM1, TERC, LRRC34,
LRRIQ4
rs4024110 CAPSL (intron) CAPSL CAPSL, UGT3A1, IL7R
rs4265380 none RUNX3 RUNX3
rs4398410 none none TP63
rs4432068 none none OSBPL8
rs4593512 none none TSPYL5
rs4668070 CERS6 (intron) CERS6 CERS6, mir-4774
rs4683205 none none CCR3
rs4713186 none C6orf100 C6orf100, TRIM27
rs4847378 FAM69A (intron) FAM69A FAM69A, RPL5
rs485499 none none IL12A
rs485789 none none IL12A
rs4906172 DYNC1H1 (intron) DYNC1H1 DYNC1H1
rs4944195 GAB2 (intron) GAB2 GAB2
rs5778 none TRHR TRHR
rs631106 none USP1 USP1, DOCK7
rs6556405 RNF145 (5’UTR) RNF145 RNF145
rs6723449 CXCR2 (intron) CXCR2 CXCR2, CXCR1, RUFY4
rs6784841 FRMD4B (intron) FRMD4B FRMD4B
rs7156191 TRAF3 (intron) TRAF3 TRAF3
rs727263 UBAC2 (intron) UBAC2 UBAC2, mir-623, GPR183
rs743776 none none IL2RB, C1QTNF6
rs743777 none none IL2RB, C1QTNF6
rs7441808 none none none
rs7787612 AUTS2 (intron) AUTS2 AUTS2
rs7801282 CRCP (intron) CRCP CRCP






rs7923800 KIAA1267 (intron) KIAA1267 KIAA1267, PRINS
rs8008961 RAD51B (intron) RAD51B RAD51B
rs8062727 none none NKD1, SNX20, NOD2
rs8129743 Runx1 (intron) Runx1 Runx1, C21orf96
rs907613 LSP1 (5’ UTR) LSP1 LSP1, SYT8, TNNI2, mir-4298
rs9292777 none none none
rs9300536 UBAC2 (intron) UBAC2 UBAC2, GPR183, GPR18
rs9303029 none C17orf62 C17orf62, NARF, C17orf101,
HEXDC, LOC100505970
261
7.6 Genes Located Near Hit-SNPs for T-bet
Hit-SNP Overlapping Within 2kbp Within 50kbp
rs9393984 none none HCG8, HCG9, HLA-A, HLA-
A29.1
rs9594738 none none none
rs9909593 IKZF3 (intron) IKZF3 IKZF3
rs9944207 SNUPN (intron) SNUPN SNUPN, SNX33, IMP3, PTPN9
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Table 7.5: Genes located in or near SNP-hits for GATA3 in Th1 Cells. We recorded
any genes containing a hit-SNP for GATA3 in addition to any genes within 2kbp of








Genes within 50kbp of Hit-SNP
rs1006353 none none MTIF3, GTF3A
rs10152590 none none none
rs10152591 none none none
rs10263639 none none none
rs10267797 none none DLD, LAMB1
rs10421601 none none POP4, VSTM2B
rs10828247 none MLLT10 MLLT10, C10orf140, C10orf114,
mir-1915
rs10861892 CMKLR1 (intron) CMKLR1 CMKLR1
rs10929322 none none ATG16L1, INPP5D
rs10930310 STK39 (intron) STK39 STK39
rs10995195 ZNF365 (intron) ZNF365 ZNF365
rs11130317 GLT8D1 (intron) GLT8D1 GLT8D1, GNL3, PBRM1, SPCS1,
NEK4
rs11135484 ERAP2 (intron) ERAP2 ERAP2, LNPEP
rs11142 SORT1 (exon) SORT1 SORT1, PSMA5, MVBPHL
rs11742570 none none none
rs12038333 CFH( (intron) CFH CFH
rs12132349 C1orf106 (intron) C1orf106 C1orf106, GPR25, CAMSAP1L1
rs1279750 none none TRIM7, OR2V2
rs12991737 none none IL18RAP, IL18R1, mir-4772
rs1323292 none none RGS1
rs133015 PLA2G6 (intron) PLA2G6 PLA2G6, MAFF, TMEM184B
rs133016 PLA2G6 (intron) PLA2G6 PLA2G6, MAFF, TMEM184B
rs133017 PLA2G6 (intron) PLA2G6 PLA2G6, MAFF, TMEM184B
rs1335512 none none MTAP
rs13418039 none none ACYP2
rs1364340 none none none
rs1406069 KIAA1267 (intron) KIAA1267 KIAA1267
rs1420106 none IL18RAP IL18RAP, IL18R1, mir-4772
rs1445899 CAPSL (intron) CAPSL CAPSL, UGT3A1, IL7R
rs1465321 IL18R1 (intron) IL18R1 IL18R1, IL1RL1, IL18RAP
rs1481892 ARNTL (intron) ARNTL ARNTL
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rs1551398 none none none
rs1551399 none none none
rs1570069 ELOVL2 (intron) ELOVL2 ELOVL2, SYCP2L, LOC100506409
rs1596017 none none ATG16L1, INPP5D, SCARNA5,
SCARN6
rs1610588 none none none
rs17035375 PLEK (intron) PLEK PLEK
rs17035378 PLEK (intron) PLEK PLEK
rs17103930 none none none
rs17411033 none none DLD,LAMB1
rs17533167 none none HLA-DQB1, HLA-DQA1, HLA-
DRB4
rs1859156 BMPR1B (intron) BMPR1B BMPR1B
rs1886730 TNFRSF14 (intron) TNFRSF14 TNFRSF14, MMEL1, C1orf93,
HES5, PANK4
rs2016755 PLA2G6 (intron) PLA2G6 PLA2G6, BAIAP2L2
rs2058622 IL18R1 (intron) IL18R1 IL18R1, IL1RL1, IL18RAP
rs2106346 TSC1 (intron) TSC1 TSC1, C9orf9, AK8
rs2145998 none none ZMIZ1, PPIF, ZCCHC24
rs216172 SMG6 (intron) SMG6 SMG6
rs2267020 BCR (intron) BCR BCR
rs2275271 CNNM2 (exon) CNNM2 CNNM2, NT5C2
rs2278563 ARID5A (intron) ARID5A ARID5A, KIAA1310
rs2282030 PMSC1 (intron) PMSC1 PMSC1, C14orf102
rs231727 none none CTLA4
rs2532234 KIAA1267 (intron) KIAA1267 KIAA1267
rs2532296 KIAA1267 (intron) KIAA1267 KIAA1267
rs261360 none none C20orf30
rs2639186 none none none
rs2702136 ITSN2 (intron) ITSN2 ITSN2
rs2703078 none none none
rs2706383 C5orf56 (intron) C5orf56 C5orf56, IRF1
rs2762060 none none none
rs281438 none ICAM4,
ICAM5
ICAM4, ICAM5, ICAM1, MRPL4,
ZGLP1, FDX1L, RAVER1, ICAM3
rs2865530 CFDP1 (intron) CFDP1 CFDP1
rs286913 EHF (intron) EHF EHF
rs3101018 none CLIC1, MSH5 CLIC1, MSH5, ABHD16A,
LY6G6F, LY6G6D, LY6G6C,
C6orf25, DDAH2, VARS, C6orf27,
C6orf26
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rs3129763 none none HLA-DQB1, HLA-DQA1, HLA-
DRB4
rs3131096 TPK1 (intron) TPK1 TPK1
rs3213621 ZNYMD10 (3’) ZNYMD10,
RASSF1
ZNYMD10, RASSF1, IFRD2,
HYAL3, NAT6, HYAL1, HYAL2,
TUSC2, NPRL2, CYB561D2,
TMEM115, CACNA2D2
rs3732123 none none IL1RL1, IL18R1, IL18RAP, mir-
4772
rs3738398 none DISC1 DISC1
rs3758253 HEMGN (5’) HEMGN HEMGN, ANP32B, C9orf156
rs3758354 none none ANXA1




rs3863439 none none GLG1, CLEC18B
rs40452 RIPK2 (intron) RIPK2 RIPK2
rs4432068 none none OSBPL8
rs4522587 ICOS (intron) ICOS ICOS
rs460901 none none SSBP2
rs4667114 none none none
rs4668070 CERS6 (intron) CERS6 CERS6, mir-4774
rs4679048 none none XYLB
rs4683205 none none CCR3
rs4686760 none none VPS8
rs4713581 none none HLA-DQA2, HLA-DQB1, HLA-
DQA1
rs4713582 none none HLA-DQA2, HLA-DQB1, HLA-
DQA1
rs4772190 UBAC2 (intron) UBAC2 UBAC2, FKSG29, mir-623
rs4888376 none none CFDP1, BCAR1
rs4917014 none none IKZF1
rs507101 SLC3A2 (intron) SLC3A2 SLC3A2, WDR74, RNU2-2,
SNHG1, SNORD22, 26, 28, 30, 25,
27, 31 and 25
rs6441957 none none CCR3
rs6651252 none none none
rs6686643 MGST3 (intron) MGST3 MGST3, ALDH9A1
rs6919110 FAM8A1 (5’ UTR) FAM8A1 FAM8A1, NUP153, CAP2
rs6997 TCTA (3’ UTR) TCTA, AMT TCTA, AMT, NICN1, RHOA
rs7004723 ASAP1 (intron) ASAP1 ASAP1
rs707952 HLA-DQA1 (exon) HLA-DQA1 HLA-DQA1, HLA-DQB1
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rs7090445 ARID5B (intron) ARID5B ARID5B
rs7117353 none C11orf41 C11orf41
rs7283760 none none DNMT3L, ICOSLG
rs734252 none MAN2A2 MAN2A2, FURIN, FES
rs738322 PLA2G6 (intron) PLA2G6 PLA2G6, TMEM, MAFF
rs7578035 none none MGAT4A, C2orf55
rs7585265 RPE (3’ UTR) RPE, C2orf67 RPE, C2orf67, UNC80
rs7734434 none none none
rs7965349 OASL (intron) OASL OASL, C12orf43, HNF1A
rs8014856 GALC (intron) GALC GALC, GPR65
rs8015102 GALC (intron) GALC GALC, GPR65
rs8027781 none none DENND4A
rs8192917 GZMB (exon) GZMB GZMB, GZMH
rs851984 ESR1 (intron) ESR1 ESR1
rs859648 none none none
rs881375 none none TRAF, PHF19
rs907613 LSP1 (5’ UTR) LSP1 LSP1, SYT8, TNNI2, mir-4298
rs9271170 none none HLA-DRB4, HLA-DQA1, HLA-
DQB1
rs9271612 none none HLA-DRB4, HLA-DQA1, HLA-
DQB1
rs9271613 none none HLA-DRB4, HLA-DQA1, HLA-
DQB1
rs9303029 none C17orf62 C17orf62, NARF, C17orf101,
HEXDC, LOC100505970
rs9314099 FAM172A (5’ UTR) FAM172A FAM172A, KIAA0825
rs9314100 FAM172A (5’ UTR) FAM172A FAM172A, KIAA0825
rs9393984 none none HCG8, HCG9, HLA-A, HLA-
A29.1
rs9442234 FAM131C (intron) FAM131C FAM131C, CLCNKB, CLCNKA,
HSPB7
rs9909593 IKZF3 (intron) IKZF3 IKZF3
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Table 7.6: Genes located in or near SNP-hits for GATA3 in Th2 Cells. We recorded
any genes containing a hit-SNP for GATA3 in addition to any genes within 2kbp of








Genes within 50kbp of Hit-SNP
rs1006353 none none MTIF3, GTF3A
rs10152591 none none none
rs10267797 none none DLD, LAMB1
rs10516286 C1QTNF7 (5’) C1QTNF7 C1QTNF7
rs10899476 GAB2 (intron) GAB2 GAB2
rs10929322 none none ATG16L1, INPP5D
rs10930310 STK39 (intron) STK39 STK39
rs10995195 ZNF365 (intron) ZNF365 ZNF365
rs11130317 GLT8D1 (intron) GLT8D1 GLT8D1, GNL3, PBRM1, SPCS1,
NEK4
rs11135484 ERAP2 (intron) ERAP2 ERAP2, LNPEP
rs11142 SORT1 (exon) SORT1 SORT1, PSMA5, MVBPHL
rs11663558 NPC1 (intron) NPC1 NPC1, ANKRD29, C18orf8
rs11692725 none none none
rs12132349 C1orf106 (intron) C1orf106 C1orf106, GPR25, CAMSAP1L1
rs12252379 none none LOC254312
rs1279750 none none TRIM7, OR2V2
rs1285403 none none none
rs12942708 none none PEMT
rs12991737 none none IL18RAP, IL18R1, mir-4772
rs1323292 none none RGS1
rs1327235 none none none
rs1388387 THADA (intron) THADA THADA
rs1406069 KIAA1267 (intron) KIAA1267 KIAA1267
rs1420106 none IL18RAP IL18RAP, IL18R1, mir-4772
rs1596017 none none ATG16L1, INPP5D, SCARNA5,
SCARN6
rs1610588 none none none
rs17103930 none none none
rs17753121 none none GTF3A, MTIF3
rs1859156 BMPR1B BMPR1B BMPR1B
rs1886730 TNFRSF14 (intron) TNFRSF14 TNFRSF14, MMEL1, C1orf93,
HES5, PANK4
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rs1893447 GAB2 (intron) GAB2 GAB2, USP35
rs1983351 SLCO3A1 (intron) SLCO3A1 SLCO3A1
rs2045592 AFF1 (intron) AFF1 AFF1
rs2058622 IL18R1 (intron) IL18R1 IL18R1, IL1RL1, IL18RAP
rs2106346 TSC1 (intron) TSC1 TSC1, C9orf9, AK8
rs2145998 none none ZMIZ1, PPIF, ZCCHC24
rs2239826 none none CCR6, FGFR1
rs2275271 CNNM2 (exon) CNNM2 CNNM2, NT5C2
rs2278563 ARID5A (intron) ARID5A ARID5A, KIAA1310
rs2287900 none CAPSL CAPSL, UGT3A1, IL7R
rs231727 none none CTLA4
rs2408025 SLC38A9 (intron) SLC38A9 SLC38A9
rs281438 none ICAM4,
ICAM5
ICAM4, ICAM5, ICAM1, MRPL4,
ZGLP1, FDX1L, RAVER1, ICAM3
rs286913 EHF (intron) EHF EHF
rs2984920 none RGS1 RGS1
rs3129763 none none HLA-DQB1, HLA-DQA1, HLA-
DRB4
rs34251816 WHSC1 (intron) WHSC1 WHSC1, LETM1
rs34361 POC5 (intron) POC5 POC5, ANKDD1B
rs3732123 none none IL1RL1, IL18R1, IL18RAP, mir-
4772
rs3758253 HEMGN (5’) HEMGN HEMGN, ANP32B, C9orf156
rs3758354 none none ANXA1
rs3792112 ATG16L1 (intron) ATG16L1 ATG16L1, SAG, SCARNA6,
SCARNA5
rs4024110 CAPSL (intron) CAPSL CAPSL, UGT3A1, IL7R
rs40452 RIPK2 (intron) RIPK2 RIPK2
rs41156 MTMR3 (intron) MTMR3 MTMR3
rs4522587 ICOS (intron) ICOS ICOS
rs460901 none none SSBP2
rs4668070 CERS6 (intron) CERS6 CERS6, mir-4774
rs4679048 none none XYLB
rs4683205 none none CCR3
rs4772190 UBAC2 (intron) UBAC2 UBAC2, FKSG29, mir-623
rs4939490 none none CD6
rs507101 SLC3A2 (intron) SLC3A2 SLC3A2, WDR74, RNU2-2,
SNHG1, SNORD22, 26, 28, 30, 25,
27, 31 and 25
rs6441957 none none CCR3
rs6478486 none none TRAF1, PHF19, PSMD5
rs6556405 RNF145 (5’ UTR) RNF145 RNF145
268
7.8 Genes Located Near Hit-SNPs for GATA3 in Th2 cells
Hit-SNP Overlapping Within 2kbp Within 50kbp
rs6604026 RPL5 (intron) RPL5,
SNORD21
RPL5, SNORD21, FAM69A, EVI5,
SNORD66
rs6685472 none none none
rs6936240 PDE7B (intron) PDE7B PDE7B
rs7004723 ASAP1 (intron) ASAP1 ASAP1
rs7165988 C15orf53 (exon) C15orf53 C15orf53





UBAC2, FKSG29, GPR183, mir-
623
rs7488228 none none none
rs7578035 none none MGAT4A, C2orf55
rs7585265 RPE (3’ UTR) RPE, C2orf67 RPE, C2orf67, UNC80
rs7602799 none none none
rs7705826 none SLC22A5 SLC22A5, C5orf56, mir-3936
rs7988412 GTF3A (intron) GTF3A GTF3A, MTIF3
rs8027781 none none DENND4A




rs851984 ESR1 (intron) ESR1 ESR1
rs881375 none none TRAF, PHF19
rs907613 LSP1 (5’ UTR) LSP1 LSP1, SYT8, TNNI2, mir-4298
rs9271612 none none HLA-DRB4, HLA-DQA1, HLA-
DQB1
rs9271613 none none HLA-DRB4, HLA-DQA1, HLA-
DQB1
rs933672 SLC38A9 (intron) SLC38A9 SLC38A9
rs9869432 LRRFIP2 (intron) LRRFIP2 LRRFIP2
269
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